Comparative Genomics of Pseudomonas aeruginosa Populations by Moore, MP
			 			Comparative	Genomics	of	
Pseudomonas	aeruginosa	Populations						
Thesis submitted in accordance with the requirements of 
the University of Liverpool for the degree of Doctor in 
Philosophy by Matthew Phillip Moore 
 
September 2017 
							
1	
Abstract		
Pseudomonas	aeruginosa	 causes	a	wide	 range	of	 infections,	 is	often	associated	with	antimicrobial	resistance	and	is	the	primary	cause	of	chronic	lung	infection	in	cystic	 fibrosis	 (CF)	and	 the	overall	morbidity	and	mortality	associated	with	the	 disease.	 As	 P.	 aeruginosa	 is	 an	 environmental	 bacterium	 that	opportunistically	 infects	 CF	 patients	 most	 infecting	 lineages	 are	 distinct.	 The	determination	 of	 common	 adaptive	 routes	 during	 infection	 is	 further	complicated	 by	 within-lineage	 heterogeneity,	 multi-lineage	 infections	 and	 the	emergence	 of	 transmissible	 strains.	 In	 order	 to	 better	 understand	 the	 genetic	basis	of	varying	pathogenicity,	a	diverse	dataset	of	1,407	P.	aeruginosa	genomes	from	 the	 environment,	 non-CF	 bronchiectasis	 and	 from	 CF	 samples	 was	analysed.	Detailed	analysis	of	mutations	potentially	associated	with	the	CF	lung	environment	 was	 conducted	 by	 comparison	 of	 the	 genomes	 from	 CF	 and	environmental	 isolates	 and	 by	 including	 a	 geographically	 and	 historically	diverse	 panel	 of	 a	 transmissible	 lineage,	 the	 Liverpool	 Epidemic	 Strain	 (LES).	Sequencing	of	isolates	from	non-CF	bronchiectasis	showed	for	the	first	time	the	commonality	in	adaptive	routes	in	non-CF	chronic	lung	diseases	and	the	utility	of	 genome	 sequencing	 to	 infer	 within	 and	 between	 host	 diversity	 and	population	 structure.	 Many	 antibiotic	 resistance	 genes	 (ARGs)	 in	 all	 samples	were	observed	 to	be	adaptive	and	a	sample	of	genomes	 from	hospital	 isolates	from	Thailand	was	used	 to	assess	 international	multi-drug	 resistance	 lineages	with	mobile	genetic	element	associated	ARGs.	This	study	has	shown,	by	analysis	of	 diverse	 datasets,	 how	 genome	 sequencing	 can	 reveal	 the	 genetic	 basis	 of	phenotypic	 heterogeneity	 and	 subsequent	 varying	 patient	 outcomes	with	 this	diverse	infection.		
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Chapter	One	
1. Introduction	
1.1. Microbial	Genomics		Chain	 termination	 ‘Sanger’	sequencing	was	conceived	by	Fred	Sanger	 in	1977.	His	method	became	the	first	commercially	available	DNA	sequencing	technology	and	 was	 later	 replaced	 by	 high-throughput	 ‘second	 generation’	 sequencers,	facilitating	 a	 methodological	 revolution	 in	 molecular	 biology.	 The	 first	 free	living	 organism	 to	 have	 its	 entire	 genome	 sequenced	 was	 that	 of	 bacterium	
Haemophilus	 influenzae	 in	 19951.	 The	 whole	 genome	 took	 13	 months	 to	complete	 and	 represented	 a	 landmark	 technical	 achievement.	 Microbiological	practices	 such	 as	 genotyping,	 molecular	 epidemiological	 surveillance,	identifying	 antibiotic	 resistance,	 taxonomy	 have	 been	 revolutionised	 by	available	genome	sequences2.	For	these	breakthroughs	to	be	possible	sequence	data	analysis	has	developed	and	shifted	with	the	change	in	platforms,	type	and	amount	 of	 output.	 Algorithms	 have	 been	 developed	 for	 de	 novo	 genome	assembly	 and	 scaffolding3,4,	 read	 mapping	 approaches5,	 variant	 calling6	 and	gene	 annotation7	 from	 which	 most	 microbial	 bioinformatics	 workflows	 are	built.	 Importantly,	 the	 majority	 of	 informatics	 software,	 code	 libraries	 and	databases,	 from	which	 the	majority	 of	 advances	 have	 been	 possible	 are	 open	source8.	 New	 insights	 have	 also	 been	 obtained	 through	 the	 application	 of	modeling,	statistical	approaches	and	machine	learning	to	genomics	data9–12.				
12	
1.1.1. Taxonomy	and	Genotyping	Fundamental	microbiological	practices	are	being	updated	by	the	availability	of	sequencing.	 The	 taxonomic	 placement	 of	 microbes	 before	 whole	 genome	sequencing	 (WGS)	 primarily	 relied	 upon	 the	 ‘gold	 standard’	 DNA-DNA	hybridization	 and	 more	 recently	 16S	 rRNA	 similarity.	 Now	 phylogenetic	approximation	 using	 some	 or	 all	 of	 the	 genome	 enable	 reconstruction	 of	detailed	 taxonomies13.	 Additionally	 average	 nucleotide	 identity	 (ANI)	 has	replaced	 the	 former	 ‘gold	standard’14.	As	a	 result	of	 these	advances	numerous	microbial	 species	 have	 been	 reclassified15;	 ANI	was,	 for	 example,	 successfully	used	to	identify	new	species	of	Vibrio	and	Burkholderia16.	Microbiological	typing	methods,	 such	 as	 serotyping	 have	 been	 largely	 replaced	 by	 molecular	 typing	methods,	which	can	be	sequenced	based	or	non-sequence	based.	Non-sequence	based	molecular	 genotyping	methods	 include	 PCR-restriction	 fragment	 length	polymorphism	(PCR-RFLP),	pulse	field	gel	electrophoresis	(PFGE),	Microarrays	and	multiple	 locus	 variable-number	 tandem	 repeat	 analysis	 (MVLA).	Multiple	genotyping	 methods	 have	 since	 been	 developed	 based	 on	 the	 DNA	 sequence	data.	 These	 include	 multi-spacer	 typing	 (MST)17	 and	 multi	 locus	 sequence	typing	 (MLST)18.	 MLST	 was	 developed	 for	 the	 identification	 of	 pathogenic	clones19.	MLST	is	based	on	variation	in	seven	housekeeping	genes	thought	to	be	non-recombining,	 not	 under	 selection	 and	 present	 (due	 to	 their	 essential	functions)	 in	 all	 members	 of	 the	 species.	 MLST	 allows	 for	 surveillance	 of	pathogenic	strains	even	when	more	discriminatory	WGS	data	is	available	as	the	sequence	type	can	quickly	be	determined	from	the	whole	genome	and	provide	useful	 information	from	samples.	As	such	it	has	been	used,	 for	example,	 in	the	
13	
typing	 and	 surveillance	 of	 Staphylococcus	 areus20,	 extended	 spectrum	 β-lactamase	producing	Escherichia	coli21,	and	Streptococcus	pneumoniae22.			
1.1.2. Bacterial	Core,	Accessory	and	Pan-genomes	The	 pangenome	 is	 the	 entire	 set	 of	 genes	 that	 comprise	 a	 species;	 wherever	there	 is	 variation	 in	 the	 gene	 families	 present	 between	members	 of	 a	 species	their	 sum	 is	 the	 pangenome.	 The	 pangenome	 can	 be	 context	 defined	 such	 as	strain	or	genus’	pangenome,	but	unless	otherwise	stated	 it	will	be	 the	species	pangenome	that	is	being	referred	to.	Gene	families	that	are	core	are	present	in	all	members	of	 the	species	and	may	be	summarised	as	 the	core	genome.	Gene	families	 that	are	accessory,	range	 from	two	 isolates	 to	n-1	 isolates,	where	n	 is	the	 total	 number	 of	 isolate	 genomes.	 Finally,	 unique	 gene	 families	 are	 found	only	in	one.	The	amount	of	intraspecies,	pangenome,	diversity	varies	(table	1.1).	It	 can	 be	 clinically	 useful	 to	 determine	 the	 pangenome	 and	 the	 field	 of	vaccinology	now	includes	‘reverse	vaccinology’;	the	process	of	identifying	from	whole	genome	sequencing	gene	products	as	vaccine	candidates.	The	term	was	first	 coined	when	 the	method	was	developed	 to	 identify	new	surface	 exposed	antigen	vaccine	candidates	from	the	genome	of	Neisseria	meningitidis	serogroup	B23.	Reverse	vaccinology	 studies	have	also	been	 conducted	 for	Mycobacterium	
tuberculosis,	 Ricksettsia	 prowazekii,	 E.	 coli,	 Bacillus	 anthracis,	 Chlamydia	
pneumonia,	 Leptospira	 interrogans,	 Porphyromonas	 gingivalis,	 Streptococcus	
pneumoniae	and	Streptococcus	pyogenes24–26.					
14	
Table	1.1.	A	small	selection	of	pangenome	statistics	for	five	organisms		
Species	 Number	
of	
genomes	
Number	
and	
percent	
of	genes	
that	are	
core	
Number	
and	
percent	of	
genes	that	
are	
accessory	
Description/comment	
Salmonella	
enterica	
206	 1,717	(16%)	 8,550	(83%)	 Pathogen	associated	with	soil,	water,	rumen	
Streptococcus	
pyogenes	
49	 986	(37%)	 1,644	(62%)	 Obligate	human	pathogen	
Chlamydia	
trachomatis	
67	 153	(15%)	 821	(84%)	 Obligate	intracellular	pathogen	
Acinetobacter	
baumannii	
40	 1,997	(28%)	 5,042	(71%)	 Soil	associated	opportunistic	pathogen	
Bacillus	cereus	 30	 3,245	(27%)	 8,666	(72%)	 Associated	with	rumen,	mammalian	and	insect	intestinal	tracts			
1.1.3. Determining	the	genetic	basis	of	bacterial	phenotypes	Identification	of	 the	virulence	factors	and	antibiotic	resistance	gene	repertoire	of	 the	 organism	 is	 crucial	 to	 understanding	microbial	 pathogens.	 Genomics	 is	enabling	researchers	to	make	inroads	into	the	prediction	of	complex	microbial	phenotypes	 relevant	 to	 the	 major	 features	 of	 infectious	 disease	 causation:	infectivity,	attachment,	invasiveness,	persistence,	resistance	and	virulence.			Genomic	 identification	 of	 virulence	 factors	 and	 antibiotic	 resistance	 has	primarily	 involved	 the	 curation	 of	 databases	 of	 genes	 and	 alleles	with	 known	phenotypic	outcomes	and	associations	with	or	putative	virulence	or	resistance	phenotype.	 Antibiotic	 resistance	 genes	 (ARGs)	 for	 example	were	 identified	 in	
Acinetobacter	baumannii	 genomes	 by	 alignment	 to	 the	 Resfinder27	 or	 ARDB28	databases.	 Similarly	 it	 was	 possible	 to	 identify	 829	 virulence	 genes	 in	 E.	 coli	
15	
strain	PA45	by	alignment	to	the	virulence	factor	database,	vfDB29.	The	method	Mykrobe	 predictor	was	 developed	 for	 prediction	 of	 antibiotic	 resistance	 in	 S.	
aureus	 and	 Mycobacterium	 tuberculosis11.	 Diagnostic	 tests	 to	 determine	antibiotic	resistance	and	susceptibility	in	M.	tuberculosis	can	take	weeks	due	its	slow	growth	rate.	In	S.	aureus,	Mykrobe	predictor	achieves	>99%	sensitivity	and	specificity	and	in	M.	tuberculosis	98.5%	specificity	and	82.6%	sensitivity11.	The	adoption	of	rapid	sequencing	for	identification	of	virulence	and	resistance	genes	from	genomic	and	metagenomic	sequences	from	clinical	samples	will	transform	how	 clinical	 microbiology	 is	 conducted13	 and	 provide	more	 information	 than	ever	 before	 for	 medical	 microbiological	 research.	 However	 these	 methods	ultimately	 depend	 on	 established	 an	 understanding	 of	 genes	 and	 their	association	 with	 phenotype.	 In	 many	 cases	 complex	 gene	 regulation	 and	pleiotropy	result	in	gene	function	being	unclear.				Methods	 are	 emerging	 that	have	 the	potential	 to	predict	bacteria	phenotypes	with	a	complex	genetic	basis.	Methods	such	as	genome	wide	association	studies	(GWAS)	developed	 for	 human	 genome	 sequencing	projects30	 take	 a	 top	down	approach	 towards	 eliminating	 bias	 and	 potentially	 revealing	 associations	between	genes	or	alleles	and	phenotypes.	GWAS	in	bacteria	is	typically	based	on	sequence	presence	or	absence	to	 identify	whether	there	 is	an	association	with	the	 observed	 effect	 (phenotype).	 Phenotypic	 classifications	 such	 as	 resistance	can	be	associated	with	responsible	genes	or	islands31–34.	Alternatively	SNP	data	may	associate	alleles	and	particular	mutations	with	phenotypic	outcomes10,35–37.	A	major	development	has	been	the	method	proposed	by	Sheppard	et	al.,31	of	a	kmer	 based	 approach	 from	which	 the	 association	 of	 both	 SNPs	 and	 sequence	
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presence/absence	 can	 be	 assessed	 allowing	 for	 core	 and	 accessory	 genome	diversity	 to	be	considered.	The	 future	of	GWAS	 is	promising	and	 the	 issues	of	recombination,	 linkage	 disequilibrium,	 strength	 of	 selection	 and	 population	stratification	 that	may	 confound	 it	 are	 being	 addressed9.	 Further,	 there	 is	 the	potential	 for	 the	 development	 of	 machine	 learning	 algorithms	 capable	 of	inferring	 non-linear	 associations,	 such	 as	 the	 random	 forest	 approach.	 The	random	forest	algorithm	is	an	ensemble	machine	learning	approach	capable	of	determining	 the	predictive	 capacity	 of	 sequences	 and	 variants	 for	 subsequent	causality	testing38.				
1.1.4. Genomic	epidemiology	Molecular	 epidemiology	 can	 be	 counted	 among	 the	 disciples	 that	 have	 most	benefitted	 from	 the	 availability	 of	 WGS	 data.	 Comparison	 of	 whole	 genomes	allows	discrimination	based	on	 SNPs,	 providing	 greater	 discriminatory	power	than	molecular	epidemiological	approaches	and	certainly	more	than	molecular	and	 microbiological	 typing	 approaches	 formerly	 used	 to	 inform	epidemiology39,40.			The	data	provided	by	whole	genome	sequencing,	so	far	primarily	from	‘second	generation’	 sequencers,	has	allowed	outbreaks	 to	be	mapped	 in	greater	detail	than	ever	before41.	Further	the	portable	sequencing	platform,	Oxford	Nanopores	MinIon	 expands	 the	 potential	 of	 genomic	 epidemiology	 and	 broader	investigation	 of	 pathogens	 in	 the	 healthcare	 setting	 worldwide.	 In	 2012	genomic	 epidemiology	 successfully	 identified	 6	 cases	 of	methicillin	 resistance	
Staphylococcus	aureus	(MRSA)	to	a	common	source,	where	corresponding	PFGE	
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profiles	were	 unable	 to	 distinguish42.	 Genomic	 epidemiology	 has	 revealed	 the	chain	 of	 transmission	 in	 Acinetobacter	 baumanni43,44,	 Klebsiella	 pneumoniae45	and	MRSA46,47.	 In	 non-communicable	 infections	 such	 as	 burns	 infections	with	
Pseudomonas	aeruginosa,	WGS	was	used	to	determine	the	source,	 the	showers	in	 a	 burns	 unit45.	 Infection	 dynamics	 may	 also	 be	 resolved	 from	 sequencing,	such	as	 in	Clostridium	difficile48.	 It	was	determined	 that	 infection	could	not	be	explained	 as	 transmission	 between	 symptomatic	 carriers	 but	 that	 either	asymptomatic	carriers	have	introduced	C.	difficille	 to	the	hospital	environment	or	that	there’s	a	broader	environmental	contamination	with	C.	dificile48.	In	2016	the	 average	 nucleotide	 identity	 (ANI)	 method	 was	 used	 to	 resolve	
Elizabethkingia	strains	during	an	outbreak.	El.	anophelis,	El.	meningoseptica	and	
El.	miricola	were	identified	as	distinct	species	and	a	core	genome	MLST	scheme	developed49.	 As	 such	 El.	meningoseptica	 were	 reassigned	 as	 El.	 anophelis49.	 A	community	 associated	 outbreak	 from	 2015	 to	 2016	 occurred	 in	 Wisconsin,	Illinois	 and	 Michigan,	 US,	 of	 the	 recently	 defined	 El.	 anophelis50.	 Genomic	epidemiology	determined	 that	 the	outbreak	was	 a	 single	 strain	 that	 had	been	growing	and	adapting	in	an	environmental	reservoir	for	~1	year	before	the	first	infection	 occurred50.	 Observations	 of	 temporal	 accumulations	 of	 mutations	allowed	the	authors	to	further	hypothesise	that	patients	were	either	exposed	to	a	 low	 diversity	 population	 or	 that	 transmission	 bottlenecks	 were	 occurring,	further	demonstrating	the	potential	epidemiological	insights	possible	with	WGS	data50.	These	 retrospective	epidemiological	 studies	have	 clearly	demonstrated	the	power	of	WGS	 to	 track	outbreaks,	 determine	 the	 chain	of	 transmission	or	common	 source	 and	 further	 yield	 clinically	 useful	 information	 about	 the	bacteria	 involved.	 The	 potential	 for	 real-time	 genomic	 epidemiology	 has	 also	
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been	demonstrated12,51.	In	2015	real	time	nanopore	sequencing	in	a	UK	hospital	demonstrated	there	was	no	common	source	of	Salmonella	enteriditis.	Outbreaks	on	different,	unlinked,	wards	harboured	genetically	distinct	isolates52.		
1.1.5. Bacterial	genome	evolution	Bacteria	are	asexually	reproducing,	unicellular	organisms.	Though	they	clonally	reproduce	 there	 is	 vast	 observable	 genetic	 diversity	 across	 the	 bacterial	kingdom	 and	 discernible	 species,	 strains	 and	 clonal	 groups	 (though	 the	boundaries	 are	 sometimes	 harder	 to	 define	 than	 is	 the	 case	with	 animals	 for	instance).	There	are	a	number	of	mechanisms	contributing	to	extant	diversity	of	bacteria	 such	as	mutation.	Mutations	occur	as	 a	 result	of	 replicative	errors	or	physical	damage	to	bacterial	DNA.	Once	present	the	relative	fitness	conferred	by	a	 mutation	 will	 determine	 whether	 it	 will	 be	 selected	 against	 (purifying	selection)	selected	for	(positive	selection)	or	be	neutral	to	selection.	Mutations	in	 coding	 sequences	 may	 also	 be	 classified	 independent	 of	 their	 impact	 on	fitness	 as	 synonymous,	 where	 the	 base	 or	 codon	 change	 does	 not	 result	 in	encoding	 of	 a	 different	 amino	 acid	 or	 non-synonymous	where	 the	 result	 of	 a	mutation	 is	 a	 change	 in	 the	 encoded	 amino	 acid.	 Further,	 non-synonymous	mutations	can	be	categorised	as	nonsense	mutations	if	they’re	disruptive	to	the	encoded	protein	by	introducing	a	frame-shift,	premature	stop	codon	or	loss	of	a	start	 or	 stop	 codon.	 A	 further	 mechanism	 for	 genetic	 change	 in	 bacteria	 is	recombination	 by	 horizontal	 gene	 transfer	 (HGT).	 Though	 prokaryotes	 lack	sexual	reproduction,	a	uniquely	eukaryotic	trait,	they	do	engage	in	homologous	and	non-	homologous	 recombination,	where	 the	 resulting	exchange	of	 genetic	material	 that	may	be	adaptive,	neutral	or	disadvantageous	as	with	mutational	
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genetic	 change.	 Genetic	 diversity	may	 also	 result	 from	 gene	 duplications.	 If	 a	copy	 of	 a	 gene	 loses	 function	 or	 gains	 a	 function	 as	 a	 result	 then	 this	 is	categorised	as	a	paralog,	whereas	orthologs	are	genes	that	have	diverged	along	with	 organisms	 (have	 common	 ancestry)	 and	 finally,	 xenologs	 are	 those	acquired	through	HGT.			The	 relative	 fitness	 of	 genetic	 variation	 in	 a	 population	 (fitness	 coefficient)	 is	determined	 by	 numerous	 molecular	 evolutionary	 processes.	 Fitness	 is	 best	conceptualised	as	a	landscape	wherein	there	are	fitness	peaks	and	valleys;	there	are	numerous	ways	to	be	on	a	peak,	including	suboptimal	ones53.	Genetic	drift	is	any	 random	change	of	 allele	 frequency	 in	 a	population,	 resulting	 from	chance	rather	than	selective	pressures.	The	effective	population	size	(Ne)	best	predicts	what	impact	genetic	drift	may	have	on	the	selection	coefficient.	In	a	population	with	 small	Ne	 alleles	may	 drift	 to	 fixation	 even	when	 there’s	 strong	 selective	pressure	acting,	for	example	to	maintain	heterogeneity,	because	chance	changes	in	 allele	 frequency	 become	 less	 unlikely.	 However,	 the	majority	 of	 mutations	accumulated	are	deleterious.	A	 large	accumulation	of	mutations	 is	 the	 leading	contributor	of	 a	high	 genetic	 load,	 suboptimal	 fitness	 as	 a	 result	 of	 genotypes	present.	 Another	 phenomena	 determining	 potential	 moves	 on	 a	 fitness	landscape	 is	 a	 form	 of	 drift:	 ‘genetic	 hitchhiking’.	 A	 neutral	 change	 in	 allele	frequency	 can	be	 led	by	 the	physical	 proximity	 (linkage	disequilibrium)	of	 an	allele	 to	 another	 that’s	under	 selection54.	Mutation	 rates	 can	also	be	 adaptive,	especially	when	populations	are	placed	under	stress55.	Though	the	genetic	load	is	increased,	a	heightened	mutation	rate	can	be	crucial	to	adapting	rapidly	to	a	high	stress	environment	 such	as	within	a	host.	Transient	hypermutable	 states	
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can	 result	 from	 DNA	 mismatch	 repair	 deficiencies,	 recombination	 or	polymerase	 fidelity56.	The	process	of	clonal	 interference	occurs	when	multiple	advantageous	mutations	accumulate	in	a	population	and	when	recombination	is	absent	 result	 in	 competition	 and	 potential	 loss	 of	 beneficial	 mutations57.	Occurring	 on	 their	 own	 these	 mutations	 would	 not	 be	 lost.	 Homologous	recombination	 can	 mitigate	 phenomena	 such	 as	 clonal	 interference	 and	combine	 advantageous	 mutations	 in	 a	 lineage.	 How	 much	 homologous	recombination	 drives	 adaptation	 in	 bacterial	 lineages	 varies58,	 for	 example,	from	 low	 in	Bacillus	 cereus	populations59,60	 to	 high	 in	Neisseria	 gonorrhoaeae	populations61.																
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1.2. Pseudomonas	aeruginosa	Discovered	 in	 1882	 Pseudomonas	 aeruginosa	 is	 a	 Gram	 negative,	 motile,	 rod-shaped	bacterium	belonging	to	the	genus	Pseudomonas.	The	pseudomonads	can	be	found	in	soil	or	marine	environments	or	associated	with	plants	and	animals.	
P.	aeruginosa	 is	of	particular	interest	due	to	its	status	as	a	major	opportunistic	pathogen	of	humans	and	other	animals.	In	humans	P.	aeruginosa	is	involved	in	a	variety	of	infections	including	burn	and	wound	infections62,	infection	of	cancer	patients	 or	 immunosuppressed	 patients63,	 eye	 infections64	 and	 chronic	 lung	infections	 of	 CF65–68	 and	 non-CF	 bronchiectasis	 patients69.	 Worldwide	 P.	
aeruginosa	 is	 a	 major	 nosocomial	 pathogen	 and	 in	 2017	 was	 placed	 in	 the	highest	priority	category	(critical)	by	the	World	Health	Organisation	(WHO)	of	bacteria	 for	which	 new	 antibiotics	 are	 urgently	 needed.	 The	 versatility	 of	 the	species	 has	 been	 attributed	 to	 its	 ability	 to	 thrive	 such	 a	 variety	 of	environmental	and	host	niches70.				
1.2.1. The	Pseudomonas	aeruginosa	genome	In	 2000	 P.	 aeruginosa	 PAO1,	 an	 isolate	 that	 was	 originally	 sampled	 from	 a	wound	and	that	became	a	well-studied	reference	 laboratory	strain,	was	whole	genome	 sequenced71.	 At	 the	 time	 it	 also	 represented	 the	 largest	 bacterial	genome	to	be	sequenced	at	6.3	million	base	pairs	(Mbp).	The	genome	sequence	revealed	a	GC	content	of	66.6%	and	5,570	open	reading	frames	(ORFs),	of	which	approximately	 8%	 were	 predicted	 to	 encode	 transcriptional	 regulators	 and	two-component	 systems71.	 Subsequently,	 PA14,	 a	 similarly	 well-studied	 P.	
aeruginosa	 strain	 was	 sequenced	 revealing	 a	 larger	 genome	 of	 6.5Mbp	 and	 a	larger	proportion	of	 genes	 (~12%)	 involved	 in	 regulation.	P.	aeruginosa	has	a	
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larger	genome	and	number	of	genes	than	other	common	nosocomial	pathogens	such	 as	 E.	 coli	 and	 S.	 areus	 that	 carry	 an	 average	 of	 4,721	 and	 3,118	 genes	respectively72.			In	order	 to	assess	 the	P.	aeruginosa	population	structure	using	whole	genome	sequencing,	 Stewart	 et	 al,73	 approximated	 the	 phylogeny	 of	 55	 P.	 aeruginosa	genomes	 and	 determined	 that	 there	 were	 three	 distinct	 groups	 containing	PAO1,	PA14	and	 taxonomic	outlier	PA7	respectively74.	Group	1	was	by	 far	 the	largest	 and	 contains	 strains	 PAO1,	 LESB58,	 DK2	 and	 PAK,	 while	 group	 2	contains	 PA14.	 Group	 3	was	 the	 smallest	 containing	 only	 PA7	 and	 one	 other	genome	at	the	time73.	With	a	greater	number	of	genomes	sequenced	a	minority	do	 not	 fit	 clearly	 into	 these	 three	 phylogenetic	 groupings,	 though	 not	 all	 are	PA7-like	 phylogenetic	 outliers75.	 It	 remains	 that	 the	majority	 place	within	 the	three	major	phylogenetic	groups	and	that	they	are	distributed	with	the	largest	number	in	group	1,	2	and	then	a	minority	in	375,76.			A	study	of	200	P.	aeruginosa	genomes	revealed	16,000	non	redundant	genes	in	the	pangenome,	15%	of	which	comprised	the	core	genome77.	On	average	40%	of	a	 P.	 aeruginosa	 genome	 is	 constant,	 with	 the	 remaining	 60%	 of	 genes	 per	genome	being	variable	to	different	extents77.	Genes	associated	with	metabolism	and	 respiration	 are	 core	 in	 the	P.	 aeruginosa	 pangenome,	 but	 also	 frequently	present	 are	 antibiotic	 resistance-associated	 genes	 including	 multidrug	 efflux	pumps,	 secretion	 systems,	 ABC	 transporters	 and	 two-component	 systems77.	This	 confirmed	 previous	 conclusions	 from	 smaller	 pangenome	 studies	 of	 P.	
aeruginosa78,79.	 In	 the	 accessory	 genome	 type	 I	 and	 IV	 secretion	 systems	
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associated	with	 the	export	of	 toxins,	proteases,	 lipases	and	other	effectors	are	present,	 in	 addition	 to	 a	 wide	 range	 of	 antibiotic	 resistance	 genes,	 including	genes	 that	 encode	 products	 that	 confer	 resistance	 to	 vancomycin77.	 The	complete	 gene	 repertoire	 confirms	 the	 view	 that	P.	 aeruginosa	 carries	 a	 high	level	 of	 versatility	 in	 a	 range	 of	 niches,	 intrinsic	 resistance	 to	 common	 anti-pseudomonad	 therapies,	 complex	 gene	 regulation	 further	 enhancing	 its	versatility,	 a	 variety	 of	 secretion	 systems	 and	 an	 ability	 to	 acquire	 genes,	including	antibiotic	resistance	genes.			In	 2017	 the	 Pseudomonas	 Database	 listed	 1,636	 P.	 aeruginosa	 and	 2,560	pseudomonad	genomes	sequenced	overall80.			
1.2.2. Complex	gene	regulation	of	Pseudomonas	aeruginosa	In	addition	to	the	diverse	pangenome	of	P.	aeruginosa,	gene	regulation	expands	the	potential	adaptability	on	a	transcriptional,	translational	and	protein	level.	P.	
aeruginosa	has	a	large	number	of	genes	overall	for	a	bacterium	and	among	the	highest	 coding	 density	 of	 regulatory	 genes71,81;	 comprised	 mainly	 of	 sigma	factors,	 two	component	 systems	and	small	RNA	(sRNA).	 Individual	genes	may	be	 regulated	 by	 multiple	 regulators,	 further	 complicating	 interconnected	networks	 and	 the	 potential	 for	 interpreting	 the	 outcome	 of	 mutations	accumulated	in	these	genes	and	inference	of	their	adaptive	potential82.			Sigma	 factors	are	 involved	 in	a	 range	of	 core	processes	 in	P.	aeruginosa,	 from	RpoD	involved	in	house-keeping	and	RpoS	involved	in	the	stationary	phase	and	stress83,	 to	 AlgU	 involved	 in	 mucoidy.	 The	mucA	 gene	 encodes	 an	 anti-sigma	
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factor	that	regulates	alginate	biosynthesis	and	may	drastically	alter	the	lifestyle	of	a	P.	aeruginosa	and	its	capabilities	as	a	pathogen.	Some	major	P.	aeruginosa	sigma	factors	are	summarised	in	table	1.2.			Table	1.2.	Major	P.	aeruginosa	sigma	factors	and	anti-sigma	factors	
Sigma	
factor	
Gene	
name	
Description	 Anti	sigma	factor	
RpoH	 rpoH	 Heat	shock	response	 Na	
RpoS	 rpoS	 Biofilm,	quorum	sensing	and		 Na	antibiotic	resistance	 Na	
RpoD	 rpoD	 Housekeeping	 Na	
RNA	pol	 rpoN	 Quorum	sensing	 Na	
AlgU	 algU	 Alingate	biosynthesis,	mucoidy	 MucA	
FliA	 fliA	 Flagella	biosynthesis	 FlgM	
PvdS	 pvdS	 Pyoverdine	 FpvR	
FiuL	 fiuL	 Ferrichrome	production	 FiuR			Two	 component	 response	 systems	 are	 the	 primary	means	 by	 which	 bacteria	sense	their	environment,	allowing	bacteria	when	stimulated	to	transcriptionally	regulate	gene	expression	in	response	to	the	environment.	In	P.	aeruginosa	PAO1	there	are	64	response	regulators	and	63	histidine	kinases84	with	which	to	sense	its	environment	and	respond	with	 transcriptional	activation.	Histidine	kinases	have	variable	detection	and	input	domains	and	as	such	can	respond	to	a	range	of	 environmental	 stimuli	 such	 as	 nutrient,	 phosphate	 and	 oxygen	 availability,	antimicrobial	peptides	and	osmolarity85,86.			Small	RNAs	regulate	gene	expression	at	the	level	of	translation,	binding	mRNA	and	resulting	in	repression	or	activation87.	Transcriptional	regulation	by	sRNAs	may	affect	genes	associated	with	iron	and	cell	envelope	homeostasis,	virulence	
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and	 metabolism88.	 In	 P.	 aeruginosa	 44	 sRNAs	 have	 been	 discovered89	 and	 in	PAO1	RNA	sequencing	(RNA-seq)	determined	a	further	500	intergenic	sRNAs90.			GacAS	 serves	 as	 an	 example	 of	 the	 further	 complexity	 and	 versatility	 made	possible	by	the	regulatory	networks	of	P.	aeruginosa.	GacAS	is	a	two	component	system	associated	with	 secondary	metabolites,	 biofilm	 formation	 and	quorum	sensing91,92,	which	might	themselves	re-model	gene	expression.	GacS	contains	a	histidine	 kinase	 domain,	 response	 regulator	 and	 phosphotransfer	 domain93,94	and	 is	 controlled	 by	 phosphorylation	 by	 GacA	 or	 LadS94	 and	 prevention	 of	phosphorylation	 by	 RetS95,96.	 In	 turn	 phosphorylated	 GacA	 activates	transcription	of	small	RNAs	RsmZ	and	RsmY.	Activated	RsmZ	and	RsmY	block	the	 negative	 regulator	 of	 RsmA	 that	 can	 then	 positively	 regulate	 a	 variety	 of	features	including	antibiotic	resistance,	quorum	sensing,	type	3	secretion,	other	transcription	factors	and	iron	homeostasis97–100.			
1.2.3. Cell	to	cell	Signaling	Cell	 to	cell	signaling,	or	Quorum	Sensing	(QS)	was	discovered	in	Vibrio	fischeri	which	 utilises	 the	 luxI-luxR	 system.	 In	 the	 luxI-luxR	 system	 luxI	 encodes	 the	acylhomoserine	 lactone	 (AHL)	signal	N-(3-oxohexanoyl)-L-homoserine	 lactone	(OHHL)	 and	 luxR	 encodes	 an	 AHL	 dependent	 transcription	 factor101–103.	 In	 P.	
aeruginosa	LuxR	homolog,	LasR	was	discovered	and	subsequently	shown	to	be	a	key	regulator	of	lasB,	lasA,	toxA	and	aprA	in	addition	to	being	a	potential	global	regulator	 of	 virulence	 factors104.	 The	 LuxI	 homolog,	 LasI105	 (the	P.	aeruginosa	autoinducer	 (PAI))	 was	 determined	 as	 N-(3-oxododecanoyl)-homoserine	lactone	(OdDHL)105.		
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	A	 second	 P.	 aeruginosa	 autoinducer,	 N-butyrylhomoserine	 lactone	 (BHL)	 was	discovered106	and	its	cognate	receptor	RhlR	subsequently	discovered107.	RhlR	is	encoded	 by	 the	 rhlABR	 gene	 cluster	 with	 BHL	 encoding	 rhlI	 downstream107.	Autoinducers	OdHL	and	BHL	activate	and	form	complexes	with	LasR	and	RhlR	and	these	complexes	bind	with	las-rhl	boxes	in	the	promoters	of	target	genes	to	start	 their	expression.	The	response	 to	 the	respective	complexes	varies	across	genes	affected	that	overall	comprise	~10%	of	the	P.	aeruginosa	genome.		The	third	QS	system	of	P.	aeruginosa	was	discovered	to	be	structurally	distinct	from	 the	 AHL	 systems	 of	 las	 and	 rhl108.	 The	 2-heptyl-3-hydroxy-4-quinolone	molecule	 represents	 the	 first	 4-quinolone	 bacterial	 signaling	 molecule	determined,	 encoded	 by	 pqsABCD,	 phnAB	 and	 pqsH109.	 The	 genes	 pqsABCD	encode	PQS	biosynthesis,	producing	a	precursor	2-heptyl-4-quinolone	(HHQ)109.	Finally,	PQS	biosynthesis	HHQ	is	converted	to	PQS	by	PqsH,	which	is	controlled	by	 LasR110.	 The	 cognate	 receptor	 of	 PQS	 signaling	 is	 PqsR,	 a	 LysR-type	transcriptional	 regulator	 that	 binds	 to	 the	 promoter	 region	 of	 the	 pqsABCDE	operon109,111.		A	 fourth	 system,	 the	 integrated	quorum	 sensing	 (IQS)	 system	 is	 comprised	of	non-ribosomal	 peptide	 synthases	 (NRPS’s).	 The	 iqs	 system	 is	 encoded	 by	 the	gene	 cluster	 ambBCDE	 and	 has	 structurally	 been	 established	 as	 2-(2-hydroxyphenyl)-thiazole-4-carbaledhyde112.	 The	 iqs	 system	 is	 capable	 of	compensating	for	a	non-functional	las	system	and	when	disrupted	a	decrease	in	
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PQS	 and	 BHL	 systems	 is	 observed	 as	 well	 as	 a	 decrease	 in	 virulence	 factors	expressed.			The	 role	 of	 the	 respective	 signaling	 systems	 is	 complex,	 involving	transcriptional	regulation	of	many	genes	in	P.	aeruginosa.	The	manner	in	which	the	four	systems	are	also	interconnected	further	complicates	comprehension	of	these	circuits112.	The	P.	aeruginosa	QS	system	however	is	known	to	be	involved	in	 regulation	 of	 virulence113,	 phosphate	 deprivation	 stress114,115,	 iron	acquisition116,	 oxygen	 deprivation117,	 nutrient	 deprivation117	 and	 response	 to	host	 factors118.	 Quorum	 sensing	 is	 an	 integral	 component	 of	 P.	 aeruginosa’s	ability	to	infect	host	plants,	protists	and	animals119.	
	
1.2.4. Metabolic	capabilities	
P.	 aeruginosa	 is	 metabolically	 versatile	 owing	 much	 of	 its	 ability	 to	 thrive	 in	diverse	niches	and	 its	subsequent	success	as	an	opportunistic	pathogen	 in	 the	ability	to	make	use	of	varied	carbon	and	nitrogen	sources78.	P.	aeruginosa	is	able	to	catabolise	amino	acids,	polyamines,	 carboxylic	acids,	 short-chain	 fatty	acids	and	 complex	 xenobiotics	 such	 as	 halogenated	 n-alkanes	 and	 aromatic	compounds	 even	 as	 sole	 carbon	 sources120,121.	 It	 is	 also	 possible	 for	 P.	
aeruginosa	 to	 grow	 aerobically	 or	 anaerobically	 making	 use	 of	 nitrate	 as	 an	electron	 acceptor	 through	 dentrification	 or	 by	 use	 of	 arginine	 and	 pyruvate	through	fermentation78.	Whole	genome	metabolic	reconstruction,	modeling	and	transposon	mutagenesis	of	PA14	and	PAO1	further	shows	the	interconnectivity	between	metabolic	pathways	and	virulence	factors122.	The	metabolic	model	for	
28	
PAO1	 (iPae1146)	 reveals	 1,146	 genes,	 1,493	 reactions	 and	 1,284	metabolites	while	 that	of	PA14	(iPae1129)	reveals	1,129	genes,	1,495	reactions	and	1,286	metabolites122.	 In	 these	models	 112	 and	 108	metabolic	 genes	 were	 linked	 to	virulence	functions	in	PAO1	and	PA14	respectively122.			Pseudomonads	 produce	 a	 number	 of	 secondary	 metabolites123	 involved	 in	 a	variety	 of	 functions.	 P.	 aeruginosa	 produces	 secondary	 metabolites	 with	antibiotic	 functions124,	 hydrogen	 cyanide117,	 those	 involved	 with	 iron	acquisition125	 and	 phenazines126.	 The	 P.	 aeruginosa	 phenazine	 pyocyanin	 has	been	implicated	in	virulence	in	a	variety	of	models	and	during	CF	lung	infection	and	ear	infection,	otitis	externa127,128.	Pyocyanin	deficiency	has	been	associated	with	 suppressed	 virulence	 in	 mouse	 models	 of	 acute	 pneumonia	 and	burns111,129,	 Drosophila	 melanogaster130,	 plant	 infection	 of	 Arabidopsis	
thaliana91,131	and	nematode	Caenorhabditis	elegans132.		
	
1.2.5. Uptake	of	Iron	The	abundance	of	the	element	iron	and	its	ability	to	exist	in	two	states	Fe2+	and	Fe3+	 make	 it	 useful	 in	 numerous	 oxidation	 and	 reduction	 reactions	 in	bacteria133.	Within	a	host	setting,	such	as	during	lung	infections	the	availability	of	 iron	 is	 reduced	 compared	 with	 the	 environmental	 niches	 from	 which	 P.	
aeruginosa	 is	 thought	 to	have	been	acquired	 typically.	As	 such	 the	ability	of	 a	bacterial	 population	 ability	 to	 scavenge	 iron	 is	 crucial	 to	 its	 survival	 and	pathogenicity.	Broadly	P.	aeruginosa	may	import	iron	by	production	of	chelating	molecules	 (siderophores)	 that	 scavenge	 Fe3+,	 the	 import	 of	 xenosiderophores	
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not	produced	by	P.	aeruginosa,	import	of	host	heme	molecules	and	extracellular	reduction	of	Fe3+	and	subsequent	import	of	Fe2+.			
P.	 aeruginosa	 produces	 two	 main	 chelating	 siderophores	 low	 affinity	pyochelin82,134	 and	 high	 affinity	 pyoverdine,	 that	P.	 aeruginosa	 is	 observed	 to	switch	to	 in	 low-iron	environments135.	Pyoverdine	production	 is	characteristic	of	 the	 fluorescent	Pseudomonas	species,	P.	aeruginosa,	P.	 flourescens,	P.	putida,	and	 P.	 syringae.	 Types	 of	 pyoverdine	 in	 P.	 aeruginosa	 (I,	 II	 and	 III)	 and	corresponding	receptors	have	been	identified,	from	which	typing	schemes	have	been	developed136,137.	Pyoverdine	is	comprised	of	a	chromophore	and	a	peptide	chain	 that	may	 be	 variable	 generating	 the	 different	 pyoverdine	 types125,136.	P.	
aeruginosa	possesses	TonB-dependent	receptors	and	transducers	such	as	FpvA	which	 allow	 the	 import	 of	 ferrisiderophores138.	 In	 contrast,	 the	 Has	 and	 Phu	systems	in	P.	aeruginosa	enable	heme	import	from	hemoproteins139.		
1.2.6. Secretion	systems	
P.	 aeruginosa	 secretion	 systems	 are	 essential	 to	 exploiting	 a	 variety	 of	environments.	There	are	numerous	bacterial	secretion	systems	(T1SS-T3SS	and	T5SS-T6SS)	 that	 conduct	 extracellular	 release	 of	 proteins	 and	 direct	 injection	into	host	eukaryotic	cells.	P.	aeruginosa	lacks	T4SS’s	but	is	otherwise	considered	a	model	organism	for	their	study140.			T1SS	are	simple	trimeric	structures141	that	secrete	molecules	such	as	AprA	and	HasAp,	 involved	 in	 collagen	degradation	and	 iron	acquisition	 respectively	 and	AprX	which	 is	 of	 unknown	 function141,142.	 T2SS,	 unlike	 T1SS,	 are	 also	 able	 to	
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allow	folded	proteins	to	pass142.	T2SS	secrete	multiple	proteins	such	as	lipases	LipA,	 LipC,	 PlcH	 and	PhlN143,	 exotoxin	A	 (ToxA)	 and	 elastase	 (LasB)144.	While	T1SS	 and	 T2SS	 function	 by	 extracellular	 secretion	 of	 proteins	 T3SS	 inject	proteins	 directly	 into	 cells.	 The	 ‘needle’	 structure	 that	 constitutes	 the	 T3SS	 is	facilitates	 effector	 secretion	 of	 exotoxins	 ExoS,	 ExoT,	 ExoU	 and	 ExoY145.	 P.	
aeruginosa	isolates	usually	contain	either	ExoS	or	ExoU	paired	with	ExoT146.		
	
1.2.7. Biofilm	Lifestyle	Biofilms	 are	 extracellular	 polymeric	 substances	 within	 which	 bacterial	communities	 can	 live147,148,	 largely	 composed	 of	 exopolysaccarides	 and	extracellular	 DNA149.	 Biofilms	 develop	 through	 a	 process	 of	 adherence,	microcolony	 formation,	maturation	 and	 then	dispersal,	 dependent	 on	 quorum	sensing150,151.	P.	aeruginosa	biofilms	utilise	the	Pel	system,	encoded	by	six	genes	in	 the	 pelABCDEF	 operon	 or	 Psl	 systems,	 encoded	 by	 15	 genes	 in	 the	
pslABCDEFGHIJKL152	system.	Psl	biofilms	are	rich	in	galactose	and	mannose153.	A	major	benefit	of	 the	biofilm	rather	 than	planktonic	 lifestyle	 is	protection	 from	immune	 defences	 and	 antibiotics154–157.	 This	 is	 not	 only	 due	 to	 slowed	progression	 through	 the	 biofilm’s	 extracellular	 matrix	 but	 also	 due	 to	 the	varying	metabolic	activities	within	the	biofilm,	such	as	dormancy158,159.	Alginate	overproduction	 in	P.	 aeruginosa	 can	 be	 observed	 in	 comparison	with	 smooth	colonies160;	 mucoid	 colonies	 may	 overexpress	 alginate	 as	 much	 as	 6x	 that	 of	smooth	 colonies161.	 Alginate	 can	 provide	 protection	 from	 phagocytosis	 and	antibiotics	and	 is	a	 free	radical	scavenger162,163.	Though	not	crucial	 for	biofilm	formation164,165	 it	 represents	a	major	component	of	 it164.	Disruptive	mutations	
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in	the	gene	mucA	that	encodes	anti-sigma	factor	gene	MucA	results	 in	alginate	overexpression	due	to	lack	of	negative	regulation	of	alginate	biosynthesis166.			
1.2.8. Antibiotic	Resistance	Core	to	the	P.	aeruginosa	species	are	intrinsic	antibiotic	resistance	mechanisms	such	 as	 efflux	 pumps	 and	 less	 directly,	 the	 biofilm	 lifestyle167.	 MexAB-OprM,	MexCD-OprJ,	MexEF-OprN	 and	MexXY	 resistance	nodule	 division	 (RND)	 efflux	pumps	 present	 in	 P.	 aerguinosa	 can	 confer	 resistance	 to	 aminoglycosides,	novobicin,	 β-lactams,	 tetracycline,	 chloramphenicol,	 cephalosporins,	fluoroquinolones,	macrolides,	 tigecycline	and	trimethoprim168–171.	These	major	RND	 efflux	 pumps	 in	 P.	 aeruginosa	 are	 encoded	 by	 operons	 in	 the	 core	genome78.	 In	 addition	 to	 intrinsic	 resistance	 its	 possible	 for	 P.	 aeruginosa	 to	acquire	resistance	to	almost	all	antibiotics	available172,173.														
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1.3. Cystic	Fibrosis	Cystic	 Fibrosis	 (CF)	 results	 from	 disruption	 in	 the	 cystic	 fibrosis	transmembrane	 conductance	 regulator	 (CFTR).	 There	 are	 multiple	 different	autosomal	 recessive	 mutations	 that	 result	 in	 the	 disruption	 of	 CFTR,	 which	normally	functions	to	regulate	ion	transport	across	epithelial	surfaces174,175.	The	most	common	causative	mutation	of	CF	is	deltaF508	CFTR176,177,	a	mutation	that	results	 in	 an	 absence	 of	 CFTR	 in	 epithelial	 cells	 due	 to	 post-translation	degradation176,177.	 CFTR	disruption	 results	 in	 a	 dehydration	 and	 thickening	 of	mucosa	 in	 the	 lungs	and	digestive	 tract	and	susceptibility	 to	 lung	 infections178	resulting	 in	 pulmonary	 exacerbations176,	 the	 need	 for	 aggressive	 antibiotic	treatment	regimes177,	progressive	lung	disease176,179	and	premature	death179.			Increasingly	 the	 picture	 of	 CF	 lung	 infection	 is	 one	 of	 complex,	 polymicrobial	infections180,	 comprised	 of	 a	 mixture	 of	 aerobic	 and	 anaerobic	 infections181.	Adult	 sputum	 samples,	 assessed	 by	 16S	 rRNA	 analysis,	 reveal	 core	 genera	present	 in	 the	 CF	 lung,	 Streptoccocus,	 Pseudomonas,	 Prevotella	 Veillonella,	
Neisseria,	 Porphorymonas	 and	 Canontella	 in	 abundance182.	 Organisms	 such	 as	the	 Streptoccous	 milleri	 group	 spp,	 Trichosporon	 spp,	 nontuberculosis	Mycobacterium	 and	 rhinovirus	 are	 emerging	 as	 pathogens,	 while	
Stenotrophomonous	maltophilia,	Achromobacter	spp,	Ralstonia	spp,	Burkholderia	
gladioli	 and	 Streptococcus	 pneumoniae,	widely	 believed	 to	 be	 pathogenic,	 are	having	 that	 status	 questioned182.	 It	 remains	 however	 that	 Haemophilus	
influenzae,	 Staphylococcus	 aureus	and	 above	 all,	P.	 aeruginosa	 predominate	 in	adult	CF	lung	infections68,183,184.		
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1.3.1. Pseudomonas	aeruginosa	Lung	Infections	in	Cystic	
Fibrosis	
P.	aeruginosa	is	the	leading	cause	of	overall	morbidity	and	mortality	in	adult	CF	patients	 as	 a	 result	 of	 progressive	 lung	 damage	 and	 chronic	 infection185.	Patients	 as	 young	 as	 three	 years	 old	 can	 show	 signs	 of	 previous	 lung	infection186,	 typically	 followed	 by	 intermittent	 infections	 during	 adolescence	and	 finally	 a	 chronic	 P.	 aeruginosa	 infection187.	 The	 risk	 of	 morbidity	 is	increased	 once	 the	 lungs	 are	 colonised	 with	 P.	 aeruginosa188	 and	 chronic	infection	 will	 result	 in	 progressive	 lung	 disease	 and	 ultimately	 premature	death189.	 By	 age	 20	 approximately	 80%	 of	 adult	 CF	 patients	 are	 chronically	infected	with	P.	aeruginosa190,191	and	the	8	year	risk	of	death	is	2.6x	higher	than	uninfected	CF	patients	as	a	result68.			Though	 in	 1996	 it	 was	 discovered	 that	 select	 lineages	 of	 P.	 aeruginosa	 were	capable	 of	 cross	 infecting	 patients192,	 it	 remains	 that	 the	majority	 of	 patients	harbour	unique	lineages.	In	Canada	P.	aeruginosa	infected	CF	patients	sampled	presented	a	total	of	157	genetic	types	(RAPD	and	PFGE	typing)	of	P.	aeruginosa,	123	of	which	were	unique	to	individual	patients193.	This	is	the	typical	picture	of	
P.	 aeruginosa	 acquisition	 though	 in	 some	 clinics	 transmissible	 strains	 can	predominate.	Where	there	is	no	cross	infection	or	common	source	of	infection	a	genotype	can	be	observed	at	a	higher	frequency	where	it	represents	a	common	environmental	 lineage	 such	 as	 clone	 C194.	 There	 is	 no	 known	 bias	 towards	 a	particular	environmental	 ‘type’,	or	phylogenetic	group	and	the	unique	lineages	infecting	 largely	 reflect	 the	 general	 diversity	 of	 environmentally	 sampled	 P.	
aeruginosa195.		
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Antibiotic	resistance	in	P.	aeruginosa	CF	lung	infections	is	a	major	problem	and	as	 such	 samples	 are	 routinely	 tested	 for	 resistance	 and	 susceptibility.	 CF	patients	 are	 treated	 with	 broad	 spectrum	 antibiotics,	 Ceftazidime172,	Meropenem196,	 Piperacillin/Tazobactam	 and	 Ciprofloxacin197.	 CF	 patients	 are	also	 treated	 with	 Tobramycin198	 that	 acts	 on	 Gram	 negatives	 and	 Colistin,	 a	polymyxin199.			
1.3.2. Transmissible	Strains		Most	often	CF	patients	acquire	an	infecting	P.	aeruginosa	from	the	environment,	patients	 harbour	 unique	 strains	 of	 which	 their	 source	 is	 unknown.	 Multiple	patients	 have	 been	 identified	 to	 be	 infected	 by	 the	 clone	 C	 strain,	 but	 is	 also	highly	 abundant	 in	 a	 variety	 of	 environments	 sampled,	 for	 example200.	 It	was	first	 suggested	 that	 cross	 infection	may	 be	 occurring	 in	 the	 1980’s	 in	 Danish	patients201	and	had	previously	been	indicated	that	siblings	share	strains202–204.	Additionally,	 there	 was	 a	 precedent	 for	 cross	 infection	 in	 CF	 clinics	 with	 the	
Burkholderia	cenocepacia	ET12	clone	outbreaks205.	Figure	1.1	shows	a	timeline	of	milestones	into	transmissible	CF	pathogen	research.		In	 1996	 PFGE	 and	 flagellin	 typing	 of	 P.	 aeruginosa	 samples	 suspected	 due	 to	antibiogram	profiles	between	pediatric	patients	attending	Alder	Hey	Children’s	Hospital	 in	Liverpool	provided	the	first	molecular	evidence	for	a	transmissible	strain	 of	P.	aeruginosa	 in	CF,	The	Liverpool	Epidemic	 Strain	 (LES)192.	 Further,	the	LES	was	discovered	 to	be	 the	 single	most	 common	strain	of	P.	aeruginosa	infecting	CF	patients	across	31	centres	 in	England	and	Wales206	and	was	 later	discovered	in	samples	from	multiple	centres	in	Canada207.		
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	Figure	1.1.	A	timeline	of	events	in	research	into	transmissible	strains	of	P.	aeruginosa	and	the	emergence	of	transmissible	B.	cenocepacia	ET12.	Adapted	from	Fothergill	et	
al.208		Following	 the	 discovery	 of	 the	 transmissible	 P.	 aeruginosa,	 the	 LES	 and	 its	association	with	poorer	prognosis	than	other	chronic	P.	aeruginosa	infections209	and	antibiotic	 resistance210,	other	 independently	evolved	 transmissible	strains	were	 discovered	 in	 various	 countries’	 CF	 clinics.	 In	 the	 UK	 the	 Manchester	Epidemic	 Strain	 (MES)	 and	 Midlands	 (Mid1)	 stains	 were	 discovered	 211,	 in	Denmark	 the	 transmissible	DK2,	 in	Australia	AES-1,	AES-2	 and	AES-3191,212,213	and	in	Canada,	Canadian	Epidemic	Strain	B214	and	the	Prairie	Epidemic	Strain215	and	 in	 the	Netherlands,	 the	Dutch	Epidemic	 Strain216.	 In	2016	Mansfeld	et	al.,	genomically	 and	 phenotypically	 assessed	 the	 Dutch	 Epidemic	 Strain	 (ST-406)	within	patient	diversity,	a	strain	 that	chronically	 infects	15%	of	CF	patients	 in	the	Netherlands216.	 SNPs	were	 identified	 in	 regulator	 genes	mexT,	exsA,	mexE,	
mexF	 and	 the	 T3SS	 and	 T6SS,	 similar	 to	 adaptative	 genes	 in	 chronic	 CF	strains216.	Importantly,	apart	from	the	Danish	and	Manchester	epidemic	strains	which	share	a	common	ancestry216,	genotyping	and	later	core	gene	and	genome	phylogenetics	 confirm	 that	 the	 emergence	 of	 transmissibility	 has	 occurred	independently	 in	 CF	 clinics	 internationally73,75,76,212,214,217.	 Though	 epidemic	
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strains	carry	genomic	and	phenotypic	markers	of	chronic	adaptation	to	the	CF	lung	there	is	as	yet	no	shared	feature	indicative	of	acquired	transmissibility.			In	 response	 to	 the	 discovery	 of	 strains	 capable	 of	 cross	 infection	 diagnostics	have	been	developed	 to	 identify	known	 transmissible	 strains	 in	 the	clinic.	For	the	LES	suppression	subtractive	hybridization	(SSH)	was	used	initially206,218–220	followed	 by	 similar	 diagnostics	 for	 the	MES,	Mid1	 and	AES-1	 strains221–223.	 In	the	 Liverpool	 CF	 clinics	 the	UK	 isolates	 are	 routinely	 typed	 by	multiplex	 PCR	tests	designed	to	identify	the	MES,	Mid1	and	LES224.	In	response	to	knowledge	of	 transmissible	strains	centres	have	 instituted	segregation	policies	to	prevent	cross	 infection	 between	 CF	 patients.	 In	 Liverpool	 segregation	 policies	 have	resulted	in	a	sharp	decrease	of	LES	positive	samples	in	the	adult	and	children’s	CF	unit65.	In	Australia	segregation	of	AES-1	positive	patients	yielded	a	decrease	of	patients	observed	to	harbour	the	strain	of	one	third225,226.		
	
	
1.3.3. Virulence	during	Pseudomonas	aeruginosa	infections	Many	 of	 the	 features	 that	 are	 characteristic	 of	 P.	 aeruginosa	 are	 potentially	implicated	 in	 virulence	 during	 CF	 lung	 infections.	 These	 include	 the	 T3SS,	flagella,	LPS	and	secreted	factors	that	result	in	inflammation	and	lung	damage.	These	 features	 and	 its	 regulatory	 plasticity	 determine	 its	 ability	 to	 survive	within-host	 stresses	 such	 as	 iron,	 oxygen	 and	 nitrogen	 availability,	 heat	 and	osmolarity.	In	particular,	the	QS	systems	of	P.	aeruginosa	regulate	up	to	10%	of	the	genome94,	including	many	virulence	determinants	with	potential	roles	in	the	pathogenicity	associated	with	CF227.	
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Features	of	acute	 infections	 in	P.	aeruginosa,	 fimbriae85,228,	 type	 IV	pili229	 	 and	LPS230	 are	 involved	 in	 establishment	 of	 CF	 lung	 infections.	 Fimbriae	 are	 a	 pili	type	 that	 utilise	 the	 chaperone/usher/pathway	 (Cup)228	 of	which	 three	 types	have	been	identified	in	P.	aeruginosa	(Cup	A,	B,	C)85,228.	Cup	attachment	factors	are	 essential	 for	 attachment	 to	 surfaces	 for	 subsequent	 biofilm	 formation228.	Type	IV	pili	are	the	primary	adhesin	responsible	 for	epithelial	cell	adhesion229	and	 there’s	 further	 interaction	 observed	 in	 vitro	 with	 the	 glycosylated	 cell	surface	 regions	 GM1	 and	 GM2	 of	 lung	 epithelial	 cells228.	 The	 two-component	system	 pilS/pilR	 controls	 transcription	 of	 the	 type	 IV	 pili231.	 The	 LPS	 is	comprised	 of	 three	 parts:	 Lipid	 A	 responsible	 for	 immune	 response232,	 an	oligosaccharide	 core	 and	 a	 variable	 O	 antigen230.	 P.	 aeruginosa	 produces	 two	LPS	types,	A	and	B233.	Similarly	to	type	IV	pili	LPS	attaches	to	GM1234	but	also	CD14	and	MD2	TLR4’s235.			Following	establishment	of	 infection	in	the	CF	lungs,	P.	aeruginosa	has	a	range	of	 virulence	 factors	 at	 its	 disposal,	 including	 the	 soluble	 lectins	 LecA	 and	LecB236,237,	the	T3SS	and	its	exotoxins.	The	T3SS	of	P.	aeruginosa	enables	direct	injection	 of	 exotoxins	 ExoS,	 ExoU,	 ExoT	 and	 ExoY	 into	 host	 cells	 and	 further,	T3SS	 exhibits	 cytotoxicity	 in	 absence	 of	 these	 exotoxins145.	 ExoS	 has	 been	demonstrated	to	cause	pulmonary	damage	in	animal	models238.	In	the	presence	of	 a	 host	 cell	 cofactor239,	 ExoS	 causes	 cytoskeleton	 disruption	 in	 the	 target	cell240.	ExoS	also	interacts	with	immune	cells	directly	by	binding	TLR4	and	TLR2	domains241	and	indirectly	resulting	in	T-cell	activation242	and	apoptosis243.	ExoS	likely	 contributes	 to	 the	damaging	 inflammation	observed	 in	 the	CF	 lung	 as	 a	result	 of	P.	 aeruginosa	 infection	 by	 activation	 of	 a	 pro-inflammatory	 cytokine	
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response241.	 Cytotoxin	 ExoS	 differs	 from	 ExoT,	 though	 similar	 in	 structure,	 in	the	pathways	it	targets	and	overall	reduced	potency244.	ExoU	is	the	most	potent	cyotoxin	 produced	 by	P.	aeruginosa245	 through	 the	 ability	 to	 disrupt	 host	 cell	membranes.	Soluble	lectins	LecA	(PA-IL)	and	LecB	(PA-IIL)	are	virulence	factors	secreted	 by	 P.	 aeruginosa246.	 Both	 have	 been	 observed	 to	 be	 causative	 of	pulmonary	lesions	and	an	increase	in	in	alveolar	permeability237.			Many	 features	 of	 P.	 aeruginosa	 during	 infection	 are	 dependent	 upon	 the	 QS	system.	 P.	 aeruginosa	 QS-regulated	 virulence	 factors	 include	 secondary	metabolites	 pyocyanin247	 and	 pyoverdine125,	 elastases215,	 proteases,	 exotoxins	and	lectins.	Exotoxin	A,	the	most	toxic	P.	aeruginosa	exotoxin	to	mice248	and	is	capable	 of	 targeted	 host	 cell	 necrosis	 similar	 to	 diphtheria	 toxin249–252.	 The	secreted	phenazine	pyocyanin	 is	 a	blue	pigment	with	a	number	of	pathogenic	properties126,129.	 Pyocyanin	 oxidises	 glutathione	 increasing	 oxidative	 and	necrotic	 stress	 in	 epithelial	 cells253.	 Pyocyanin	 has	 also	 been	 observed	 to	inactivate	ATPase	resulting	in	further	chloride	channel	dysfunction	in	CF126,129.	The	 immune	 response	 is	 also	 suppressed	 by	 pyocyanin	 by	 the	 induction	 of	neutrophil	apoptosis254,	resulting	 in	 increase	IL-8	production240.	Many	 isolates	of	 the	 transmissible	 P.	 aeruginosa	 strain,	 the	 LES,	 are	 pyocyanin	overproducers255.	Elastase	is	a	zinc	metalloprotease	with	proteolytic	activity256,	also	known	as	LasB.	LasB	virulence	occurs	due	to	its	pro-inflammatory	effect	by	the	increase	of	IL-8144,257.	Additionally,	elastase	can	cleave	proteinase-activated	receptor	 2,	 reducing	 the	 host	 response258	 and	 targets	 cytokines	 such	 as	interferon	 gamma	 and	 tumor	 necrosis	 factor259.	 Pyoverdine	 is	 a	 major	 iron	chelating	siderophore	in	P.	aeruginosa	 that	 is	also	a	virulence	factor	during	CF	
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lung	 infections240.	Pyoverdine	has	a	major	 role	 in	 regulating	 its	own	secretion	and	 also	 the	 secretion	 of	 exotoxin	 A	 and	 proteases240,260–262.	 	 P.	 aeruginosa	proteases	 have	 a	 well	 understood	 virulence	 role	 during	 eye	 infections263	including	 keratitis264	 and	 are	 increasingly	 understood	 to	 have	 a	 role	 in	respiratory	pathogenicity.	The	T1SS	secretes	protease	virulence	factor,	alkaline	protease263	 .	 Alkaline	 protease	 degrades	 fibrin	 and	 has	 been	 implicate	 in	pneuomonia265.	 Protease	 IV	 virulence	 is	 due	 to	 its	 degradation	 of	 surfactant	proteins	A,	B	and	D266.	Rhamnolipids	produced	by	P.	aeruginosa	have	a	role	 in	motility	 similar	 to	 that	 of	 type	 IV	 and	 flagella267	 and	 are	 involed	 in	 biofilm	formation268.	Rhamnolipids	 are	 glycolipids	 secreted	by	P.	aeruginosa	 and	 they	impact	 virulence	 by	 their	 detergent	 qualities	 on	 lung	 surfactant	 facilitating	phospholipases269,	P.	aeruginosa	 invasion270,	 inhibition	 of	 phagocytosis271	 and	reduction	of	mucociliary	clearance272.			
1.3.4. Adaptation	to	the	cystic	fibrosis	lung	environment	The	study	of	evolving	P.	aeruginosa	populations	has	been	advanced	by	genome	sequencing,	 confirming	 prior	 knowledge	 of	 genetic	 changes	 associated	 with	chronicity	 and	 generating	 genetic	 datasets	 of	 genes	 and	 alleles	 inferred	 to	 be	adaptive	 with	 known	 and	 unknown	 functional	 roles35,77,273,274.	 Diverse	environmental	 lineages	 of	 P.	 aeruginosa	 infect	 CF	 patients	 resulting	 in	considerable	phenotypic	background	diversity	confounding	attempts	to	identify	features	 causative	 of	 varying	 clinical	 outcomes.	 Further,	 background	 genetic	variation	 confounds	 the	 determination	 of	 features	 associated	 with	 clinical	outcomes	such	as	persistence,	antibiotic	resistance,	pathogenicity	and	capacity	
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immune	evasion.	Understanding	how	P.	aeruginosa	adapts	to	the	lung	has	been	derived	 from	 sequential	 sampling	 of	 patients,	 inference	 of	 convergence	 and	experimental	evolution66.	Phenotypic	observations	over	the	course	of	infections	have	identified	trends	in	P.	aeruginosa	CF	lung	populations.	During	an	infection	many	 non-mucoid	 lineages	 will	 adopt	 the	 alginate	 over	 producing	 mucoid	phenotype	and	is	associated	particularly	with	chronic	infections166.	Further,	the	adoption	 of	 a	 biofilm	 lifestyle	 using	 the	 alginate,	 pel	 or	 psl	exopolysaccharides153,161,165,	 auxotrophy275,	 loss	 of	 motility276,	hypermutability277,	 antibiotic	 resistance167,187	 and	 a	 general	 reduction	 in	 the	expression	 of	P.	aeruginosa	 virulence	 factors66.	 QS	 systems	 and	 key	 virulence	feature,	 the	 T3SS	 have	 also	 been	 observed	 to	 become	 defective	 during	infections278.		Within	the	CF	lung	different	environmental	 lineages	may	coexist;	 lineages	that	are	 distinct	 by	 genotyping,	 phylogenetic	 placement	 or	 genetic	 distance,	representing	lineages	inferred	to	be	distinct	at	the	point	of	infection279.	Further,	genomic	 analysis	 demonstrates	 that	 lineages	 may	 diversify	 into	 sub-lineages	with	 distinct	 evolutionary	 trajectories280.	 It	 has	 been	 shown	 for	 example	 that	hypermutable	sub-lineages	that	emerge	can	coexist	with	normal	mutators279,281.	Whether	there	are	multiple	environmental	lineages	present	or	not,	the	study	of	a	 lineage	 or	 sub-lineage	 is	 itself	 obscured	 by	 the	 emergence	 significant	heterogeneity	within	populations279,282.	Understanding	this	complexity	also	has	practical	implications.	Studies	of	distinct	colonies	sampled	from	a	single	patient	such	as	within	those	identified	as	differentially	mucoid	or	non-mucoid	there	can	be	a	range	of	susceptible	and	resistant	isolates	to	antibiotics	tested283,284.		
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	Figure	1.2.	Genes	that	are	commonly	inferred	to	be	adapted	during	CF	lung	infection.	Genes	encoding	regulators	are	in	red	and	those	that	encode	sigma	factors	in	blue.	Adapted	from	Winstanley	et	al.	66			Genome	sequencing	 is	 increasingly	 revealing	 the	genetic	basis	of	 evolutionary	change	 during	 CF	 infections273,274,281,285–287,	 figure	 1.2	 from	 Winstanley	 et	 al.,	summarises	genes	across	multiple	studies	inferred	to	be	adaptive	to	the	CF	lung.	Some	genes	are	directly	 linked	 to	phenotypic	changes	such	as	 loss	of	 function	mutations	 in	 anti-sigma	 factor	 encoding	 mucA	 that	 normally	 negatively	regulates	 alingate	production166.	 The	 loss	 of	MucA	 function	 results	 in	 alginate	overproduction	 and	 has	 been	 observed	 to	 occur	 independently	 in	 different	infections166.	 Additionally	 compensatory	 mutations	 have	 been	 observed	 to	revert	alginate	overproduction161,288.	Other	genetic	changes	commonly	inferred	to	 be	 adaptive	 have	 known	 functions.	 Hypermutability	 can	 be	 achieved	 by	
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numerous	 potential	 nonsense	 mutations;	 disruptive	 mutations	 in	 either	 DNA	mismatch	repair	genes	mutS,	mutL,	muM	and	uvrD	may	result	in	a	hypermutator	lineage289.	Many	genes	that	can	be	inferred	to	be	adaptive	have	regulatory	roles	including	 lasR	 that	encodes	 the	QS	regulator	LasR	and	genes	rpoN,	mexT,	retS,	
exsD	and	ampR66.																					
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1.4. Aims	of	this	study	This	 study	 uses	 >1,000	 P.	 aeruginosa	 genomes	 to	 better	 understand	 genetic	variation	 that	 predisposes	 lineages	 to	 establishing	 CF	 lung	 infections	 and	 the	genetic	 basis	 for	 adaptation	 in	 the	 lung.	 CF	 and	 non-CF	 bronchiectasis	associated	 isolate	 genomes,	 the	 transmissible	 LES	 and	 multidrug	 resistant	isolates	from	Thailand	were	sequenced	in	addition	to	environmental	genomes.	The	aims	were	to	use	comparative	genomics	in	order	to:			
• Identify	genes	that	may	bias	acquisition	in	CF	
• Identify	genes	that	are	adaptive	during	CF	lung	infections	
• Map	genetic	diversity	accounting	for	phenotypic	heterogeneity	observed	during	P.	aeruginosa	infections	
• Reveal	the	genetic	bases	of	antibiotic	resistance	in	P.	aeruginosa													
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Chapter	Two	
2. General	Methods	
2.1. Whole	genome	sequencing		Sequencing	was	 conducted	 at	 the	 Centre	 for	 Genomic	 Research	 (CGR)	 on	 the	Illumina	 HiSeq	 platform	 and	 University	 of	 Liverpool	 and	 Laval	 University,	Quebec	(IBIS)	on	the	Illumina	MiSeq	platform.	Additional	P.	aeruginosa	genomes	were	 downloaded	 via	 the	 Pseudomonas.com	 database290.	 The	 ‘wider	 P.	
aeruginosa	 population’	 for	 phylogenetic	 analyses	 refers	 to	 423	 genomes	comprising	the	Kos	et	al.	dataset76	and	reference	genomes	PAO171,	PA14,	PA774	and	LESB58291.			
2.2. Adapter	Trimming	and	Quality	Filtering	Genomes	sequenced	at	the	CGR	on	the	Illumina	HiSeq	platform	where	Illumina	sequence	 adapters	 were	 also	 removed	 (adapter	 trimming)	 and	 sequencing	reads	were	 quality	 filtered	 according	 to	 Phred	 scores.	 Genomes	 sequenced	 at	IBIS	 were	 adapter	 trimmed	 and	 quality	 filtered	 after	 download	 using	 Trim	Galore!	(-q	20	–o	trimmed	--paired)292.		
2.3. Genome	Assembly	and	Draft	Genome	Quality	Assessment	All	genomes	that	were	de	novo	assembled	and	scaffolded	from	sequencing	reads	were	 using	 the	 A5-miseq	 assembly	 pipeline293.	 When	 working	 with	 the	 LES	genomes	 (Chapter	 5),	 A5	 assembled	 contigs	 were	 instead	 scaffolded	 to	reference	 genome	 LESB58	 with	 abacas294.	 Genome	 assembly	 quality	 was	assessed	 using	 quast-3.1295	 and	 interpreted	 as	 a	 combination	 of	 contig	 length	based	metrics:	number	of	contigs,	N50	and	longest	contig	length.		
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2.4. Read	Mapping,	Variant	Calling	and	Annotation	Sequencing	reads	were	aligned	 to	a	 reference	P.	aeruginosa	 genomes	PAO1	or	LESB58	 (read	 mapping)	 using	 bwa0.7.5a	 mem296	 with	 standard	 parameters.	The	 reference	 genome	 (.fasta)	was	 first	 indexed	with	bwa-0.7.5a	 index296	 and	samtools-0.1.18-r580297	 faidx.	 The	 sequence	 dictionary	 was	 created	 with	picard-tools-1.135298	 CreateSequenceDictionary.	 The	 resulting	 sequence	alignment	map	(.sam)	file	from	read	mapping	with	bwa	mem	was	converted	to	a	binary	 alignment	map	 (.bam)	 file	 using	picard-tools	 SortSam.	Duplicates	were	marked	 using	 picard-tools	MarkDuplicates	 and	 a	 bam	 file	 index	 created	with	picard-tools	 BuildBamIndex.	 The	 Genome	 Analysis	 Toolkit-3.4	 (GATK)299	Realignor	 Target	 Creator	was	 used	 to	 designate	 targets	 for	 indel	 realignment	and	indels	are	realigned	with	GATK	IndelRealigner.	Variants	were	called	using	GATK	 HaplotypeCaller	 (-ploidy	 1	 –emitRefConfidence	 GVCF)	 to	 produce	 a	variant	call	(.vcf)	file	prepared	for	genotyping.	The	vcf	file	was	genotyped	using	GATK	GenotypeGVCFs	 and	 filtered	with	 vcffilter300,	 basic	 filtering	 (DP	 >9	 and	QUAL	>10).		Variant	annotation	was	performed	by	snpEff-4.1l301	with	the	default	parameters	for	gatk	output	(eff	-gatk)	to	the	reference	genome	databases	PAO1	(uid57945)	or	 LESB58	 (uid59275).	 Additionally	 it	 was	 evaluated	 whether	 a	 gene	 has	 a	larger	deletion	not	detectable	due	 to	 lack	of	 sequencing	 reads	 and	absence	of	genomic	context	 in	vcf	 files.	First	bam	 files	were	 indexed	with	samtools	 index	and	the	reads	aligned	to	open	reading	frames	as	determined	by	snpEff	database	regions	were	assessed	 for	coverage	using	samtools	depth.	The	samtools	depth	
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results	 were	 processed	 to	 get	 an	 approximate	 ‘alignment’	 length	 from	which	larger	 deletions	 can	 be	 determined	 by	 subtracting	 from	 the	 total	 gene	 length	(awk	‘{if($3>0)	total+=1}END{print	total}).			
2.5. Multi	Locus	Sequence	Typing	in	silico	In	 all	 chapters	 except	 Chapter	 3,	 multi	 locus	 sequence	 type	 (MLST)	 was	performed	using	a	combination	of	mlst302	and	the	CGE	webserver303.	If	profiles	were	 incomplete	 they	were	 checked	 for	 the	 closest	 ST	 to	 their	 partial	 profile	using	 the	 pubMLST	 database304.	 In	 Chapter	 3	 SRST2305	 was	 instead	 used	 for	extracting	MLST	profiles	from	short	reads.			
2.6. Whole	genome	pairwise	alignments	Mummer	 was	 used	 for	 whole	 genome	 pairwise	 alignments	 (nucmer	 –showsnps)306.	 Ambiguous	 bases	 were	 removed	 before	 counting	 variant	 sites	and	insertions	and	deletions	collapsed.			
2.7. Core	Genome	Extraction	For	 all	 P.	 aeruginosa	 core	 SNP	 trees,	 core	 genome	 polymorphic	 sites	 were	extracted	by	Panseq307.	Fragments	(500bp)	that	are	present	in	all	genomes	to	at	least	90%	similarity	were	determined	as	core.	For	assessment	of	recombination	core	 locus	 alleles	 were	 extracted	 from	 Panseq	 and	 aligned	 using	 clustalW308,	implemented	 in	 the	 biopython	 AlignIO	 module309.	 Core	 genome	 multiple	alignments	 were	 concatenated	 into	 a	 core	 genome	 supermatrix.	 Maximum	likelihood	 (ML)	 phylogenetic	 trees	 were	 approximated	 using	 IQtree	 with	automatic	model	 selection	 and	 1000	 ultrafast	 bootstraps	 or	MEGA-6310,	 using	
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the	 HKY85	 substitution	 model	 and	 1000	 bootstraps.	 Gubbins	 was	 used	 for	prediction	 of	 recombinant	 SNPs	 in	 the	 full	 core	 genome	 supermatrix,	 using	 a	starting	tree	before	final	(clonal	frame)	tree	approximation	using	RaxML311,312,	using	the	CAT+GTR	substitution	model.	Gubbins	was	set	to	a	maximum	of	 five	iterations	 is	 RAxML	 trees	 didn’t	 converge	 after	 two	 iterations.	 Trees	 were	visualised	with	the	interactive	tree	of	life	software313.																				
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Chapter	Three	
Adaptation	to	the	Cystic	Fibrosis	Lung	by	Loss	of	Function		
3. Introduction	
3.1. Adaptive	loss	of	function	Bacterial	 populations	 can	 be	 expected	 to	 adapt	 to	 a	 changing	 environment	 or	when	transplanted	into	a	new	environment.	The	genetic	basis	generally	of	this	adaptation	 comprises	mutations	 that	 fine	 tune	 existing	 features314–316,	 gain	 of	genes	 by	 horizontal	 gene	 transfer317	 and	 by	 loss	 or	 disruption	 of	 genes.	 A	mutation	resulting	in	loss	of	function	of	that	gene	may	be	adaptive	if	the	feature	is	detrimental	or	simply	without	benefit	 in	a	new	or	changing	environment	at	some	 cost	 of	 production.	 Indirectly,	 loss	 of	 regulatory	 function	 can	 increase	fitness	 due	 to	 subsequent	 remodeling	 of	 genes	 expressed318.	 Another	phenomenon	 in	 which	 loss	 of	 functions	 may	 be	 advantageous	 is	 in	 the	emergence	 of	 sub-populations	 utilising	 ‘public	 goods’	 without	 the	 cost	 of	contributing	 themselves.	These	 ‘cheats’	 thus	gain	a	 competitive	advantage	but	are	mechanistically	self-limiting	(as	in	quorum	sensing	dependent	public	goods	due	 to	 the	 loss	 of	 sufficient	 signal	 density)	 or	 as	 a	 replacing	 ‘cooperators’	resulting	 in	 loss	of	 the	public	good	upon	which	 the	adaptation	depends319.	An	example	of	adaptation	as	a	result	of	 loss	of	 function	mutations	 is	 the	resulting	loss	of	features	that	are	detrimental	upon	the	introduction	of	antibiotics.	Loss	of	features	 that	 allow	 antibiotic	 entry,	 such	 as	 loss	 of	 function	 in	 the	 outer	
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membrane	protein	OprF	in	E.	coli320.	The	adaptive	landscape	by	loss	of	function	is	expansive	may	be	rapidly	utilised	in	response	to	change321.			The	 large	 number	 of	 genes	 in	 a	 typical	P.	 aeruginosa,	 genome	 coding	 density	dedicated	 to	 regulatory	 genes71,200	 	 and	 observed	 metabolic	 versatility322	suggest	that	P.	aeruginosa	is	well	placed	to	rapidly	adapt	to	a	new	environment	by	 loss	of	 function.	 In	 addition	 to	 features	developed	 in	 the	 environment	 that	are	 beneficial	 during	 infection,	 the	 standing	 genetic	 variation	 of	P.	aeruginosa	and	its	plasticity	make	it	a	formidable	opportunistic	pathogen322.			
3.1.1. Developing	a	representative	panel	of	P.	aeruginosa	In	2013	De	Soyza	et	al.	reported	the	development	of	a	panel	of	43	P.	aeruginosa	for	collaborative	study	of	diverse	lineages323.	The	panel	was	assembled	as	part	of	a	European	Cooperation	in	Science	and	technology	(COST)	project	and	will	be	referred	 to	 as	 the	 COST	panel.	 Isolates	 selected	 comprised	 commonly	 studied	clones,	 isolates	 of	 transmissible	 strains,	 and	 sequential	 isolates	 from	 CF	patients.	 Isolates	 that	 were	 diverse	 in	 virulence,	 serotype,	 genotype	 and	geography	were	also	included.	Isolates	IST27	and	IST27N	a	mucoid	isolate	and	spontaneously	 non-mucoid	 variant	 of	 IST27	 respectively	 were	 included	 to	assess	the	phenotypic	switch	in	this	important	characteristic.	Additional	mucoid	phenotype	 isolates	 NH57388A	 and	 968333S	 were	 also	 included.	 Another	important	phenotype	 to	pathogenesis	 is	 lipopolysaccharide	 (LPS)	 composition	and	as	such	isolates	with	defined	LPS	structures	were	included.	Phenotyping	of	all	of	 the	43	panel	strains	was	carried	out	 to	also	assess	growth	density	at	15	hours,	motility	 by	 swimming,	 swarming	 and	 twitching,	 pyocyanin	 production,	
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antibiotic	 resistance,	 auxotrophy,	 LPS	 composition,	 quorum	 sensing,	 biofilm	formation	and	mucoidy.	Phage	typing	was	also	performed.	While	there	was	no	genotype	or	set	of	genotypes	specifically	associated	to	CF/non-CF	reflecting	the	fact	 that	 they’re	 primarily	 acquired	 from	 the,	 principle	 components	 analysis	(PCA)	 showed	 a	 positive	 correlation	 between	 CF/non-CF	 status	 and	 in	 vivo	virulence	(G.	mellonella	model),	biofilm	formation	and	alginate	production.	PCA	also	 confirmed	 the	 positive	 correlation	 of	 pyocyanin	 production	 and	 in	 vivo	virulence324.		
	
3.1.2. The	International	Pseudomonas	Genomics	Consortium	
Dataset	Expanding	on	 the	development	of	 a	 representative	panel	 of	P.	aeruginosa	 and	more	 recent	 studies	 showing	 the	 diversity	 even	 within	 hosts282,325,326	 the	International	 Pseudomonas	 aeruginosa	 Genomics	 Consortium	 (led	 by	 Roger	Levesque,	 Universite	 Laval,	 Quebec,	 Canada)	 developed	 the	 International	
Pseudomonas	 Genomics	 Consortium	 Database	 (IPCD)75.	 This	 database	containing	 >1,000	 newly	 sequenced	 P.	 aeruginosa	 genomes	 aims	 to	 integrate	genomic	data	with	phenotypic,	virulence,	clinical	and	environmental	metadata.	In	 addition	 to	 the	 representative	 panel	 this	 complex	 database	 attempts	 to	unravel	 the	 genetic	 bases	 of	 diversity	 in	 P.	 aeruginosa.	 	 Provisionally	 these	genomes	were	 published	 and	 their	 phylogeny	 reconstructed75	 analysis	 of	 the	core	and	pan	genome	is	currently	being	conducted	(unpublished).				
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3.1.3. Aims		This	study	made	use	of	the	COST	representative	panel	of	P.	aeruginosa	and	IPCD	datasets	to	assess	adaptation	by	loss	of	function	in	CF	infections.	The	aims	of	this	chapter	were	to:		
• Assess	the	presence	of	loss	of	function	mutations	in	the	COST	International	Panel	of	phenotypically	and	genotypically	diverse	P.	
aeruginosa	
• Investigate	environmental	P.	aeruginosa	genomes	for	loss	of	function	mutations	characteristic	of	adaptation	to	the	CF	lung	environment	
• Identify	new	genes	that	appear	to	be	adaptive	by	loss	of	function	
• Identify	genes	that	are	maintained	during	CF	infections														
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3.2. Methods	Genome	 sequencing,	 raw	 sequence	 read	 filtering	 and	 adapter	 trimming,	 read	mapping	 and	 variant	 calling	 were	 performed	 as	 described	 in	 Chapter	 Two:	General	 Methods.	 All	 variant	 results	 in	 this	 chapter	 were	 obtained	 by	 read	mapping	and	variant	calling	to	PAO1.	Additionally	a	select	few	genomes	were	de	
novo	assembled	and	scaffolded	as	described	in	General	Methods.			
3.2.1. Loss	of	function	mutations	For	both	the	COST	International	Panel	genomes	and	the	IPCD	genomes	genomes	were	 mapped	 to	 reference	 genome	 PAO1	 as	 described	 in	 General	 Methods,	variants	 called	 and	 the	 effect	 of	 variants	 predicted.	Nonsense	mutations	were	then	 combined	 with	 evidence	 for	 deletions	 30bp+	 in	 size,	 up	 to	 complete	absences	 as	 evidence	 of	 loss	 of	 function.	 Statistical	 significance	 of	 difference	between	 environmental	 and	 CF	 genome	 nonsense	mutations,	 larger	 deletions	and	 absences	 were	 performed	with	 the	 chi	 squared	 goodness	 of	 fit	 test	 with	Yates	continuity	correction	in	R.	The	Benjamini-Hochberg	(BH)	multiple	testing	correction	 was	 applied	 to	 the	 significant	 p	 values	 with	 a	 false	 detection	 rate	(FDR)	of	5%.									
53	
3.3. Results		
3.3.1. COST	International	Panel	of	Pseudomonas	aeruginosa	Isolate	 genomes	 LESB58	 and	 PA14	 were	 not	 included	 in	 read	 mapping	 and	variant	calling	analysis	as	they’re	complete	genomes	in	addition	to	PAO1	as	it’s	the	 reference	 genome	 used	 for	 read	 mapping,	 variant	 calling	 and	 effect	prediction	 for	 these	 datasets.	 Because	 of	 problems	with	 contamination,	 strain	NN2	has	been	omitted	from	further	inclusion	in	the	COST	panel	and	2192	is	not	analysed	here,	because	the	data	are	a	composite	of	different	isolates	(table	3.1).																			
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Table	3.1.	International	COST	panel	isolate	genomes	mapped	to	PAO1	for	variant	calling	
Isolate	 Analysed	by	variant	calling	
RP1	 Yes	
AUS23	 Yes	
DK2	 Yes	
AMT	0060-1	 Yes	
AMT	0060-2	 Yes	
AMT	0060-3	 Yes	
PAK	 Yes	
IST	27	mucoid	 Yes	
IST	27N	 Yes	
968333S	 Yes	
679	 Yes	
NH57388A	 Yes	
1709-12	 Yes	
Jpn	1563	 Yes	
LMG	14084	 Yes	
Pr335	 Yes	
U018a	 Yes	
CPHL	9433	 Yes	
LES400	 Yes	
LES431	 Yes	
39016	 Yes	
Mi162	 Yes	
C3719	 Yes	
AES-1R	 Yes	
AUS52	 Yes	
AA2	 Yes	
AMT0023-30	 Yes	
AMT0023-34	 Yes	
CHA	 Yes	
15108/-1	 Yes	
13121/-1	 Yes	
39177	 Yes	
KK1	 Yes	
A5803	 Yes	
TBCF10839	 Yes	
57P31PA	 Yes	
AA44	 Yes	
AA43	 Yes	
LESB58	 No		
PA01	 No	(reference)	
PA14	 No		
NN2	 No	
2192	 No	
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3.3.2. Loss	of	Function	in	the	COST	Panel	Genomes	All	 genomes	 analysed	were	 investigated	 for	 loss	 of	 function	 events	 (nonsense	mutations	and	larger	deletions)	that	are	thought	to	be	associated	with	CF.	Genes	involved	in	mucoidy,	DNA	mismatch	repair,	gacA/S	switch	to	chronicity,	biofilm	dispersal	 gene	rbdA	 and	motility	gene	 fleR	were	among	 those	 investigated	 for	loss	of	function.	The	approach	was	also	taken	to	identify	genes	that	appear	to	be	independently	acquiring	nonsense	mutations	to	discover	new	genes	associated	with	adaptation	to	the	CF	lungs	by	loss	of	function.		Loss	of	function	in	anti-sigma	factor	gene,	mucA	is	associated	with	the	mucoidy	phenotype.	 Nine	 isolate	 genomes	 contained	 evidence	 for	 loss	 of	 function	 in	MucA	 (table	 3.2).	 All	 isolates	 with	 loss	 of	 function	 in	 MucA,	 except	 968333S	from	a	non-cystic	fibrosis	bronchiectasis	patient	sample,	were	sampled	from	CF	infections.	 Compensatory	 mutations	 are	 possible	 that	 revert	 alginate	overproduction	 once	 negative	 regulation	 by	mucA	 is	 lost.	 Genes	 involved	 in	alginate	 biosynthesis	 algD	 (PA4530),	 alg8	 (PA3541),	 alg44	 (PA3542	 ),	 algK	(PA3542),	algE	 (PA3544),	algG	 (PA3545)	 ,	algX	 (PA3546),	algL	 (PA3547),	algI	(PA3548),	algJ	(PA3549),	algF	(PA3550),	algA	(PA3551)	and	sigma	factor	gene	
algU	that	could	be	compensatory	by	 loss	of	 function	to	the	mucoid	phenotype,	were	 investigated	 for	 nonsense	mutations	 and	 larger	 deletions/absences.	 The	genome	 of	 strain	 AUS23	 contains	 a	 2bp	 insertion	 in	 sigma	 factor	 algU.	 The	genome	of	strain	Mi162	contains	a	2bp	insertion	at	reference	position	3975435	and	 a	 2bp	 deletion	 at	 reference	 position	 3975437,	 so	 it	 is	 unlikely	 these	mutations	 are	 entirely	 disruptive.	 LES400	 and	 LES431	 contain	 a	 nonsense	mutation	in	algF.		
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Table	3.2.	Evidence	for	loss	of	function	in	mucA	in	the	COST	panel	genomes	
Isolate	 Mutation	and	impact	 Reference	
position	
Source	of	
isolation	AMT	0060-2	 1bp	frameshift	deletion	 832286	 CF	(early)	IST	27	mucoid	 1bp	frameshift	deletion	 832338	 CF	IST	27N	 1bp	frameshift	deletion	 832338	 CF	968333S	 7bp	frameshift	deletion	 832140	 Non-CF	Bronchiectasis	NH57388A	 89bp	deletion	 CF	AUS23	 5bp	frameshift	insertion	 832197	 CF	DK2	 1bp	frameshift	deletion	 832338	 CF	(transmissible)	AUS52	 C-A	premature	stop	codon*	 832194	 CF	1bp	frameshift	deletion	 832358	 	AMT0060-1	 1bp	frameshift	insertion	 832274	 CF	1bp	frameshift	deletion	 832286	 	
		Nonsense	mutation	in	DNA	mismatch	repair	genes,	mutS,	mutL,	mutM	and	uvrD	can	 be	 evidence	 for	 hypermutable	 lineages	 of	 P.	 aeruginosa.	 Isolate	 968333S	presents	an	11bp	frame-shifting	deletion	in	mutS.			The	 quorum	 sensing	 transcriptional	 regulator	 gene	 lasR	 has	 acquired	 a	nonsense	 mutation	 in	 seven	 of	 the	 panel	 genomes	 and	 was	 the	 gene	 was	completely	absent	in	a	further	two	(table	3.3).	CF	isolate	genome	AMT0023-34	carries	a	1bp	frame-shifting	insertion	in	lasR	whereas	an	earlier	isolate	from	the	same	patient	does	not	 carry	 a	 loss	of	 function	 in	 lasR	 (AMT0023-30).	 Isolates	carrying	a	nonsense	mutation	in	lasR	were	primarily	sourced	from	CF	patients,	but	 also	 included	 isolates	 sourced	 from	 a	 community	 acquired	 pneumonia	(CAP)	patient	(A5803)	and	a	non-CF	burn	patient	isolate	(Mi162).	Additionally	
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an	environmental	isolate	from	a	tobacco	plant	(CPHL9433)	carried	a	nonsense	mutation	in	lasR	(table	3.3).		Table	3.3.	Evidence	for	loss	of	function	in	lasR	in	the	COST	panel	genomes	
Isolate	 Mutation	and	impact	 Reference	
position	
Source	of	
Isolation	CPHL	9433	 2bp	frameshift	insertion	 1558835	 Tobacco	plant	LES400	 7bp	frameshift	insertion	 1558527	 CF	Mi162	 168bp	frameshift	insertion	 1558840	 Non-CF	burn	AMT0023-34	 1bp	frameshift	deletion	 1558316	 CF	(late)	AUS23	 G-T,	premature	stop	codon	 1558480	 CF	(transmissible)	AUS52	 G-T,	premature	stop	codon	 1558603	 CF	(transmissible)	A5803	 G-A,	premature	stop	codon	 1558349	 CAP*		KK1	 Complete	absence	of	
lasR	 1558171-1558890	 CF	DK2	 Complete	absence	of	
lasR	 1558171-1558890	 CF	(transmissible)	
		Four	 isolate	 genomes	 contained	 a	 nonsense	mutation	 in	 the	 biofilm	 dispersal	gene	 rbdA.	 They	 were	 isolated	 from	 CF	 (C3719,	 TBCF10839),	 the	 hospital	environment	 (Pr335)	 and	 a	 (keratitis)	 eye	 infection	 (39177).	 Transmissible	isolates	LES400	and	LES431	were	observed	to	have	acquired	a	premature	stop	codon	 in	 fleR.	 Transmissible	 strain	 isolates	 C3719	 and	 AUS52	 were	phenotypically	 non-motile	 but	 the	 potential	 genetic	 basis	 could	 not	 be	determined.			
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3.3.2.1. Independent	acquisition	of	nonsense	mutations	The	independent	acquisition	of	nonsense	mutations	was	determined	to	identify	genes	that	may	be	adaptive	by	loss	of	function.	Different	loss	of	function	alleles	were	 identified	by	nonsense	mutations	presenting	 in	 the	 same	 genes	but	 in	 a	different	position	or	where	they	are	represented	by	a	different	mutation	at	the	same	 position.	 As	 such	 unique	 single	 nonsense	mutations	 carried	 in	 different	genomes	 must	 represent	 multiple	 acquisitions	 and	 if	 associated	 with	 a	particular	phenotype	or	isolate	source,	may	be	inferred	to	be	adaptive.			In	total	there	were	799	different	genes	with	nonsense	mutations,	410	of	which	were	 present	 in	 only	 one	 genome.	 For	 those	 in	 two	 or	 more	 genomes	 an	assessment	of	whether	they	have	been	independently	acquired	or	are	shared	by	closely	 related	 isolates	 was	 carried	 out.	 Those	 that	 have	 acquired	 loss	 of	function	 mutations	 independently	 were	 inferred	 to	 be	 adaptive,	 table	 3.4	displays	 those	 in	which	 there	were	 three	or	more	 independent	acquisitions	of	loss	of	function	in	the	COST	panel	genomes.	Genes,	mucA,	lasR	that	have	already	been	 evaluated	 for	 loss	 of	 function	 due	 to	 their	 known	 roles	 in	 CF	 lung	infections	 were	 also	 identified	 by	 this	 method	 as	 the	 two	 genes	 most	 often	acquiring	nonsense	mutations	independently.								
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Table	 3.4.	 Genes	 in	 which	 nonsense	 mutations	 have	 been	 acquired	independently	3	or	more	times	across	the	COST	panel	genomes	
Gene	 Independent	
occurrences	
Genomes	 Gene	description	
lasR	 7	 7	 Transcriptional	regulator	of	quorum	sensing	
mucA	 6	 9	 Anti-sigma	factor	for	alginate	biosynthesis	
mexA	 4	 6	 mexAB-oprM	efflux	pump	
rbdA	 4	 4	 Biofilm	dispersal	
wbpM	 3	 17	 O-antigen	lipopolysaccharide		PA3124	 3	 10	 Probable	transcriptional	regulator	
exoY	 3	 7	 Adenylate	cyclase	PA4798	 3	 5	 Hypothetical	protein	PA2037	 3	 3	 Hypothetical	protein	PA0313	 3	 3	 L-cysteine	transporter	of	ABC	system	YecS	
mexB	 3	 3	 mexAB-oprM	efflux	pump	
lpxO2	 3	 3	 lpxO2	lipopolysaccharide	biosynthetic	protein	PA4469	 3	 3	 Hypothetical	protein	PA1221	 3	 3	 Hypothetical	protein	
ladS	 3	 3	 Histidine	kinase	PA4063	 3	 3	 Hypothetical	protein	PA0987	 3	 3	 Hypothetical	protein			Both	mexB	and	mexA	of	the	mexAB-oprM	multidrug	efflux	pump	were	observed	to	have	independently	acquired	nonsense	mutations	3	and	4	times	respectively	(table	3.5).	When	the	entire	operon	was	investigated	for	loss	of	function,	eleven	isolate	 genomes	 contained	 evidence	 for	 loss	 of	 function	 in	 the	 MexAB-OprM	multidrug	 efflux	 pump	 (table	 3.5).	 Sequential	 isolates	 AA2	 (early)	 AA43	 and	AA44	 (late)	 contained	 the	 same	 frameshift	 mutation	 in	mexA.	 Isolates	 IST27	(mucoid)	and	IST27N	(spontaneous	non-mucoid)	contained	the	same	frameshift	mutation	 in	 the	 oprM	 gene	 of	 the	 operon.	 The	 ‘CF	 late’	 isolate	 AMT0023-34	contained	a	premature	stop	codon	in	mexB	whereas	early	isolate	AMT0023-30	
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did	not	contain	any	loss	of	function	mutations	in	the	operon.	The	transmissible	strain	isolate	DK2	had	a	78bp	deletion	in	mexB	and	also	a	frameshift	in	mexA.			Table	 3.5.	 Evidence	 for	 loss	 of	 function	 in	 the	mexAB-oprM	 operon	 across	 the	COST	panel	genomes	
Gene	 Isolate	 Mutation	and	impact	 Reference	
position	
Source	of	
isolation	
mexB	 AUS23	 C-T	premature	stop	codon	 475507	 CF	(transmissible)	LES431	 1bp	frameshift	insertion	 473231	 CF	(transmissible)	AMT0023-34	 C-T	premature	stop	codon	 474952	 CF	(late)	DK2	 78bp	deletion	 	
mexA	 AA2	 1bp	frameshift	deletion	 472324	 CF	(early)	AA43	 1bp	frameshift	deletion	 472324	 CF	(late)	AA44	 1bp	frameshift	deletion	 472324	 CF	(late)	DK2	 2bp	frameshift	insertion	 472744	 CF	(transmissible)	NH57388A	 1bp	frameshift	deletion	 472570	 CF	AUS52	 1bp	frameshift	deletion	 472223	 CF	
oprM	 IST27	 2bp	frameshift	deletion	 477519	 CF	IST27N	 2bp	frameshift	deletion	 477519	 CF	
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3.3.3. International	Pseudomonas	Genomics	Consortium	
Dataset	To	assess	whether	there	was	an	association	with	 loss	of	 function	of	 individual	genes	 and	 CF	 infections,	 gene	 absences	 including	 genes	 carrying	 inactivating	nonsense	mutations	were	compared	between	an	environmental	population	of	P.	
aeruginosa	and	those	isolated	from	CF	lung	infections.	Reads	were	mapped	to	P.	
aeruginosa	 reference	 genome	 PAO1	 and	 assessed	 for	 absence,	 large	 deletions	and	small	frameshifting	indels	and	premature	stop	codons	as	described.			Isolate	genomes	from	CF	infections	and	those	sampled	in	the	environment	were	obtained	 from	 the	 IPCD	 dataset.	 Some	 CF	 patients	 had	 contributed	 multiple	isolates	so	to	avoid	bias	(enrichment	of	results	by	multiple	isolates	of	the	same	within	 patient	 population)	 one	 genome	 was	 randomly	 selected	 from	 each.	Where	 patients	 had	 provided	 isolates	 representing	 multiple	 ST’s	 it	 was	determined	whether	the	ST’s	were	sufficiently	different	to	most	likely	represent	independent	 environmental	 lineages	 and	 a	 representative	 of	 each	 randomly	selected.	 The	 CF	 genome	 set	was	 corrected	 as	 such	 resulting	 in	 388	 genomes	from	 a	 total	 of	 458.	 The	 environmental	 isolates	were	 obtained	 from	multiple	countries	and	diverse	ecological	niches	including	river	samples	from	Australia,	West	 Africa	 and	 Belgium,	 a	 poultry	 water	 line	 sample	 from	 Canada,	 lake	samples,	 Japanese	 coastal	 and	 open	 ocean	 sea	water	 samples,	 soil	 and	 plants	samples	from	the	U.S.A.,	sea	water	samples	from	Tunisia	and	shallow	well	water	sample	 from	 Puerto	 Rico.	 Environmental	 genomes	 isolated	 from	 the	 hospital	environment	were	excluded	due	to	potential	overlap	with	infecting	populations	resulting	in	a	final	environmental	genome	dataset	of	137	from	a	total	of	178.		
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3.3.4. Genes	overrepresented	for	loss	of	function	in	CF	
compared	with	the	environment	There	were	 90	 different	 genes	 in	 the	 CF	 genomes	 that	were	 significantly	 (chi	squared	p	<	0.05)	overrepresented	 for	 loss	of	 function	mutations	amongst	 the	genomes	of	CF	isolates	(table	3.6)	compared	with	those	from	the	environment.	Of	 these,	 34	 were	 significant	 to	 p	 <	 0.005.	 The	 most	 significantly	overrepresented	gene	for	loss	of	function	in	CF	compared	with	the	environment	was	type	IV	fimbrial	biogenesis	encoding	gene,	pilC	(p	=	3.74x10-9).	There	were	36	 genes	 of	 unknown	 function	 (hypothetical	 or	 conserved	 hypothetical),	including	 genes	 among	 the	 most	 significantly	 overrepresented	 for	 loss	 of	function	 such	 as	 PA0561	 (p=2.4x10-7)	 and	 PA1153	 (𝑝=	 2.9	× 10-6).	 The	 genes	that	 were	 overrepresented	 for	 loss	 of	 function	 in	 CF	 compared	 with	 the	environment	 were	 associated	 with	 a	 variety	 of	 functions	 including	 motility	(flhB),	 adhesion	 (cup	 genes),	 pyoverdine	 biosynthesis	 (pvdO,	 pvdE,	 pvdF),	pyoverdine	 receptor	 (fpvA),	 antiobiotic	 resistance	 (mpl)	 and	 alginate	biosynthesis	 (mucA).	 Due	 to	 multiple	 genes	 being	 tested	 for	 a	 significant	difference	 in	 absence	 and	 inactivating	 mutations	 (n	 =	 5606)	 the	 Benjamimi-Hochberg	(BH)	multiple	testing	criteria	was	applied	with	a	false	detection	rate	of	5%.	The	 top	19	chi	 squared	p-values	were	 lower	 than	 the	BH	critical	value	and	so	remained	significant	(p	=	3.74x10-9	–	1.14x10-4);	these	rows	are	in	bold	in	table	3.6.				
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Table	3.6.	All	genes	significantly	(chi	squared	p	<.05)	overrepresented	for	loss	of	function	 in	 CF	 genomes	 compared	with	 the	 environment.	 Significant	 P	 values	smaller	 than	 the	 Benjamimi-Hochberg	 (BH)	 critical	 value	 (FDR	 5%)	 are	highlighted	in	bold	
Locus	tag	 Gene	
name	
Description	of	function	 Chisq	P	
Value	
BH	
critical	
value	
PA4527	 pilC	 still	frameshift	type	4	fimbrial	
biogenesis	protein	PilC		
3.74E-09	 9.09E-06	
PA4526	 pilB	 type	4	fimbrial	biogenesis	
protein	PilB	
8.81E-08	 1.82E-05	
PA4312	 		 conserved	hypothetical	
protein	
2.36E-07	 2.73E-05	
PA0561	 	 hypothetical	protein	 2.66E-06	 3.64E-05	
PA1153	 		 hypothetical	protein	 2.92E-06	 4.55E-05	
PA0619	 	 probable	bacteriophage	
protein	
3.44E-06	 5.45E-05	
PA2566	 		 conserved	hypothetical	
protein	
4.19E-06	 6.36E-05	
PA2403	 	 hypothetical	protein	 6.81E-06	 7.27E-05	
PA2398	 fpvA	 ferripyoverdine	receptor	 1.68E-05	 8.18E-05	
PA1887	 	 hypothetical	protein	 1.69E-05	 9.09E-05	
PA2397	 pvdE	 pyoverdine	biosynthesis	
protein	PvdE	
2.98E-05	 1.00E-04	
PA2564	 	 hypothetical	protein	 3.23E-05	 1.09E-04	
PA5516	 pdxY	 pyridoxamine	kinase	 3.32E-05	 1.18E-04	
PA3486	 vgrb4
G	
Type	VI	secretion	system	 3.43E-05	 1.27E-04	
PA2395	 pvdO	 PvdO	 5.55E-05	 1.36E-04	
PA3487	 tle5	 Lipid	metabolism	 7.35E-05	 1.45E-04	
PA3488	 tli5	 	 7.35E-05	 1.55E-04	
PA1889	 		 hypothetical	protein	 8.14E-05	 1.64E-04	
PA2396	 pvdF	 pyoverdine	synthetase	F	 1.14E-04	 1.73E-04	
PA4075	 		 hypothetical	protein	 1.95E-04	 1.82E-04	
PA4020	 mpl	 UDP-N-acetylmuramate:L-alanyl-gamma-D-glutamyl-meso-diaminopimelate	ligase	 2.54E-04	 1.91E-04	
PA0763	 mucA	 anti-sigma	factor	MucA	 3.22E-04	 2.00E-04	
PA4514	 piuA	 probable	outer	membrane	receptor	for	iron	transport	 5.66E-04	 2.09E-04	
PA2256	 pvcC	 paerucumarin	biosynthesis	protein	PvcC	 6.09E-04	 2.18E-04	
PA2457	 	 Hypothetical	protein	 1.29E-03	 2.27E-04	
PA1150	 pys2	 Pyocin	S2	 1.31E-03	 2.36E-04	
PA4999	 waaL	 O-antigen	ligase	 1.34E-03	 2.45E-04	
PA1628	 		 probable	3-hydroxyacyl-CoA	dehydrogenase	 1.51E-03	 2.55E-04	
PA2319	 	 Probable	transposase	 2.11E-03	 2.64E-04	
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PA3434	 	 Probable	transposase	 2.11E-03	 2.73E-04	
PA4310	 pctB	 chemotactic	transducer	PctB	 2.22E-03	 2.82E-04	
PA3993	 	 Probable	transposase	 2.96E-03	 2.91E-04	
PA4797	 	 Probable	transposase	 2.96E-03	 3.00E-04	
PA2388	 fpvR	 FpvR	 3.59E-03	 3.09E-04	
PA4133	 cytN	 cytochrome	c	oxidase	subunit	(cbb3-type)	 3.81E-03	 3.18E-04	
PA2300	 chiC	 chitinase	 5.12E-03	 3.27E-04	
PA3346	 	 two-component	response	regulator	 5.12E-03	 3.36E-04	
PA5226	 		 hypothetical	protein	 5.65E-03	 3.45E-04	
PA2386	 pvdA	 L-ornithine	N5-oxygenase	 5.68E-03	 3.55E-04	
PA0558	 	 Hypothetical	protein	 5.70E-03	 3.64E-04	
PA0445	 	 Probable	transposase	 5.74E-03	 3.73E-04	
PA2690	 	 Probable	transposase	 5.74E-03	 3.82E-04	
PA2387	 fpvI	 FpvI	 5.84E-03	 3.91E-04	
PA2426	 pvdS	 sigma	factor	PvdS	 6.65E-03	 4.00E-04	
PA2427	 		 hypothetical	protein	 6.65E-03	 4.09E-04	
PA0626	 	 hypothetical	protein	 6.66E-03	 4.18E-04	
PA2456	 	 Hypothetical	protein	 7.75E-03	 4.27E-04	
PA0623	 		 probable	bacteriophage	protein	 7.76E-03	 4.36E-04	
PA3867	 	 Probable	DNA	invertase	 9.40E-03	 4.45E-04	
PA3866	 	 Pyocin	S4	 9.56E-03	 4.55E-04	
PA4092	 hpaC	 4-hydroxyphenylacetate	3-monooxygenase	small	chain	 1.01E-02	 4.64E-04	
PA5255	 algQ	 Alginate	regulatory	protein	AlgQ	 1.01E-02	 4.73E-04	
PA1888	 	 hypothetical	protein	 1.05E-02	 4.82E-04	
PA0614	 		 hypothetical	protein	 1.20E-02	 4.91E-04	
PA0618	 	 probable	bacteriophage	protein	 1.23E-02	 5.00E-04	
PA0624	 		 hypothetical	protein	 1.23E-02	 5.09E-04	
PA0628	 	 conserved	hypothetical	protein	 1.23E-02	 5.18E-04	
PA0981	 	 Hypothetical	protein	 1.53E-02	 5.27E-04	
PA4071	 		 hypothetical	protein	 1.56E-02	 5.36E-04	
PA0627	 	 conserved	hypothetical	protein	 1.63E-02	 5.45E-04	
PA0648	 	 Hypothetical	protein	 1.85E-02	 5.55E-04	
PA4113	 ydeA	 probable	major	facilitator	superfamily	(MFS)	transporter	 1.87E-02	 5.64E-04	
PA2565	 	 hypothetical	protein	 1.91E-02	 5.73E-04	
PA0647	 	 Hypothetical	protein	 2.03E-02	 5.82E-04	
PA1154	 		 conserved	hypothetical	protein	 2.19E-02	 5.91E-04	
PA0728	 	 probable	bacteriophage	integrase	 2.48E-02	 6.00E-04	
PA0622	 	 probable	bacteriophage	protein	 2.50E-02	 6.09E-04	
PA0724	 coaA	 Probable	coat	protein	A	of	bacteriophage	Pf1	 2.62E-02	 6.18E-04	
PA2393	 	 Putative	dipeptidase,	involved	 2.64E-02	 6.27E-04	
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in	pyoverdine	biosynthesi	
PA1339	 aatP	 AatP	 2.75E-02	 6.36E-04	
PA1937	 	 conserved	hypothetical	protein	 2.80E-02	 6.45E-04	
PA0615	 		 hypothetical	protein	 2.85E-02	 6.55E-04	
PA0616	 	 hypothetical	protein	 2.85E-02	 6.64E-04	
PA0617	 		 probable	bacteriophage	protein	 2.85E-02	 6.73E-04	
PA0625	 	 hypothetical	protein	 2.85E-02	 6.82E-04	
PA1151	 imm2	 Pyocin	S2	immunity	protein	 2.95E-02	 6.91E-04	
PA3869	 	 Hypothetical	protein	 3.03E-02	 7.00E-04	
PA2203	 		 probable	amino	acid	permease	 3.19E-02	 7.09E-04	
PA0977	 	 hypothetical	protein	 3.23E-02	 7.18E-04	
PA0983	 	 Conserved	hypothetical	protein	 3.89E-02	 7.27E-04	
PA0081	 fha1	 Fha1	 3.97E-02	 7.36E-04	
PA4082	 cupB5	 adhesive	protein	CupB5	 4.14E-02	 7.45E-04	
PA3825	 		 Cyclic-guanylate-specific	phosphodiesterase	 4.15E-02	 7.55E-04	
PA0729	 	 Hypothetical	protein	 4.18E-02	 7.64E-04	
PA1449	 flhB	 flagellar	biosynthetic	protein	FlhB	 4.48E-02	 7.73E-04	
PA1626	 		 probable	major	facilitator	superfamily	(MFS)	transporter	 4.53E-02	 7.82E-04	
PA5546	 	 conserved	hypothetical	protein	 4.53E-02	 7.91E-04	
PA0980	 	 Hypothetical	protein	 4.79E-02	 8.00E-04	
PA2392	 pvdP	 Pyoverdine	biosynthesis	 4.80E-02	 8.09E-04	
PA3865.1	 	 pyocin	S4	immunity	protein	 4.91E-02	 8.18E-04												
66	
The	 majority	 of	 associated	 functions	 to	 genes	 significantly	 (p	 <	 0.5)	overrepresented	for	loss	of	function	in	CF	compared	with	the	environment	are	hypothetical	genes	of	unknown	function	(24.32%),	followed	by	those	related	to	phage,	 transposon	 and	 plasmid	 (19.81%),	 adaptation	 and	 protection	 (9.09%)	and	transport	of	small	molecules	(8.10%)	(figure	3.1).	
	Figure	 3.1.	 	 PseudoCAP	 functional	 categories	 associated	 with	 the	 genes	significantly	 overrepresented	 for	 loss	 of	 function	 in	 the	 CF	 isolate	 genomes	(<0.05	chi	squared	significance)		
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For	the	35	genes	that	were	overrepresented	for	loss	of	function	in	CF	compared	with	 the	environment	and	are	hypothetical	 genes,	 those	of	unknown	 function,	the	functions	of	 full	gene	homologs	 in	the	Pseudomonas	Database	orthologous	gene	 set	 were	 sought.	 Table	 3.7	 displays	 the	 details	 of	 orthologous	 group	membership	 and	 function	within	 other	members	 of	 the	 species	 or	 genus.	 For	eleven	 of	 these	 genes	 of	 unknown	 function	 in	 PAO1,	 between	 24	 and	 332	members	 of	 various	 orthologous	 groups	 in	 various	 Pseudomonas	 were	 found	but	were	also	of	unknown	function.	The	majority	of	associated	funtions	(n	=	11)	were	 related	 to	 phage	 and	 transposable	 elements	 (PA0628,	 PA0627,	 PA1154,	PA1937,	 PA1153,	 PA0626,	 PA0614,	 PA0624,	 PA0615,	 PA0616,	 PA0625	 and	PA0983).			Table	 3.7.	 Orthologs	 and	 their	 functions	 of	 the	 genes	 significantly	overrepresented	for	loss	of	function	(chi	squared	p	<	0.05)	that	are	of	unknown	function	in	PAO1		
PAO1	
locus	ID	
Orthologous	group	ID	 Functional	description	
PA4312	 POG003910	 Putative	deacetylase	
PA2566	 POG003005	 Pyridine	nucleotide-disulfide	oxidoreductase	
PA0628	 POG000611		 phage	late	control	gene	D	protein	
PA0627	 POG000610	 putative	phage	protein	X	
PA1154	 POG001113	 Transposase	
PA1937	 POG000943	 Transposase	
PA5546	 POG005077	 Putative	cyclopropan-fatty-acyl-phospholipid	synthase	
PA0561	 POG000545	 Hypothetical	
PA1153	 POG001112	 Prophage	antirepressor	
PA1887	 POG003523	 Hypothetical	
PA2564	 POG001050	 Methyltransferase	type	12	
PA1889	 POG003521	 Hypothetical	
PA4075	 POG001611	 Methyltransferase	
PA5226	 POG004807	 putative	chromosome	segregation	ATPase	
PA2427	 POG003109	 putative	pvdY	
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PA0626	 POG000609	 Phage	tail	protein	
PA1888	 POG003522	 Hypothetical	
PA0614	 POG000597	 Putative	holin	
PA0624	 POG000607	 mu-like	prophage	FluMu	gp41	family	protein	
PA4071	 POG001615	 Hypothetical	
PA2565	 POG003006	 Hypothetical	
PA0615	 POG000598	 phage	protein	
PA0616	 POG000599	 putative	baseplate	assembly	protein	V		
PA0625	 POG000608	 tail	length	determinator	protein		
PA0977	 POG000942	 Hypothetical	
PA0647	 POG000627	 Hypothetical	
PA0648	 POG000628	 Hypothetical	
PA0729	 POG000705	 RelE/ParE	family	plasmid	stabilisation	system	protein	
PA0980	 POG000944	 Hypothetical	
PA0981	 POG000945	 Hypothetical	
PA0983	 POG000943	 Transposase	
PA2457	 	POG002259	 yd	repeat	containing	protein	
PA2564	 POG001050	 Trans-aconitate	2-methyltransferase	
PA3869	 POG001802	 Type	II	secretory	pathway,	component	ExeA	
PA4312	 POG003910	 Putative	deacetylase														
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3.3.5. Genes	underrepresented	for	loss	of	function	in	CF	
compared	with	the	environment	There	 were	 1409	 different	 genes	 significantly	 (chi	 squared,	 p	 <	 .05)	underrepresented	for	loss	of	function	in	CF.	A	little	over	half	of	these	genes	(n	=	749)	were	significant	in	the	range	of	p	=	0.01-0.046.	There	were	375	genes	that	were	 significant	 to	 p	 <	 0.005.	 Table	 3.10	 displays	 the	 50	 most	 significantly	underrepresented	 for	 loss	 of	 function.	 BH	 multiple	 testing	 correction	 was	performed	also	for	genes	underrepresented	for	loss	of	function	in	CF	compared	with	 the	 environment.	 The	 top	300	 chi	 squared	p-values	 remained	 significant	were	smaller	than	the	BH	critical	value.	The	full	list	of	genes	underrepresented	in	CF	for	loss	of	function	are	provided	in	supplementary	table	1.														
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Table	 3.8.	 The	 top	 50	 most	 significantly	 (<0.05	 chi	 squared	 P	 value)	underrepresented	genes	for	loss	of	function	in	CF	genomes	compared	with	the	environment.	 Significant	 P	 values	 smaller	 than	 the	 Benjamimi-Hochberg	 (BH)	critical	value	(FDR	5%)	are	in	highlighted	in	bold		
Locus	
tag	
Gene	
name	
Description	of	function	 Chisq	p-
value	
BH	
Critical	
value	
PA4586	 		 hypothetical	protein	 1.49E-19	 8.92E-06	
PA4162	 	 probable	short-chain	dehydrogenase	 2.75E-18	 1.78E-05	
PA3105	 xcpQ	 general	secretion	pathway	protein	D	 9.22E-17	 2.68E-05	
PA4192	 	 probable	ATP-binding	component	of	ABC	transporter	 1.09E-16	 3.57E-05	
PA4193	 		 probable	permease	of	ABC	transporter	 1.09E-16	 4.46E-05	
PA4194	 	 probable	permease	of	ABC	transporter	 1.09E-16	 5.35E-05	
PA4195	 		 probable	binding	protein	component	of	ABC	transporter	 1.09E-16	 6.24E-05	
PA4191	 	 probable	iron/ascorbate	oxidoreductase	 3.04E-16	 7.14E-05	
PA1858	 str	 streptomycin	3''-phosphotransferase	 8.22E-16	 8.03E-05	
PA3469	 	 conserved	hypothetical	protein	 2.16E-15	 8.92E-05	
PA5318	 		 hypothetical	protein	 4.56E-15	 9.81E-05	
PA3841	 exoS	 exoenzyme	S	 1.44E-14	 1.07E-04	
PA4879	 		 conserved	hypothetical	protein	 3.28E-14	 1.16E-04	
PA3362	 	 hypothetical	protein	 4.91E-14	 1.25E-04	
PA2130	 cupA3	 usher	CupA3	 5.15E-14	 1.34E-04	
PA2771	 	 diguanylate	cyclase	with	a	self-blocked	I-site	 5.79E-13	 1.43E-04	
PA2772	 		 hypothetical	protein	 8.97E-13	 1.52E-04	
PA1036	 	 hypothetical	protein	 2.49E-12	 1.61E-04	
PA5321	 dut	 deoxyuridine	5'-triphosphate	nucleotidohydrolase	 6.52E-12	 1.69E-04	
PA4985	 	 Uncharacterized	protein	 8.84E-12	 1.78E-04	
PA0244	 		 hypothetical	protein	 2.69E-11	 1.87E-04	
PA2182	 	 hypothetical	protein	 3.13E-11	 1.96E-04	
PA0347	 glpQ	 glycerophosphoryl	diester	phosphodiesterase	 4.21E-11	 2.05E-04	
PA0191	 	 probable	transcriptional	regulator	 4.31E-11	 2.14E-04	
PA2583	 		 probable	sensor/response	regulator	hybrid	 6.50E-11	 2.23E-04	
PA2190	 	 conserved	hypothetical	protein	 7.91E-11	 2.32E-04	
PA1868	 xqhA	 secretion	protein	XqhA	 8.24E-11	 2.41E-04	
PA3387	 rhlG	 beta-ketoacyl	reductase	 2.48E-10	 2.50E-04	
PA4222	 		 probable	ATP-binding	component	of	ABC	transporter	 2.48E-10	 2.59E-04	
PA2188	 	 probable	alcohol	dehydrogenase	(Zn- 2.49E-10	 2.68E-04	
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dependent)	
PA2183	 		 hypothetical	protein	 2.64E-10	 2.77E-04	
PA2127	 cgrA	 cupA	gene	regulator	A	 3.11E-10	 2.85E-04	
PA1576	 		 probable	3-hydroxyisobutyrate	dehydrogenase	 3.35E-10	 2.94E-04	
PA2184	 	 conserved	hypothetical	protein	 3.80E-10	 3.03E-04	
PA2200	 		 Cyclic-guanylate-specific	phosphodiesterase	 3.90E-10	 3.12E-04	
PA2185	 katN	 non-heme	catalase	KatN	 4.42E-10	 3.21E-04	
PA0261	 		 hypothetical	protein	 5.74E-10	 3.30E-04	
PA5404	 	 hypothetical	protein	 6.17E-10	 3.39E-04	
PA2135	 		 probable	transporter	 6.55E-10	 3.48E-04	
PA2112	 	 conserved	hypothetical	protein	 7.62E-10	 3.57E-04	
PA4063	 		 hypothetical	protein	 7.64E-10	 3.66E-04	
PA2187	 	 hypothetical	protein	 8.11E-10	 3.75E-04	
PA2296	 		 hypothetical	protein	 1.15E-09	 3.84E-04	
PA2186	 	 hypothetical	protein	 1.35E-09	 3.93E-04	
PA2440	 		 hypothetical	protein	 1.41E-09	 4.01E-04	
PA0499	 	 probable	pili	assembly	chaperone	 3.30E-09	 4.10E-04	
PA2295	 		 probable	permease	of	ABC	transporter	 3.39E-09	 4.19E-04	
PA3063	 pelB	 PelB	 3.49E-09	 4.28E-04	
PA2167	 		 hypothetical	protein	 3.59E-09	 4.37E-04	
PA2116	 	 conserved	hypothetical	protein	 3.64E-09	 4.46E-04													
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The	 majority	 of	 associated	 functions	 to	 genes	 underrepresented	 for	 loss	 of	function	 in	 CF	 compared	 with	 the	 environment	 were	 hypothetical	 genes	 of	unknown	function	(32.75%).	Associated	functions	included	membrane	proteins	(9.37%),	putative	enzymes	(7.91%),	 transport	of	small	molecules	(7.32%)	and	transcriptional	regulators	(7.67%);	these	represent	approximately	a	third	of	the	associated	functions	(figure	3.2).			
		Figure	 3.2.	 Functional	 categories	 represented	 by	 the	 genes	 underrepresented	for	loss	of	function	in	the	CF	isolate	genomes	(<0.05	chi	squared	significance)	
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3.3.5.1. Comparison	 of	 associated	 functional	 categories	 in	
over	 and	 underrepresented	 genes	 in	 CF	 isolates	
compared	with	environmental	isolates	There	 were	 differences	 in	 the	 functional	 categories	 associated	 with	 over	 or	underrepresented	 genes	 for	 loss	 of	 function	 (supplementary	 figure	 1).	 Genes	associated	with	cell	division,	chaperones	and	heat	shock	proteins,	transcription	RNA	 processing	 and	 degradation	 and	 also	 translation	 post-transcriptional	modification	and	degradation	were	never	overrepresented	 for	 loss	of	 function	in	 the	CF	 isolate	genomes.	The	 largest	associated	 function	 is	unknown	 in	both	genes	overrepresented	and	underrepresented	for	loss	of	function.	Hypothetical	genes	 represented	 32.67%	 of	 all	 functional	 associations	 of	 underrepresented	genes	 and	 24.32%	 of	 overrepresented.	 Genes	 associated	 with	 functions	transport	of	small	molecules,	 related	 to	phage	 transposon	or	plasmid,	motility	and	attachment	adaptation	&	protection	and	cell	wall/LPS/capsule	represent	a	greater	proportion	of	functional	associations	for	genes	that	are	overrepresented	for	loss	of	function	rather	than	underrepresented.			
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		Figure	 3.3.	 Comparison	 of	 associated	 pseudoCAP	 functional	 categories	 from	overrepresented	and	underrepresented	genes	 for	 loss	of	 function	 in	CF	(<0.05	chi	squared	significance)	
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3.4. Discussion	This	chapter	focused	on	two	approaches,	inference	of	adaptive	loss	of	function	by	 the	 number	 of	 independent	 acquisitions	 in	 the	 CF	 population	 and	comparison	 of	 a	 panel	 of	 CF	 isolate	 genomes	 and	 environmental	 isolate	genomes.	 The	 first	 depends	 on	 the	 expectation	 that	 for	 a	 particular	 gene	 it	should	 be	 unlikely	 that	 a	 variety	 of	 environmental	 niches	 from	 which	 P.	
aeruginosa	 infections	 are	 acquired	 would	 have	 the	 same	 selective	 pressures	compared	 with	 the	 comparably	 discrete	 environment	 of	 the	 CF	 lung.	Comparison	 of	 the	 CF	 and	 environmental	 isolates	 has	 been	made	 possible	 by	sequencing	 a	 large	 number	 of	 genomes.	 This	 has	 the	 benefit	 of	 potentially	capturing	bias	 in	acquisition	and	also	the	ability	to	assess	 larger	deletions	and	gene	absences.			
3.4.1. Genes	underrepresented	for	Loss	of	Function	in	CF	
Compared	with	the	Environment	There	were	 1409	 different	 genes	 significantly	 (p=<0.05)	 underrepresented	 in	the	 CF	 genomes	 compared	 with	 the	 environment.	 Compared	 with	 those	overrepresented	 for	 loss	 of	 function	 they	 were	 more	 involved	 in	 amino	 acid	biosynthesis	 and	 metabolism,	 antibiotic	 resistance	 and	 susceptibility,	biosynthesis	of	cofactors	and	prosthetic	groups	and	carries,	cell	division,	central	intermediary	metabolism,	chaperones	and	heat	shock	proteins,	DNA	replication	recombination	 modification	 and	 repair,	 energy	 metabolism,	 fatty	 acid	 and	phospholipid	 metabolism,	 membrane	 proteins,	 protein	 secretion/export	apparatus,	 putative	 enzymes,	 transcriptional	 regulators	 and	 two	 component	
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systems.	These	results	provide	a	wealth	of	 information	of	genes	 that	might	be	important	for	P.	aeruginosa	to	maintain	in	CF.			The	top	50	most	significantly	underrepresented	genes	in	CF	for	loss	of	function	were	associated	with	diverse	 functions.	For	example	 the	gene	xcpQ	 associated	with	protein	secretion140	is	present	and	without	nonsense	mutations	in	53.28%	of	 environmental	 genomes	 compared	with	 87.63%	 of	 those	 from	 CF.	 Specific	antibiotic	resistance	genes	also	appear	to	be	more	conserved	in	CF	than	in	the	environment	 such	 as	 the	 streptomycin	 resistance	 gene	 str.	 The	 str	 gene	(PA1858)	 is	 present	 and	without	 loss	 of	 function	mutations	 in	 93.29%	 of	 CF	genomes	 compared	 with	 64.96%.	 Sensor/response	 regulator	 hybrid	 gene	PA2583	has	 been	 observed	 to	 be	 upregulated	 in	 colistin	 resistant	 strains	 and	knocking	 it	 out	 has	 a	 detrimental	 effect	 on	 expression	 of	 pmrA	 and	 arnB	involved	 in	polymyxin	 resistance327.	PA2583	 is	 significantly	underrepresented	for	loss	of	function	in	CF	(p	=	6.5	x	10-11);	it	was	present	and	without	nonsense	mutations	in	85.56%	of	CF	genomes	compared	with	58.39%	of	environmental.	LysR-type	 regulator	 gene	 PA0191	 has	 been	 observed	 to	 be	 induced	 in	 the	presence	of	monosulfactam328	and	is	underrepresented	for	loss	of	function	in	CF	(chi	squared,	p	=	4.31	x	10-11).			
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3.4.2. Genes	Overrepresented	for	Loss	of	Function	in	CF	
Compared	with	the	Environment	Genes	 previously	 identified	 to	 be	 adaptive	 by	 loss	 of	 function	 in	 CF	 were	observed	 to	 be	 overrepresented	 for	 loss	 of	 function	 in	 this	 dataset66.	 Loss	 of	function	in	the	mucA	gene	was	significantly	overrepresented	in	the	CF	genomes	compared	with	the	environment	(p	=	3.2	x	10-4).	Of	388	P.	aeruginosa	genomes	from	CF,	58	carried	loss	of	function	mutations	in	mucA	compared	with	4	of	137	from	the	environment.	Seven	CF	isolate	genomes	with	loss	of	function	in	mucA	however	were	observed	 to	 carry	potential	 compensatory	mutations	by	 loss	of	function	 in	at	 least	one	of	 these	genes	 involved	 in	alginate	biosynthesis.	There	wasn’t	however	evidence	 for	an	overrepresentation	of	 loss	of	 function	 in	DNA	mismatch	repair	genes	mutS,	mutL,	mutM	and	uvrD	(p	=	0.32).	Loss	of	function	was	observed	in	at	 least	one	of	 these	genes	 in	21	of	388	CF	genomes	and	4	of	137	environmental.	It	has	previously	been	observed	that	iron	acquisition	by	the	heme,	rather	than	the	more	common	pyoverdine	mechanism	is	preferred	during	CF326	 infections.	Consistent	with	this	13	different	pyoverdine	biosynthesis	and	receptor	genes	were	observed	to	be	overrepresented	for	loss	of	function	in	CF	(table	3.6).	Loss	of	quorum	sensing	regulator	LasR	has	been	associated	with	CF	lung	infections278	and	though	inferred	to	be	adaptive	by	loss	of	function	in	the	representative	panel	it	was	not	observed	to	be	significantly	overrepresented	for	loss	of	function	in	the	IPCD	CF	genomes.			Genes	 associated	 with	 antibiotic	 resistance	 and	 susceptibility	 were	 also	observed	 to	 be	 overrepresented	 for	 loss	 of	 function	 in	CF,	 both	where	 loss	 of	function	is	associated	with	increased	and	decreased	antibiotic	resistance.	UDP-
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N-acetylmuramate-alanyl-gamma-D-glutamyl-meso-diaminopimelate-ligase	gene	(mpl)	was	observed	to	be	significantly	overrepresented	for	loss	of	function	in	CF	isolate	genomes	compared	with	the	environment	(p	=	2.53	x10-4).	Loss	of	function	in	mpl	has	previously	been	identified	in	a	transmissible	CF	strain,	 the	LES280.	Disruption	of	mpl	has	been	associated	with	piperacillin	and	ceftazidime	resistance	 due	 to	 an	 accumulation	 of	 immature	 cell	wall	 components	 and	 up-regulation	 of	 AmpC	 expression329.	 The	 TonB	 dependent	 siderophore	 receptor	PiuA	 is	 observed	 to	 be	 significantly	 overrepresented	 for	 loss	 of	 function.	Previously	 disruption	 of	 the	piuA	 gene	 has	 been	 observed	 to	 increase	MICs	 8	fold	 to	 the	 BAL30072	 monosulfactam	 siderophore328,	 though	 another	 study	demonstrated	 the	 potential	 for	 compensatory	 iron	 import	 mechanisms	 in	
vivo330.	 Though	 the	MexAB-oprM	 efflux	 pump	 is	 a	major	multidrug	 resistance	mechanism	 the	 operon	 mexAB-oprM	 is	 observed	 in	 65	 CF	 genomes	 carry	nonsense	 mutations,	 larger	 deletions	 and	 absences	 in	 the	 operon	 compared	with	6	environmental	genomes.		
3.4.3. Limitations	and	future	work	Different	 members	 of	 the	 species	 may	 carry	 orthologous	 genes	 of	 different	types.	 These	 can	 be	 associated	with	 the	 phylogenetic	 grouping,	 but	 so	 far	 the	evidence	suggests	that	the	population	involved	with	opportunistic	CF	infections	(not	 including	 transmissible	 lineages)	 mirrors	 that	 of	 the	 environment195.	Therefore	 bias	 in	 the	 species	 towards	 types	 shouldn’t	 explain	 a	 significant	overrepresentation	 of	 absence	 of	 that	 gene	 in	 CF	 isolate	 genomes.	 	 It	 does	however	 reduce	 the	 sample	 size	 as	 the	 comparison	 should	 be	 considered	 as	between	sub-populations	of	 the	potential	proportion	carrying	 that	homolog	 in	
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the	 environment.	 For	 example,	 separate	 types	 of	 P.	 aeruginosa	 siderophore	receptor	 gene	 fpvA	 have	 been	 identified	 (corresponding	 to	 type	 I,	 II,	 or	 III	pyoverdine)125.	The	reference	genome	PAO1	that	all	genomes	were	mapped	to	carries	the	fpvA	gene	encoding	type	I.	Type	I	FpvA	was	carried	in	25%	of	the	CF	genomes	compared	with	55.26%	of	those	from	the	environment.	Additionally	a	further	 two	 genomes	 from	 CF	 carry	 the	 type	 I	 fpvA	 gene	 but	 have	 each	independently	 acquired	 nonsense	 mutations.	 Overall	 lack	 of	 type	 I	 FpvA	 is	significant	in	CF	compared	with	the	environment	(chi	squared,	p	=	1.68	x10	-5).	Mapping	 against	 a	 reference	 genome	 carrying	 one	 type	 of	 FpvA	 however	reduces	 the	 sample	 size	 rendering	 the	 result	more	 likely	 to	 be	 as	 a	 result	 of	chance	 alone.	 The	 evolutionary	 considerations	 are	 also	 changed	 by	 this	knowledge,	an	alternative	hypothesis	being	that	CF	isolates	carrying	other	types	of	 FpvA	 are	 favoured	 rather	 than	 the	 absence	 of	 function.	 Greater	environmental	 sampling	 to	 increase	 knowledge	 of	 such	 cases	 is	 desirable,	 or	identification	of	orthologous	types	and	subsequent	mapping	and	variant	calling	against	a	representative	panel	of	reference	genomes.			Within	 host	 evolutionary	 dynamics	 may	 also	 explain	 some	 observations.	 P.	
aeruginosa	 secretes	many	 costly	metabolites	 during	 CF	 lung	 infection.	 Cheats,	members	of	the	population	that	enjoy	the	benefit	of	these	products	with	none	of	the	 cost331,	 can	 have	 a	 competitive	 advantage	 over	 producers	 though	 this	 is	clearly	self-limiting	as	the	cheats	to	producers	(upon	which	they	depend)	ratios	may	rapidly	 change319,332.	 In	 the	CF	 lung,	non-producers	of	 costly	 siderophore	pyoverdine,	 occur	 due	 to	 loss	 of	 function333.	 In	 some	 cases	 the	 retention	 of	pyoverdine	 receptor	 genes	 suggest	 that	 these	 are	 cheats	 rather	 than	 simple	
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non-producers	 of	 a	 costly	 and	 unnecessary	 or	 actively	 disadvantageous	feature333.			
3.4.4. Chapter	summary	The	COST	representative	panel	was	whole	genome	sequenced	to	investigate	CF	associated	mutations.	It	was	demonstrated	that	lasR	and	mucA	commonly	associated	with	CF	infections	were	adaptive	by	loss	of	function	and	new	genes	potentially	associated	such	as	mexB	proposed.			Subsequent	analysis	of	loss	of	function	in	the	IPCD	CF	compared	with	environmental	isolate	genomes	showed:		
• 92	genes	overrepresented	for	loss	of	function	in	CF	
• MucA	loss	of	function	significantly	overrepresented	in	CF	
• Genes	where	loss	of	function	is	commonly	associated	with	CF	such	as	
mutS,	mutL,	mutM,	uvrD	and	lasR	not	significantly	overrepresented	compared	with	the	environment	
• >1,000	genes	underrepresented	for	loss	of	function	to	be	further	investigated						
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Chapter	Four	Whole	 Genome	 Sequencing	 of	 Historically	 and	Geographically	 Diverse	 Pseudomonas	 aeruginosa	Liverpool	Epidemic	Strain	Isolates	
4. Introduction	
4.1. Background	of	LES	strains	The	 discovery	 of	 the	 Liverpool	 Epidemic	 Strain	 (LES)	 provided	 the	 first	molecular	 evidence	 to	 confirm	 suspicions	 of	 P.	 aeruginosa	 cross	 infection	between	CF	patients192.	Molecular	surveys	of	CF	clinics	 following	 its	discovery	revealed	 that	 the	 LES	 was	 the	 most	 common	 single	 clone	 in	 CF	 clinics	nationwide211.	 Further,	 intercontinental	 spread	 of	 the	 strain	was	 observed	 as	the	 LES	 and	 the	 ‘LES-like’	 were	 isolated	 and	 typed	 from	 CF	 patients	 in	Canada334.	 Distinct	 transmissible	 strains	 have	 since	 been	 observed	 in	 the	Midlands	 and	 Manchester	 U.K.,	 the	 ‘Midlands’	 and	 ‘Manchester	 Epidemic	Strains’335,	in	Australia	strains	‘AES1’288,336,	 ‘AESII’	and	‘AESIII’337,	Denmark	the	‘DK2’279	strain,	Belgium338	and	in	Canada	the	 ‘Prairie	Epidemic	Strain’339.	Prior	to	 the	 discovery	 of	 cross	 infecting	 lineages	 of	 P.	 aeruginosa	 in	 CF	 the	
Bukrholderia	 cenocepacia	 ET12	 lineage	 had	 been	 discovered	 to	 transmit	between	 patients	 prompting	 segregation	 of	 patients	 in	 affected	 clinics205,340.	Following	the	discovery	of	the	LES	segregation	of	patients	was	implemented	for	LES-positive	 clinics,	 successfully	 diminishing	 new	 instances	 in	 some	 U.K.	clinics225.	 The	 LES	 also	 appears	 to	 super-infect	 patients,	 replacing	 existing	chronic	P.	aeruginosa	 lung	 infections341.	 Patients	 chronically	 infected	with	 the	
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LES	 also	 carry	 a	 poorer	 prognosis	 and	 isolates	 present	 elevated	 levels	 of	antibiotic	resistance210.			
4.1.1. Epidemiology	The	 LES	 was	 discovered	 in	 1996	 when,	 prompted	 by	 patterns	 of	 resistance	across	 P.	 aeruginosa	 positive	 CF	 patients,	 a	 molecular	 investigation	 was	conducted	 at	 Alder	 Hey	 Children’s	 Hospital,	 Liverpool,	 U.K.	 Molecular	 typing	revealed	 that	 55/65	 patients	 were	 harbouring	 the	 same	 strain	 making	 cross	infection	highly	likely;	it	was	suggested	that	ceftazidime	monotherapy	may	have	resulted	in	the	emergence	of	the	strain192.	Following	the	discovery	of	the	LES,	a	molecular	 epidemiological	 survey	 was	 undertaken	 in	 England	 that	 was	published	 in	 2004211.	 In	 total,	 1225	P.	 aeruginosa	 isolates	 from	 CF	 infections,	from	 31	 clinical	 centres	were	 genotyped.	 It	 was	 demonstrated	 that	while	 the	majority	 (78%)	 of	 patient’s	 harboured	 individual	 genotypes,	 transmissible	strains	were	 the	most	 common	 single	 genotypes211.	 Fifteen	 centres	 presented	93	 isolates	 of	 the	 LES	making	 it	 the	most	 common	 single	 clone.	 These	 initial	findings	were	corroborated	by	later	studies,	finding	that	in	Scotland	the	LES	was	also	 present	 in	 10/43	 patients	 sampled342	 and	 that	 in	 the	 adult	 CF	 centre	 in	Liverpool	 63/80	 patients	 were	 LES	 positive206.	 Later,	 in	 2008	 the	 LES	 was	sampled	from	clinics	in	Canada343.		
4.1.2. Microbiology	and	clinical	features	It	has	been	shown	that	some	isolates	of	the	LES	over-produce	quorum	sensing	regulated	 secreted	 virulence	 factors	 such	 as	 pyocyanin	 LasA	 and	 elastase,	
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raising	their	virulence	in	 infection	models344,255.	However,	 the	quorum	sensing	regulator	 LasR	 is	 also	 frequently	 observed	 to	 be	 independently	 mutated	resulting	 in	 loss	 of	 function104,154,278.	 The	 LES	 is	 additionally	 an	 unusual	 P.	
aeruginosa	 for	 having	 lost	 its	 motility	 and	 always	 lacking	 a	 flagella345,	presumably	due	to	a	fixed	nonsense	mutation	in	the	gene	fleR.		
	The	mechanism	of	transmission	by	the	LES	is	not	yet	understood	but	studies	of	the	 hospital	 environment	 have	 found	 no	 lasting	 environmental	 reservoirs346.	Repeated	sampling	of	nearby	dry-surfaces	demonstrates	that	the	LES	is	present	only	initially346.	Similarly	the	LES	does	present	in	air	samples	for	a	short	time346.	In	addition	to	the	ability	to	cross	infect	CF	patients,	the	LES	has	demonstrated	a	number	 of	 interesting	 clinical	 features.	 The	 LES	 can	 super-infect	 existing	chronic	P.	aeruginosa	 lung	infections	in	CF341,	 infection	of	both	non-CF	parents	of	a	CF	patient	has	been	reported347,	the	LES	has	also	been	implicated	in	non-CF	bronchiectasis	 lung	 infections	 and	 transmission	 to	 a	 pet	 cat,	 Osiris,	 has	occurred348.		
	
4.1.3. The	LES	genome	Isolates	pre-dating	the	discovery	of	the	LES	were	identified	from	frozen	samples	by	 typing.	 LES	 reference	 isolate	 LESB58	 is	 the	 oldest	 dated	 isolate	 as	 it	 was	archived	in	1988.	LESB58	was	the	first	LES	isolate	genome	to	be	sequenced	and	this	 was	 published	 in	 2009	 by	Winstanley	 et	 al.291.	 LESB58	 was	 observed	 to	have	a	6.7Mbp	genome	carrying	6,027	genes,	5,931	of	which	are	protein	coding.	The	 LES	 genome	 was	 aligned	 to	 P.	 aeruginosa	 reference	 genomes	 already	
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sequenced,	PA01,	PA14	and	PA7	and	determined	to	contain	574,	528	and	825	orthologs	 respectively291.	 It	 was	 also	 possible	 to	 determine	 that	 the	 LESB58	genome	 carries	 5	 genomic	 islands	 and	 6	 prophages	 (table	 4.1).	 A	 10,344bp	region	of	prophage	2	is	homologous	with	a	region	prophage	3.	Prophage	3	and	5	have	two	homologous	regions349.	Additionally	prophage	4	shows	homology	with	D3112	 phage	 and	 prophage	 6	 belongs	 to	 the	 filamentous	 phage	 family	
Inoviridae	 (Pf1)349.	 A	 rat	 infection	model	 determined	 that	 LES	 prophages	 2,	 3	and	 5	 demonstrated	 that	 they	 were	 associated	 with	 in	 vivo	 competitiveness	while	prophage1	is	defective291.			Table	4.1.	Genomic	island	and	prophage	regions	identified	in	LESB58291	
Region	name	 Start	 End	 No.	of	genes	LESGI-1	 2504700	 2551100	 31	LESGI-2	 2751800	 2783500	 18	LESGI-3	 2796836	 2907406	 107	LESGI-4	 3392800	 3432228	 32	LESGI-5	 4931528	 4960941	 26	Prophage	1	 665561	 680385	 19	Prophage	2	 863875	 906018	 44	Prophage	3	 1433756	 1476547	 53	Prophage	4	 1684045	 1720850	 48	Prophage	5	 2690450	 2740350	 65	Prophage	6	 4545190	 4960941	 12		Additional	 LES	 genomes	 were	 sequenced	 for	 comparative	 genomic	 studies	assessing	within	and	between	strain	diversity214,334.	Dettman	et	al.,	conducted	a	comparative	 genomics	 study	 of	 epidemic	 (LES)	 and	 non-epidemic	 strain	genomes.	 Reconstructing	 a	 phylogenetic	 tree	 of	 polymorphic	 sites	 in	 the	 core	genome	 of	 LES	 and	 non-LES	 isolate	 genomes	 combined	 they	 showed	 that	 the	British	 and	 Canadian	 LES	 formed	 a	 monophyletic	 group214.	 Further,	 it	 was	
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determined	which	genes	contributed	the	most	diversity	on	 the	branch	 leading	to	the	LES	clade	to	infer,	by	their	functional	categories,	mutational	changes	that	may	 be	 characteristic	 of	 the	 strain.	 Functional	 categories,	 kinase	 activity,	arginine	metabolism,	 redox,	protein	 secretion	and	cation	 transport	were	most	overrepresented	for	mutations	by	function	in	the	core	genome214.			A	 detailed	 comparison	 was	 then	 conducted	 by	 Jeukens	 et	 al.,	 of	 British	 and	Canadian	LES	 isolate	genomes.	 Isolates	LES400,	LES431	and	LESB65	 from	 the	U.K.,	 combined	 with	 reference	 LESB58	 and	 LESlike1,	 LESlike4,	 LESlike5	 and	LESlike7	 isolates	 from	 Canada	 (Ontario,	 Ottawa,	 Toronto	 and	 Hamilton	respectively)	 were	 whole	 genome	 sequenced334.	 In	 the	 accessory	 genome	 of	these	strains	it	was	shown	that	LESB58	genomic	islands	and	prophages	varied.	LES	prophage	5	was	absent	in	5/7	genomes	while	genomic	island	4	was	present	in	 all.	 Analysis	 of	 core	 genome	 polymorphisms	 determined	 that	 LES400	 and	LES431	 the	 oldest	 isolates	 after	 LESB58	 were	 genetically	 most	 similar	 to	LESB58334.	The	genes	lasR,	vfr,	exsA,	ropN,	cyaB	and	ampD	were	identified	to	be	the	most	diverse	in	the	core	genome.	Further	1	in	6	mutations	in	genes	across	the	genomes	were	carried	in	regulatory	genes334.						
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4.1.4. 	Aims	of	this	study	The	aim	of	this	chapter	was	to	use	whole	genome	sequencing	of	a	historically	and	geographically	diverse	panel	of	Liverpool	Epidemic	Strain	genomes	to	assess:		
• If	the	Canadian	and	UK	LES	are	genetically	distinct	
• The	genomic	epidemiology	of	the	isolates	
• Adaptive	strategies		
• Pangenome	structure	of	the	most	diverse	set	of	the	LES	yet																	
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4.2. Methods		Genome	 sequencing,	 raw	 sequence	 read	 filtering	 and	 adapter	 trimming,	 read	mapping	 and	 variant	 calling	 and	 genome	 assembly	 were	 performed	 as	described	 in	Chapter	Two:	General	Methods.	All	 sequencing	reads	mapped	 for	variant	calling	in	this	chapter	were	mapped	to	LESB58	as	described	in	General	Methods.	 Variant	 calling	 from	 mapped	 reads	 was	 used	 for	 all	 analysis	 of	mutations	whereas	assembled	genomes	were	used	for	all	other	analyses.				
4.2.1. Scaffolding	to	reference	LESB58	The	syntenies	of	all	de	novo	assembled	contigs	were	determined	by	scaffolding	against	the	genome	of	LESB58291	using	ABACAS294.	Contigs	containing	sequence	accessory	to	the	LESB58	genome	were	appended	to	the	end	of	the	draft	genome.			
4.2.2. 	Percent	identity	of	LESB58	prophages	and	genomic	
islands		A	 database	 of	 LES	 genomes	 was	 generated	 using	 blast+	 makeblastdb	 against	which	 each	 LESB58	 prophage	 and	 genomic	 island	 was	 aligned	 using	 blast+,	blastn	 (window	 size	 28).	 The	 contribution	 to	 percent	 identity	 by	 duplications	was	 corrected	 for	 by	 reciprocally	 aligning	 those	 regions	 with	 known	duplications	 with	 blastn.	 By	 aligning	 the	 duplications	 from	 respective	prophages	 it	 could	be	determined	how	much	of	 the	overall	 alignment	 for	 that	prophage	was	a	result	of	 the	duplicated	sequence.	The	results	were	visualised	as	a	heatmap	according	to	final	percent	identity	with	the	LESB58	prophages	and	
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genomic	 islands	 and	 generated	 using	 the	 interactive	 tree	 of	 life	 software	(iTol)313.			
4.2.3. Pan	genome	analysis	The	 pan-genome	 was	 determined	 using	 large	 scale	 blast	 score	 ratio	 pipeline	(LS-BSR)350,	 with	 standard	 parameters	 and	 alignment	 by	 blastn.	 The	 pan-genome	matrix	was	randomly	sampled	at	different	depths	for	100	iterations	to	determine	 the	 core	 and	 accumulation	 curves	 using	 LS-BSR	 post	 processing	script	BSR_to_gene_accumulation_scatter.py350	and	visualised	respectively	using	the	 boxplot	 package	 in	 R.	 Pan-genome	 statistics	were	 generated	with	 LS-BSR	post-processing	 tool	 pan_genome_stats.py350.	 Core	 and	 accessory	 gene	 curves	were	visualised	using	boxplots	in	R.			
4.2.4. Inference	of	positive	selection	Pseudoalignments	 were	 generated	 of	 LESB58	 genes	 to	 which	 reads	 were	aligned	 to	 the	 full	 length	 of	 the	 gene	 and	 incorporating	 variants	 from	 GATK.	Multiple	 alignments	 were	 produced	 by	 clustalW.	 Maximum	 likelihood	 gene	trees	 were	 approximated	 using	 RaxML	 with	 the	 GTR	 substitution	 model311.	Inference	 of	 codon	 selection	 was	 peformed	 using	 hyphy351,	 dNdS	 ratios	averaged	 across	 all	 codons	 (omega)	 of	 <1	 and	 purifying	 selection	 is	 inferred	whereas	>1,	positive	selection	is	inferred.					
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4.3. Results	A	 geographically	 diverse	 and	 historic	 sample	 of	 the	 LES	was	 selected	 for	 this	study	 and	 a	 total	 of	 93	 such	 isolates	were	 sequenced.	 In	 order	 to	 analyse	 the	most	 diverse	 sample	 possible,	 these	 were	 combined	 with	 50	 LES	 genomes	already	published	from	comparative	genomics	studies	and	representative	sub-samples	 from	within-patient	 studies.	 The	 genomes	 that	 have	 been	 sequenced	are	from	a	diverse	range	of	hosts	too,	such	as	bronchiectasis	patients,	primary	cilliary	dykinesis	 (PCD)	patients,	 a	pet	 cat,	 the	non-CF	parents	of	 a	CF	patient	and	CF	patients.	The	geographic	source	of	these	143	LES,	primarily	from	various	centres	in	the	UK	and	also	Canada	are	listed	in	table	4.2.			Table	4.2.	LES	genomes	analysed	in	this	study,	the	source	of	isolation	according	to	PHE	area	designations,	pathology	and	sequencing	centre	or	publication	from	which	they	were	obtained	(Darch	et	al.352,	Williams	et	al.280,	Jeukens	et	al.334)	
Isolate	 Year	if	
known	
Country	 City	or	region	 Pathology	 Sequencing	
centre	or	
data	source	
49070	 2004	 UK	 Liverpool	 CF	 Liverpool	CGR	
CF8S1_27	 2009	 UK	 Liverpool	 CF	 Liverpool	CGR	
72G	 2003	 UK	 Liverpool	 CF	 Liverpool	CGR	
o59100	 2005	 UK	 Liverpool	 CF	 Liverpool	CGR	
49400	 2004	 UK	 Liverpool	 CF	 Liverpool	CGR	
49492	 2004	 UK	 Liverpool	 CF	 Liverpool	CGR	
49348	 2003	 UK	 Liverpool	 CF	 Liverpool	CGR	
30567S	 2003	 UK	 Liverpool	 CF	 Liverpool	CGR	
89577	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
89570	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
CF3S1_08	 2009	 UK	 Liverpool	 CF	 Liverpool	CGR	
89244	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
89347	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
89093	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
89568	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
89224	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
89221	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
89150	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
89212	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
89204	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
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89153	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
CF3S1_21	 2009	 UK	 Liverpool	 CF	 Liverpool	CGR	
10333	 2004	 UK	 Nottingham		 CF	 Liverpool	CGR	
10262	 2004	 UK	 Nottingham		 CF	 Liverpool	CGR	
11112	 2004	 UK	 Birmingham	 CF	 Liverpool	CGR	
8835	 2004	 UK	 Wrexham	 CF	 Liverpool	CGR	
9857	 2004	 UK	 London	 CF	 Liverpool	CGR	
8995	 2004	 UK	 Sheffield		 CF	 Liverpool	CGR	
9920	 2004	 UK	 Clatterbridge	 CF	 Liverpool	CGR	
417GLY	 2000	 UK	 Liverpool	 Non-CF	 Liverpool	CGR	
B9	 1995	 UK	 Liverpool	 CF	 Liverpool	CGR	
CF4S1_08	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
OSIRIS	 2007	 UK	 Liverpool	 Pet	cat	 Liverpool	CGR	
119579	 2013	 UK	 Liverpool	 PCD	 Liverpool	CGR	
139124	 2013	 UK	 Liverpool	 PCD	 Liverpool	CGR	
139125	 2013	 UK	 Liverpool	 PCD	 Liverpool	CGR	
79426	 2007	 UK	 Liverpool	 Empyema	 Liverpool	CGR	
79427	 2007	 UK	 Liverpool	 Empyema	 Liverpool	CGR	
PHE_LES1	 2010	 UK	 Scotland	 CF	 Liverpool	CGR	
PHE_LES2	 2013	 UK	 London	 CF	 Liverpool	CGR	
B35	 1998	 UK	 Liverpool	 CF	 Liverpool	CGR	
CF4S1_32	 2009	 UK	 Liverpool	 CF	 Liverpool	CGR	
PHE_LES3	 2012	 UK	 East	Midlands	 CF	 Liverpool	CGR	
PHE_LES4	 2013	 UK	 London	 CF	 Liverpool	CGR	
PHE_LES5	 2014	 UK	 West	Midlands	 CF	 Liverpool	CGR	
PHE_LES6	 2011	 UK	 East	Midlands	 CF	 Liverpool	CGR	
PHE_LES7	 2014	 UK	 West	Midlands	 CF	 Liverpool	CGR	
PHE_LES8	 2011	 UK	 North	East	 CF	 Liverpool	CGR	
PHE_LES9	 2011	 UK	 South	East	 CF	 Liverpool	CGR	
PHE_LES10	 2014	 UK	 East	 CF	 Liverpool	CGR	
PHE_LES11	 2013	 UK	 Yorkshire	 CF	 Liverpool	CGR	
PHE_LES12	 2013	 UK	 London	 CF	 Liverpool	CGR	
49388	 2004	 UK	 Liverpool	 CF	 Liverpool	CGR	
CF5S1_04	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
PHE_LES13	 2013	 UK	 Wales	 CF	 Liverpool	CGR	
PHE_LES14	 2012	 UK	 North	West	 CF	 Liverpool	CGR	
PHE_LES15	 2012	 UK	 South	West	 CF	 Liverpool	CGR	
PHE_LES16	 2014	 UK	 East	 CF	 Liverpool	CGR	
PHE_LES17	 2012	 UK	 North	West	 CF	 Liverpool	CGR	
PHE_LES18	 2012	 UK	 London	 CF	 Liverpool	CGR	
PHE_LES19	 2012	 UK	 London	 non-CF	 Liverpool	CGR	
PHE_LES20	 2012	 UK	 North	East	 CF	 Liverpool	CGR	
PHE_LES21	 2013	 UK	 East	 CF	 Liverpool	CGR	
PHE_LES22	 2013	 UK	 East	Midlands	 Bronchiectasis	 Liverpool	CGR	
30642g	 2003	 UK	 Liverpool	 CF	 Liverpool	CGR	
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CF5S1_20	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
PHE_LES23	 2013	 UK	 London	 CF	 Liverpool	CGR	
PHE_LES24	 2013	 UK	 London	 CF	 Liverpool	CGR	
PHE_LES25	 2013	 UK	 Wales	 CF	 Liverpool	CGR	
PHE_LES26	 2013	 UK	 South	East	 CF	 Liverpool	CGR	
PHE_LES27	 2013	 UK	 West	Midlands	 Liverpool	CGR	
PHE_LES28	 2013	 UK	 East	 CF	 Liverpool	CGR	
PHE_LES29	 2013	 UK	 West	Midlands	 Liverpool	CGR	
PHE_LES30	 UK	 Liverpool	 Liverpool	CGR	
89192	 2008	 UK	 Liverpool	 CF	 Liverpool	CGR	
CF7S1_10	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF9S1_24	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
120MO	 2003	 UK	 Liverpool	 CF	 Liverpool	CGR	
CF7S1_15	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
49513	 2004	 UK	 Liverpool	 CF	 Liverpool	CGR	
CF8S1_02	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF177_P138	 UK	 Birmingham	 CF	 Birmingham	Nick	Loman	
CF54_NCTC13415	 UK	 Birmingham	 Birmingham	Nick	Loman	
CF60_P44	 UK	 Birmingham	 CF	 Birmingham	Nick	Loman	
Md1_LES	 UK	 Birmingham	 CF	 Birmingham	Nick	Loman	
CF7S1_39	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF8S1_33	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF8S1_36	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF9S1_11	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF10S1_11	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF10S1_21	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
LESB58_2	 1988	 UK	 Liverpool	 CF	 Liverpool	CGR	
CF1S1_20	 2009	 UK	 Liverpool	 CF	 Dettman	et	al.	
JD304	 Canada	 Ottawa	 CF	 Dettman	et	al.	
JD310	 Canada	 Ottawa	 CF	 Dettman	et	al.	
JD315	 Canada	 Hamilton	 CF	 Dettman	et	al.	
JD322	 Canada	 Toronto	 CF	 Dettman	et	al.	
JD324	 Canada	 Toronto	 CF	 Dettman	et	al.	
JD326	 Canada	 Hamilton	 CF	 Dettman	et	al.	
JD329	 Canada	 London	 CF	 Dettman	et	al.	
JD335	 Canada	 Toronto	 CF	 Dettman	et	al.	
LES400	 1998	 UK	 Liverpool	 CF	 Jeukens	et	al	
LES431	 2000	 UK	 Liverpool	 Non-CF	 Jeukens	et	al	
LESB58	 1988	 UK	 Liverpool	 CF	 Jeukens	et	al	
LESB65	 2003	 UK	 Liverpool	 CF	 Jeukens	et	al	
LESlike_1	 2005	 Canada	 Ottawa	 CF	 Williams	et	al.	
LESlike_4	 2005	 Canada	 Toronto	 CF	 Williams	et	al.	
LESlike_5	 2007	 Canada	 Toronto	 CF	 Williams	et	al.	
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LESlike_7	 2006	 Canada	 Hamilton	 CF	 Williams	et	al.	
CF1S1_33	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF3S1_12	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF3S1_24	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF4S1_2	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF4S1_26	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF5S1_34	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF5S1_38	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF6S1_1	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF6S1_18	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF7S1_36	 2009	 UK	 Liverpool	 CF	 Williams	et	al.	
CF3S2_19	 UK	 Liverpool	 CF	 Williams	et	al.	
CF3S2_25			 UK	 Liverpool	 CF	 Williams	et	al.	
CF3S2_35	 UK	 Liverpool	 CF	 Williams	et	al.	
CF3S2_24	 UK	 Liverpool	 CF	 Williams	et	al.	
CF3S2_31	 UK	 Liverpool	 CF	 Williams	et	al.	
CF3S2_5	 UK	 Liverpool	 CF	 Williams	et	al.	
LiP9	 UK	 East	Midlands	 CF	 	Quebec	
LiP13	 UK	 East	Midlands	 CF	 	Quebec	
LiP10a	 UK	 East	Midlands	 CF	 	Quebec	
LiP10b	 UK	 East	Midlands	 CF	 	Quebec	
LiP8	 UK	 East	Midlands	 CF	 	Quebec	
LiP1a	 UK	 East	Midlands	 CF	 	Quebec	
LiP1c	 UK	 East	Midlands	 CF	 	Quebec	
LiP2c	 UK	 East	Midlands	 CF	 	Quebec	
LiP2a	 UK	 East	Midlands	 CF	 	Quebec	
LiP2b	 UK	 East	Midlands	 CF	 	Quebec	
LiP11	 UK	 East	Midlands	 CF	 	Quebec	
LiP14	 UK	 East	Midlands	 CF	 	Quebec	
LiP12	 UK	 East	Midlands	 CF	 	Quebec	
LiP5	 UK	 East	Midlands	 CF	 	Quebec	
LiP7	 UK	 East	Midlands	 CF	 	Quebec	
SED11	 UK	 East	 CF	 Darch	et	al.	
SED1	 UK	 East	 CF	 Darch	et	al.	
SED20	 UK	 East	 CF	 Darch	et	al.					
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4.3.1. Genome	Assembly	quality	Genome	 sizes	 ranged	 from	 6,256,335bp	 (PHELES12)	 to	 6,764,430bp	(PHELES27),	a	range	of	508,095bp	and	mean	overall	of	6,473,573.9bp.	The	GC	content	of	the	genomes	ranged	from	65.22%	(PHELES27)	to	66.54%	(JD315),	a	range	of	1.32%	and	a	mean	of	65.92%.			To	assess	genome	assembly	quality,	contig	 length	based	metrics,	N50,	number	of	 contigs	 and	 largest	 contig	 were	 used.	 LESB58	 and	 LES431	 are	 complete	genomes	 so	 were	 excluded	 from	 this	 comparison.	 N50	 ranged	 from	 5342	(JD324)	 to	4,752,040	 (LES400)	with	a	mean	of	428722.17.	Number	of	 contigs	(above	1000bp)	ranged	from	1488	(JD324)	to	3	(LESB65)	(Table	4.3).			Table.	4.3.	Ranges	for	genome	contig	length	based	assembly	quality	metrics,	genome	size	and	GC%	content		
Genome	size	 6256335-6764430	
GC	content%	 65.22-66.54	
Number	of	contigs*	 3-1488	
N50	 5342-4,752,040	*contigs	>1000bp	counted	
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4.3.2. Core	genome	SNP	phylogeny	The	 core	 genome	 was	 3,761,492bp	 and	 contained	 972	 phylogenetically	informative	 sites.	 An	 unrooted	 maximum	 likelihood	 phylogeny	 was	approximated	from	the	143	taxa	LES	core	genome	resulting	in	653	splits	using	the	TVM+R3	substitution	model	(IQ-TREE-1.5.6)	selected	by	ModelFinder	with	1000	 ultrafast	 bootstraps	 (supplementary	 figure	 4).	 Two	 major	 clades	containing	 genomes	 of	 isolates	 primarily	 from	 Canada	 and	 the	 second	 with	genomes	 exclusively	 isolated	 from	 the	 UK	 with	 LESB58	 and	 LESB58_2	 as	 an	outgroup	to	both.	Gubbins	was	used,	using	the	LES	core	genome	alignment	and	ML	 phylogenetic	 tree	 as	 a	 starting	 tree,	 to	 approximate	 a	 core	 genome	phylogeny	 with	 branch	 lengths	 and	 topology	 corrected	 for	 the	 presence	 of	recombinant	 SNPs	 (the	 clonal	 frame)	 (figure	 4.1).	 Recombinant	 SNPs	 were	predicted	to	account	for	2.87%	of	all	core	genome	SNPs.	Supplementary	figure	5	displays	 the	 core	 genome	 tree	 as	 a	 cladogram	with	 branch	 lengths	 displayed.	Supplementary	 figure	6	displays	 recombinant	 SNPs	based	on	 their	position	 in	the	 core	 genome	 alignment	 alongside	 the	 tree.	 The	 core	 genome	 was	 also	extracted	 for	 the	 143	 LES	 taxa	 and	 non-LES	 outgroup	 PAO1	 (supplementary	figure	5),	confirming	LESB58	as	an	outgroup	to	the	UK	LES	for	further	analysis.									
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	Figure	 4.1.	 LES	 core	 genome	 phylogeny	 (n	 =	 143).	 Maximum	 likelihood	approximation	with	 IQ-TREE-1.5.6	 using	 the	 TVM+R3	 substitution	model	 and	1000	ultrafast	bootstraps		
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In	addition	to	phylogenetic	clustering	of	 isolate	genomes	from	Canada	and	the	UK	respectively,	there	is	clustering	of	genomes	within	the	UK	clade	(figure	4.2).	However,	 placement	 in	 the	 core	 SNP	 tree	 is	 not	 consistent	 with	 source	 of	isolation	 in	 every	 case.	 For	 all	 inconsistencies	where	 further	patient	data	was	available,	the	patients	had	previously	lived	or	at	least	presented	a	sample	at	the	location	with	which	 their	 isolate	genome	clusters	on	 the	 tree.	All	UK	 locations	referred	to	are	Public	Health	England	(PHE)	designated	regions.			PHELES10	 and	 PHELES16	 are	 isolates	 provided	 from	 patients	 in	 the	 East	 of	England	in	2014	that	cluster	instead	with	isolates	from	the	East	Midlands.	Both	patients	 presented	 samples	 prior	 to	 2014	 in	 the	 East	 Midlands	 CF	 Unit.	 The	patient	 that	 provided	 PHELES11	 in	 Scotland,	 that	 also	 clusters	with	 genomes	from	the	East	Midlands	previously	provided	a	P.	aeruginosa	sample	in	the	East	Midlands	 with	 the	 LES	 associated	 serotype	 (O6).	 The	 greatest	 discrepancies	between	locations	of	isolation	and	genomic	epidemiology	were	for	isolates	LiP6	and	PHELES19	clustering	with	the	 isolates	 in	Canada.	Further	 investigation	by	colleagues	 at	 PHE	 revealed	 that	 LiP6	was	 isolated	 from	 a	 patient	 in	 the	 East	Midlands	that	had	previously	lived	in	Canada.						
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			Figure	4.2.	LES	core	genome	(n	=	143	genomes)	RAxML	tree	based	on	SNP	sites	filtered	 to	 remove	 recombinant	 SNPs	 by	 gubbins.	 Colour	 strip	 and	 branches	coloured	by	PHE	regions	according	to	geographic	source	of	isolation							
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4.3.3. LES	Pangenome	A	 matrix	 of	 gene	 content	 in	 the	 LES	 pangenome	 was	 determined.	 The	pangenome	matrix	was	sampled	at	various	depths	per	genome	(n=143)	for	100	iterations	and	plotted	for	core	and	accumulated	genes	(figure	4.4).	Figure	4.4a	shows	 the	 conservation	 of	 genes	 within	 the	 LES.	 The	 trend	 of	 accumulated	genes	(figure	4.4b)	indicates	that	the	LES	has	an	open	pan-genome.	The	number	of	 genes	 in	 the	 core	 genome	was	 4195	while	 466	were	 unique.	 The	 LES	 core	genome	therefore	accounts	 for	90%	of	 the	pangenome	and	an	average	of	3.26	new	genes	are	added	with	each	new	genome	sequenced.			Pan	genome	matrix	values	were	designated	as	group1	 if	 they	belonged	 to	LES	phylogenetic	 group	 1	 (figure	 4.2a)	 or	 group	 2	 if	 they	 belonged	 to	 LES	phylogenetic	 group	 2	 (figure	 4.2b).	 There	 were	 no	 set	 differences	 observed	between	 the	 groups	 in	 presence	 or	 absence	 of	 genes	 and	 similarly	 no	 set	difference	following	exclusion	of	LESB58	and	re-sequenced	LESB58	(LESB58_2)	are	an	outgroup	to	both	groups.		
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a.	
b.		Figure	 4.3.	 Pangenome	 matrix	 randomly	 sampled	 at	 various	 depths	 for	 100	iterations.	(a)	shows	the	core	genome	and	(b)	the	accumulation	of	genes	overall.	On	 the	 x	 axis	 number	 of	 genes	 added	 and	 on	 the	 y	 axis	 number	 of	 genomes	added		
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4.3.4. Distribution	of	LESB58	Prophage	and	Genomic	Islands	
amongst	the	wider	LES	collection	The	reference	genome	LESB58	carries	5	genomic	islands	and	6	prophages;	these	were	each	aligned	 to	each	of	 the	143	LES	genomes	 to	assess	percent	 identity.	Figure	4.4	presents	a	heatmap	of	the	percent	identity	for	each	genomic	island	or	prophage.	 In	 the	majority	of	genomes	LESB58	genomic	 islands	and	prophages	are	mostly	 present	 but	 also	 vary	 from	 complete	 or	 near	 complete	 absence	 to	100%	 identity.	 Prophage	 5	 is	 absent	 in	 the	 majority	 of	 genomes,	 percent	identity	0-14%	in	124/143	genomes.	Prophage	5	is	present	at	>99%	in	LES431	and	LES400.			Table	4.4.	Mean	and	range	of	percent	identity	of	blast	alignment	with	LESB58	genomic	islands	and	prophages	across	the	LES	genomes	(n=143)		
LESB58	region	 Mean	percent	identity	 Range	of	percent	identity	
LESGI1	 91.9	 36.6-100	
LESGI2	 99.89	 89.14-100	
LESGI3	 98.51	 0-100	
LESGI4	 85.72	 6.98-100	
LESGI5	 65.03	 0-100	
prophage2	 70.78	 0-100	
prophage3	 71.23	 0-100	
prophage4	 98.94	 0-100	
prophage5	 12.35	 0-100	
prophage6	 94.91	 0-100							
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	Figure	4.4.	LES	core	genome	(n	=	143	genomes)	RAxML	tree	based	on	SNP	sites	filtered	to	remove	recombinant	SNPs	by	gubbins.	Colour	strip	and	branches	coloured	by	PHE	regions	according	to	geographic	source	of	isolation.	Alongside	the	tree	is	a	heatmap	for	each	corresponding	genome	of	LESB58	genomic	island	and	prophage	percent	identity		
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4.3.5. Mutational	Diversity	within	the	UK	LES	Genomes	To	 analyse	 the	 mutational	 diversity	 across	 the	 UK	 LES	 genomes,	 those	 with	short	 reads	 available	 (n=122)	 (table	 4.2)	 were	 mapped	 to	 reference	 genome	LESB58,	 variants	 called	 and	 annotated.	 Mutations	 were	 classified	 as	synonymous	 or	 non-syonymous.	 Non-synonymous	 mutations	 were	 further	classified	according	to	whether	they	were	predicted	to	be	nonsense	mutations,	missense	 mutations	 (causing	 a	 codon	 change	 and	 subsequent	 amino	 acid	substitution),	 in-frame	 insertions	 and	 deletions	 and	 upstream	or	 downstream	modifiers.	 The	 genome	with	 the	 largest	 number	 of	mutations	 compared	with	LESB58	was	 that	 of	 isolate	 CF9S1_24	with	 1202,	whilst	 the	 genome	with	 the	least	was	B9	with	100.		In	total,	8	isolate	genomes	contained	>500	mutations,	43	contained	 >200	 but	 <500	 and	 the	 remaining	 70	 genomes	 excluding	 B9	contained	between	100	and	200	mutations.	The	mean	number	of	mutations	per	genome	relative	to	LESB58	was	223.			
4.3.6. Nonsense	Mutations		There	were	a	 total	of	1812	nonsense	mutations	 in	 the	122	genomes	analysed,	1347	frame-shifting	indels	and	465	premature	stop	codons.	There	are	24	genes	with	nonsense	mutations	carried	in	10	or	more	genomes	in	the	population	and	as	 many	 as	 carrying	 a	 nonsense	 mutation	 in	 120	 genomes	 (table	 4.4.).	Functionally,	 these	 genes	 are	 involved	 in	 small	 molecule	 transport	(PLES_56861,	 mexB,	 glpT,	 PALES_34011,	 oprD),	 the	 cell	 wall/LPS/capsule	(mucA,	mpl,	 mraW,	 PALES_46251,	mltD)	 in	 addition	 to	 redox	 (PLES_20241),	motility	and	attachment	(fleR),	carbon	compound	metabolism	and	hypothetical	
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genes	of	unknown	function.	The	LES	is	characteristically	non-motile	as	a	result	of	 loss	 of	 flagellin	 encoding	 gene	 fleR.	 In	 this	 study	 120	 of	 the	 122	 genomes	analysed	 carried	 the	 same	 nonsense	mutation	 in	 fleR.	 The	 genes	 PLES_46401	and	 PLES_47271	 encoding	 hypothetical	 proteins	 also	 present	 with	 nonsense	mutations	 in	>50%	of	 the	genomes.	Additionally	anti	 sigma	 factor	mucA	has	a	nonsense	mutation	in	23	isolate	genomes.		In	addition	to	nonsense	mutations,	mapped	reads	were	assessed	for	larger	gene	deletions	and	absences.	There	were	892	different	genes	that	appear	to	have	lost	function	 in	 at	 least	1	 genome.	Of	 the	892	genes	with	 any	 loss	of	 function	293	appear	to	have	lost	function	in	only	1	genome.	There	are	69	different	genes	with	loss	of	function	in	>50%	of	the	genomes.	Motility	gene	fleR	has	a	premature	stop	codon	 in	120/122	genomes	analysed	and	a	28bp	deletion,	 spanning	 the	 same	region	in	a	further	genome,	that	of	isolate	8835.	There	is	no	evidence	for	loss	of	function	in	fleR	in	a	single	isolate	genome,	that	of	LiP1a.											
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Table	4.5.	Genes	across	the	UK	LES	genomes	carrying	a	nonsense	mutation	in	ten	or	more	alleles			
Gene	
name	
Number	of	
genomes	
Gene	description	
fleR	 120	 Flagellar	motility	gene	PLES_46401	 96	 Hypothetical	protein	PLES_47271	 84	 Hypothetical	protein	
oprD	 49	 Imipenem	outer	membrane	porin	
mltD	 44	 Murein	transglycosylase	D	precursor	PLES_56861	 27	 Putative	choline	transporter	
mexB	 25	 Multidrug	efflux	pump	
lasR	 24	 Transcriptional	regulator	of	quorum	sensing	
mucA	 23	 Anti-sigma	factor	for	alginate	biosynthesis	PLES_59241	 20	 Hypothetical	protein	PLES_26281	 20	 Hydrophobe/amiphile	efflux	PLES_07981	 19	 Hypothetical	protein	PLES_50281	 15	 Hypothetical	protein	PLES_48481	 13	 Hypothetical	protein	
glpT	 13	 Sn-glycerol-3-phosphate	transporter	
ambB	 13	 AMB*	biosynthesis	
pqqF	 12	 pyrroloquinoline	quinone	biosynthesis	protein	F	
exsA	 12	 Transcriptional	regulator	of	type3	secretion	
mraW	 10	 S-adenosyl-methyltransferase		
lpxO2	 10	 Lipopolysaccaride	biosynthesis	PLES_46251	 10	 Glycosyl	transferase	
mpl	 10	 Inactivation	leads	to	overproduction	of	beta-lactamases	PLES_20241	 10	 Putative	oxidase	PLES_34011	 10	 TonB	dependent	receptor	*Antimetabolite	L-2-Amino-4-methoxy-trans-3-butenoic	Acid			
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To	 determine	which	 functions	 the	 genes	most	 often	 carrying	 loss	 of	 function	genes	were	associated	with	 their	pseudoCAP	categories,	 summarised	 in	 figure	4.5.	The	categories	are	displayed	as	associations	to	genes	that	have	evidence	for	loss	of	 function	as	a	 function	of	 the	number	of	genomes	harbouring	disrupted	alleles.	 The	majority	 of	 associated	 functions	 are	 unknown,	 hypothetical	 genes	(71.3%).	 The	 proportions	 of	 associated	 categories	 without	 considering	hypothetical	genes	are	summarised	in	figure	4.8.	The	category	associated	with	the	 greatest	 proportion	 is	 ‘non-coding	 RNA	 genes’	 (16.25%)	 followed	 by	‘transport	 of	 small	 molecules’	 (14.07%)	 and	 ‘transcriptional	 regulators’	(13.54%).	 Of	 the	 proportion	 of	 associated	 functional	 categories	 that	 are	transcriptional	regulators,	two-component	systems	represent	37.7%.	
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	Figure	4.5.	PseudoCAP	functional	categories	associated	with	genes	carrying	nonsense	mutations	in	ten	or	more	of	the	UK	LES	genomes			
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4.3.6.1. Independent	acquisition	of	loss	of	function	To	identify	genes	that	may	be	adapting	by	loss	of	function	in	the	UK	population,	the	independent	acquisition	of	nonsense	mutations	was	inferred	by	number	of	unique	nonsense	mutations	per	gene	in	the	population.	Where	a	mutation	was	the	same	by	position	they	were	inferred	to	have	been	inherited.	In	genes	in	the	population	 where	 per	 genome	 there	 is	 a	 combination	 of	 shared	 and	 unique	nonsense	mutations	 it	 was	 parsimoniously	 inferred	 that	 the	 shared	 positions	precede	 the	 uniques.	 600	 different	 genes	 in	 the	 population	 were	 inferred	 to	have	lost	function	by	acquisition	of	a	nonsense	mutation.	The	majority	of	genes	affected	(347/600)	present	a	nonsense	mutation	in	only	one	isolate	genome.	As	such	 these	 represent	347/500	genes	 for	which	 there	 is	 only	one	 independent	acquisition.	The	remaining	153	genes	with	a	mutation	in	two	genomes	or	more	range	 from	 being	 maintained	 in	 2-120	 of	 122	 UK	 LES	 genomes.	 Table	 4.6	displays	this	distribution.			Table	4.6.	The	number	of	different	genes	that	have	independently	acquired	loss	of	function	the	same	amount	of	times	in	the	population	
Number	of	independent	acquisitions	 Number	of	genes	30	 1	18	 1	15	 1	12	 1	10	 1	8	 2	7	 1	6	 1	5	 4	4	 5	3	 11	2	 71	1	 500			
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The	number	of	genomes	in	which	these	genes	carried	a	nonsense	mutation	also	vary	and	was	not	associated	with	the	number	of	acquisitions.	Table	4.6	displays	the	genes	that	have	most	often	independently	acquired	nonsense	mutations	(4	or	more	 acquisitions).	 The	 number	 of	 acquisitions	 of	 nonsense	mutations	 per	gene	ranges	from	4	to	30	across	16	different	genes	that	have	acquired	nonsense	mutations	 4	 or	 more	 times.	 The	 number	 of	 genomes	 in	 which	 nonsense	mutations	 are	 present	 in	 these	 genes	 range	 from	 PLES_16021	 with	 5	independent	 acquisitions	 in	 5	 genomes,	 to	 PLES_46401	 (with	 4	 acquisitions	maintained	 in	96/122	genomes).	The	gene	most	often	 independently	mutated	
oprD,	 was	 observed	 to	 carry	 a	 nonsense	 mutation	 in	 49/122	 genomes.	 The	genes	 are	 associated	with	 functions	 such	 as	 antibiotic	 resistance,	 (mpl,	mexB,	
oprD,	 PALES_16021,	 glpT),	 quorum	 sensing	 (lasR),	 mucoidy	 (mucA),	 iron	acquisition	 (PLES_34011,	 pchE).	 There	 were	 also	 hypothetical	 genes	 with	unknown	functions,	PLES_59241,	PLES_48481	and	PLES_46401.											
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Table	4.7.	Genes	that	have	independently	acquired	a	loss	of	function	mutation	=>4	times	in	the	UK	LES	population	
Indepen
dent	
acquisiti
ons	
Gene	name	
or	LESB58	
locus	tag	
Genomes	in	
which	these	
mutations	are	
observed	
Gene	description	
30	 oprD	 49	 Imipenem	outer	membrane	porin	18	 lasR	 24	 Transcriptional	regulator	of	quorum	sensing	12	 PLES_59241	 20	 Hypothetical	membrane	protein	15	 mexB	 25	 Multidrug	efflux	pump	transporter,	part	of	the	mexAB-
oprM	operon	10	 mucA	 23	 Anti-sigma	factor	for	alginate	biosynthesis	8	 mltD	 44	 Murein	transglycosylase	D	precursor	8	 glpT	 13	 sn-glycerol-3-phosphate	transporter	7	 pncA	 9	 nicotinamidase	6	 PLES_34011	 10	 tonB	dependent	receptor	5	 PLES_48481	 13	 Hypothetical	protein	5	 PLES_46251	 10	 Putative	glycosyl	transferase	5	 opmQ	 7	 Putative	outer	membrane	protein	precursor	5	 PLES_16021	 5	 Transcriptional	regulator	(marR	ortholog,	involved	in	repression	of	MDR	mar	operon)	4	 PLES_46401	 96	 Hypothetical	protein	with	filamentous	haemagglutinin	outer	membrane	domain)	4	 mpl	 10	 UDP-N-acetylmuramate:L-alanyl-gamma-D-glutamyl-meso-diaminopimelate	ligase	4	 PLES_03151	 9	 Transcriptional	regulator	4	 PLES_47771	 8	 Two-component	sensor	4	 pchE	 7	 dihydroaeruginoic	acid	synthase	
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The	porin	gene	oprD	had	independently	lost	function	more	than	any	other	gene	in	 the	 population.	 49	 genomes	 contain	 nonsense	mutations	 in	oprD	 due	 to	 at	least	30	independent	events.	In	total	there	is	evidence	for	inactivation	of	oprD	in	55	 genomes;	 an	 additional	 6	 genomes	 contain	 larger	 deletions	 ranging	 from	141bp	 to	647bp	of	 the	1,326bp	gene	with	an	absence	of	mapped	reads.	 Small	insertions	 ranging	 1-30bp	 comprised	 the	 majority	 of	 instances	 of	 loss	 of	function	in	the	gene.	Loss	of	function	was	achieved	by	frame-shifting	insertions	in	 12	 of	 30	 independent	 events	 and	 maintained	 in	 24	 of	 55	 genomes.	 Five	independent	 acquisitions	 maintained	 in	 16	 genomes	 were	 by	 substitution	resulting	in	a	premature	stop	codon.	Finally,	there	were	7	occurrences	of	single	base	pair	frame	shifting	deletions,	resulting	in	loss	of	function	in	9/55	genomes.		In	 26	 of	 122	 genomes	 there	 was	 a	 loss	 of	 function	 mutation	 by	 nonsense	mutations	 in	 the	 gene	 encoding	 an	 anti-sigma	 factor	 for	 alginate	 production,	
mucA.	 Loss	 of	 function	 in	MucA	 is	 known	 to	 be	 associated	with	 the	mucoidy	phenotype	by	 subsequent	 overproduction	 of	 alginate.	No	 genetic	 evidence	 for	compensatory	 loss	 of	 function	 mutations	 in	 alginate	 biosynthesis	 genes	 was	observed.			Loss	of	 function	mutations	were	observed	 in	mexB	 in	26	genomes,	 among	 the	highest	 number	 of	 genomes	 for	 any	 of	 the	 genes	 carrying	 loss	 of	 function	mutations.	Additionally	Loss	of	function	was	observed	to	have	been	acquired	15	times	 independently	 (table	 4.6).	 Loss	 of	 function	 in	 the	 efflux	 pump	 can	 also	occur	 via	 mutations	 in	 mexA	 or	 oprM.	 Combined	 evidence	 of	 nonsense	mutations	demonstrates	evidence	for	loss	of	function	in	the	operon	in	32	isolate	
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genomes.	 For	 31	 of	 these	 genomes	 loss	 of	 function	 is	 evidenced	 by	 nonsense	mutations	(6	in	mexB	and	5	in	mexA),	rather	than	larger	deletions	or	absences	and	 as	 such	 is	 possible	 to	 infer	 how	 often	 the	 operon	 has	 independently	 lost	function.	 Overall	 the	 operon	 has	 independently	 acquired	 loss	 of	 function	mutations	at	least	21	times.		
	Quorum	sensing	regulator	lasR	was	found	to	harbor	nonsense	mutations	in	24	genomes,	acquired	18	times	in	the	population.	Further	there	is	complete	absence	of	lasR	in	isolates	10262,	CF5S1_04	and	Md1-264	in	addition	to	a	31bp	deletion	in	isolate	244.	In	total	there	were	28	of	122	with	loss	of	function	in	
lasR.				Of	 the	 122	 UK	 LES	 genomes	 analysed,	 8	 genomes	 were	 identified	 as	 having	evidence	of	being	hypermutable	by	the	presence	of	nonsense	mutations	in	DNA	mismatch	 repair	 genes:	mutS,	mutM,	mutL	 or	 uvrD	 (table	 4.8).	 Some	 of	 these	mutations	appear	 to	be	shared	 in	closely	related	genomes.	LiP10a	and	LiP10b	(from	the	same	patient)	and	LiP13	(from	a	different	patient)	contain	the	same	4bp	 frame-shifting	 deletion	 in	mutM.	 PHELES3	 shares	with	 PHELES6	 57bp	 of	the	 58bp	 deletion	 in	mutS,	 but	 PHELES6	 that	 has	 an	 additional	 1bp	 frame-shifting	indel	in	mutL.							
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Table	4.8.	Nonsense	mutations	in	DNA	mismatch	repair	genes,	mutS,	mutL,	
mutM,	uvrD	
Isolate		 Genetic	evidence	for	hypermutability	LiP2c	 mutS	1bp	insertion	frameshift	79426	 mutS	premature	stop	codon	gained	LiP10a	 mutM	4bp	deletion	frameshift	LiP10b	 mutM	4bp	deletion	frameshift	LiP13	 mutM	4bp	deletion	frameshift	89224	 mutL	5bp	insertion	frameshift	PHELES6	 mutS	57bp	deletion	&	mutL	1bp	deletion	frameshift	PHELES3	 mutS	58bp	deletion	
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	Figure	 4.6.	 LES	 core	 genome	 phylogeny	 (figure	 4.1).	 Genomes	 with	 genetic	evidence	for	DNA	mismatch	repair	deficiencies	labeled	in	orange	
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In	 total	 the	18	genes	most	often	 independently	 acquiring	nonsense	mutations	are	 associated	with	 12	 different	 pseudoCAP	 categories.	 For	 each	 category	 the	number	 of	 associations	 is	 a	 function	 of	 the	 number	 of	 genomes	 in	which	 that	gene	has	a	nonsense	mutation.	Each	gene	may	also	be	associated	with	multiple	categories.	 In	 total	 there	 are	 593	 associations	 to	 functional	 categories	 (figure	4.7).	 The	 function	 most	 often	 associated	 with	 the	 genes	 most	 often	independently	acquiring	nonsense	mutations,	 as	a	percentage	of	 all	 functional	associations,	 is	 that	 of	 unknown	 or	 hypothetical	 (21.75%),	 followed	 by	transport	of	small	molecules	(18.71%)	and	cell	wall/LPS/capsule	(12.98%).			
		Figure	 4.7.	 PseudoCAP	 functional	 categories	 associated	 with	 the	 genes	 most	often	independently	acquiring	nonsense	mutations	as	a	function	of	the	number	of	genomes	in	which	a	loss	of	function	allele	is	carried	
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4.3.7. Missense	Mutations		To	assess	missense	mutations	that	might	be	adaptive	in	the	UK	LES	population,	genes	with	 loss	 of	 function	were	 not	 considered.	 Across	 the	 remaining	 genes	there	 were	 13,691	 synonymous	 and	 non-syonymous	 mutations.	 Table	 4.9	shows	 how	 many	 of	 these	 mutations	 are	 in-frame	 insertions	 or	 deletions,	synonymous	mutations,	upstream	and	downstream	modifiers	of	coding	regions	and	 those	 that	 are	missense	mutations.	 In	 genes	without	 evidence	 for	 loss	 of	function,	non-synonymous	changes	were	greater	in	number	than	those	that	are	synonymous.			Table	4.9.	Count	of	mutations	by	functional	impact	in	the	UK	LES	population	
Predicted	functional	impact	of	
mutation	
Number	of	SNPs	compared	with	
LESB58	
Synonymous	 3212	
Upstream	modifier	 1251	
Downstream	modifier	 24	
In	frame	insertion	 167	
In	frame	deletion	 141	
Missense	 8895	
Total	 13690			There	are	2427	different	genes	with	at	least	one	missense	mutation	compared	with	LESB58.	Of	these	60%	(1478	genes)	have	a	single	missense	variation,	which	may	be	present	in	a	varying	number	of	genomes	(table	4.9).				
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Table	 4.10.	 The	 number	 of	 unique	 missense	 mutations	 per	 gene	 in	 the	population	and	the	number	of	different	genes	with	that	many	unique	missense	mutations	
Number	of	unique	missense	mutations	 Number	of	genes	20	 1	19	 1	17	 1	15	 1	14	 2	13	 1	12	 3	10	 5	9	 1	8	 7	7	 12	6	 12	5	 31	4	 76	3	 229	2	 566	1	 1478			For	all	genes	with	at	least	one	missense	mutation	the	associations	to	pseudoCAP	functional	 categories	 were	 determined	 as	 a	 percent	 of	 the	 overall	 categories	associated	 (figure	 4.9).	 The	 highest	 proportion	 of	 associations	 was	 those	 of	unknown	function	due	to	hypothetical	genes	(20.28%),	followed	by	transport	of	small	molecules	 (10.96%),	membrane	proteins	 (9.37%)	and	putative	enzymes	(9.31%).								
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	Figure	4.8.	PseudoCAP	functional	categories	associated	with	genes	with	one	or	more	missense	mutations	across	the	UK	LES	genomes			
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There	 are	 2,428	 genes	 with	 at	 least	 one	 missense	 mutation	 in	 the	 UK	 LES	genomes.	Missense	mutations	range	from	being	present	in	only	one	genome	to	fixation	 in	 the	 UK	 population	 compared	with	 LESB58.	 Genes	with	 a	missense	mutation	in	>100	genomes	are	presented	in	table	4.11.	There	were	11	different	genes	with	a	missense	mutation	fixed	in	the	population.																					
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Table	4.11.	The	genes	in	which	a	non-syonymous	(missense)	mutation	is	shared	in	 >100	 isolates	 across	 the	 UK	 LES	 genomes.	 Fixed	 mutations	 (in	 all	 122	genomes)	in	bold			
	
Gene	name	or	
locus	tag	
Number	
of	
genomes	
Gene	function	
gyrB	 122	 DNA	gyrase	subunit	B	
PLES_28161	 122	 putative	two-component	sensor	
PLES_05421	 122	 hypothetical	protein	
PLES_45841	 122	 hypothetical	protein	
PLES_54891	 122	 putative	transporter	
PLES_31551	 122	 hypothetical	protein	
fis	 122	 DNA-binding	protein	Fis	
PLES_15441	 122	 putative	mechanosensitive	ion	channel		
PLES_44361	 122	 putative	ring-cleaving	dioxygenase	
PLES_48951	 122	 putative	hydroxylase	
PLES_13941	 122	 putative	amino	acid	permease	PLES_52231	 121	 hypothetical	protein	PLES_11151	 121	 carboxylesterase	
nosR	 120	 regulatory	protein	NosR	PALES_44581	 120	 putative	ATP-binding/permease	fusion	ABC	transporter	
metX	 120	 homoserine	O-acetyltransferase	PLES_19231	 120	 putative	secretion	protein	PLES_48781	 119	 putative	metallopeptidase	PLES_58511	 119	 hypothetical	protein	PLES_30291	 116	 putative	alcohol	dehydrogenase	(Zn-dependent)	PLES_01041	 116	 putative	sulfate	transporter	PLES_48791	 115	 putative	transcriptional	regulator	PLES_29121	 102	 putative	ATP-binding/permease	fusion	ABC	transporter	
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4.3.7.1. Genes	with	a	diversity	of	missense	mutations	 in	 the	
population	Genes	that	carry	10	or	more	different	missense	mutations	in	the	population	are	displayed	 in	 table	 4.12.	 They	 include	 genes	 that	 are	 associated	 with	 with	quorum	sensing	(lasR),	alginate	biosynthesis	(algG),	antibiotic	resistance	(pmrB,	
pmrA	 exsD	 mpl,	 ftsl,	 mexB),	 a	 hypothetical	 protein	 (PLES_19111).	 Of	 the	 14	genes,	5	are	predicted	to	encode	regulators.		Table	 4.12.	 Genes	 with	 ten	 or	 more	 unique	 missense	 mutations	 in	 the	population		
Gene	name	
or	locus	
tag	
Unique	
mutatio
ns	
Number	
of	
genomes	
Gene	function	
lasR	 20	 35	 transcriptional	regulator	LasR	
algG	 19	 31	 alginate-c5-mannuronan-epimerase	AlgG	
pmrB	 17	 16	 PmrB:	two-component	regulator	system	signal	sensor	kinase	PmrB	
spoT	 15	 20	 guanosine-3'	PLES_19111	 14	 18	 hypothetical	protein	
rpoD	 14	 17	 RNA	polymerase	sigma	factor	RpoD	
ftsI	 13	 85	 penicillin-binding	protein	3	
gyrA	 12	 56	 DNA	gyrase	subunit	A	
mpl	 12	 24	 UDP-N-acetylmuramate:L-alanyl-gamma-D-glutamyl-	meso-diaminopimelate	ligase	
mexB	 12	 16	 Resistance-Nodulation-Cell	Division	(RND)	multidrug	efflux	transporter	MexB	
exsA	 10	 33	 transcriptional	regulator	ExsA	
pmrA	 10	 17	 PmrA:	two-component	regulator	system	response	regulator	PmrA	
exsD	 10	 12	 ExsD	
rpoB	 10	 10	 DNA-directed	RNA	polymerase	subunit	beta				
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Diversification	of	a	gene	in	a	population	can	be	due	to	positive	selection	or	drift,	as	 such	 it	 the	 dN/dS	 ratios	 were	 calculated	 for	 the	 genes	 with	 the	 highest	number	of	unique	missense	mutations.	Alleles	from	genomes	without	missense	or	 without	 mutations	 altogether	 were	 included	 in	 the	multiple	 alignments.	 A	dNdS	 ratio	 >1	 can	 indicate	 positive	 selection,	while	 a	 ratio	 of	 <1	 can	 indicate	purifying	 selection.	 Table	 4.12	 displays	 the	 genes	 with	 10	 or	 more	 unique	missense	mutations.	The	dN/dS	ratio	for	the	majority	(10/14)	revealed	a	ratio	of	>1	that	indicates	positive	selection	(table	4.13).			Table	4.13.	Genes	ten	or	more	unqiue	missense	mutations	in	the	population.	Average	dNdS	ratios	across	codons	calculated		
Gene	 Average	
dN/dS	over	
all	codons	
Gene	function	
spoT	 1.442445966	 guanosine-3'	
rpoD	 1.0721435	 RNA	polymerase	sigma	factor	RpoD	
rpoB	 0.957809229	 DNA-directed	RNA	polymerase	subunit	beta	
pmrB	 1.127049428	 PmrB:	two-component	regulator	system	signal	sensor	kinase	PmrB	
pmrA	 1.424881821	 PmrA:	two-component	regulator	system	response	regulator	PmrA	PLES_19111	 0.87522896	 hypothetical	protein	
mpl	 0.982156966	 UDP-N-acetylmuramate:L-alanyl-gamma-D-glutamyl-	meso-diaminopimelate	ligase	
mexB	 1.428139835	 Resistance-Nodulation-Cell	Division	(RND)	multidrug	efflux	transporter	MexB	
lasR	 1.393989122	 transcriptional	regulator	LasR	
gyrA	 0.156205563	 DNA	gyrase	subunit	A	
ftsL	 1.49594221	 penicillin-binding	protein	3	
exsD	 1.468284208	 ExsD	
exsA	 1.304668628	 transcriptional	regulator	ExsA	
algG	 1.430029314	 alginate-c5-mannuronan-epimerase	AlgG			
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4.4. Discussion	Previously	 a	 limited	 sample	 of	 LES	 genomes	 was	 available	 for	 comparative	genomics214,334	and	studies	focused	on	the	within-host	diversity	and	adaptation	of	LES	lineages	during	chronic	lung	infections352,280.	The	panel	of	LES	isolates	for	this	 study	 have	 greater	 geographic	 diversity,	 a	 larger	 sample	 size,	 are	historically	 diverse	 and	 represent	 a	 diversity	 of	 associated	 pathologies	 than	previous	 studies.	 Using	 this	 larger	 dataset	 it	 has	 been	 possible	 to	 assess	 the	genomic	 epidemiology,	 pangenome	 structure	 and	 potential	 genetic	 basis	 of	ongoing	adaptation	in	greater	detail.			The	U.K.	and	Canadian	LES	form	distinct	clades	with	the	exception	of	LiP6	and	PHELES19,	sourced	in	the	U.K.	but	clustering	phylogenetically	with	the	majority	Canadian	clade.	For	LiP6	further	patient	information	was	available	that	they	had	previously	lived	in	Canada,	so	is	credible	that	this	isolate	was	instead	acquired	there.	Generally	within	 the	UK	 too	 genomes	 cluster	 according	 to	 their	 source.	Upon	rooting	 the	 tree	with	a	non-LES	outgroup,	PAO1,	 the	Canadian	genomes	cluster	with	the	root	of	the	LES	tree	and	LESB58,	the	oldest	known	isolate,	roots	the	 U.K.	 genomes.	 Previously	 it	 wasn’t	 possible	 to	 determine	 this	 ordering	 of	Canadian	 and	 U.K.	 LES	 genomes	 as	 only	 a	 small	 set	 were	 available	 for	comparison334.	The	Canadian	clade	further	encompasses	ST-146’s	(the	majority	of	LES	 isolates)	 and	ST-683’s.	The	 inner	node	 confidence	 separating	Canadian	ST-683’s	and	ST-146’s	is	94%	(supplementary	figure	5).		Deficiency	in	DNA	mismatch	repair	genes	mutS,	mutL,	mutM	and	uvrD	have	been	observed	 in	 P.	 aeruginosa	 to	 result	 in	 the	 hypermutable	 phenotype353.	 The	
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benefits	 of	 rapid	 evolution	 in	 hypermutable	 lineages	 comes	 at	 the	 cost	 of	 an	accumulation	of	disadvantageous	mutations	also353.	Though	in	one	study	of	the	Danish	 transmissible	 lineage	 of	 P.	 aeruginosa	 as	 many	 as	 48%	 of	 lineages	harboured	DNA	mismatch	repair	deficiency	mutations282.	In	this	dataset	8/122	genomes	 are	 identified	 as	 potentially	 hypermutable	 due	 to	 DNA	 mismatch	repair	 deficiency	 (table	 4.8).	 There	 also	 evidence	 for	 cross	 infection	 of	potentially	 hypermutable	 strains	 between	 the	 patient	 infected	 with	LiP10a/LiP10b	and	the	patient	infected	with	LiP13	due	to	their	adjacency	in	the	core	SNP	tree	(figure	4.6)	and	of	mutM	sharing	the	same	4bp	deletion.	There	is	also	potential	that	PHELES3	and	PHELES6	from	different	patients	but	adjacent	in	the	core	SNP	tree	share	the	same	58bp	deletion	where	PHELES3	harbours	a	57bp	deletion	otherwise	that	is	otherwise	the	same.	Hypermutator	lineages	of	P.	
aeruginosa	 have	 been	 implicated	 in	 convergent	 accumulation	 of	 mutations	associated	with	chronic	CF	lung	infections325,	have	previously	been	observed	in	the	LES280	and	other	transmissible	strains282.			The	 LES	 tonB-dependent	 receptor	 gene	 PLES_34011	 was	 observed	 to	 have	independently	acquired	nonsense	mutations	6	times	in	the	population,	carried	in	 10	 genomes.	 TonB-dependent	 receptor	 gene	 homolog	 (PA1922)	 disruptive	mutations	have	previously	been	associated	with	chronic	P.	aeruginosa	CF	 lung	infections354,355.			Loss	of	motility	has	been	associated	with	chronic	P.	aeruginosa	isolates181	and	a	defining	characteristic	of	the	Liverpool	Epidemic	Strain	is	its	lack	of	motility	due	to	 a	 fixed	 nonsense	 mutation	 flagellar	 motility	 gene	 fleR334.	 Of	 122	 U.K.	 LES	
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isolates	analysed	120	have	the	fixed	C-A	mutation	at	LESB58	reference	position	4656647	 that	 introduces	 a	premature	 stop	 codon	 in	 fleR,	truncating	 the	 gene.	An	additional	isolate	(8835)	has	a	28bp	deletion	in	fleR	spanning	the	same	locus	of	the	nonsense	mutation.		LiP1a	is	the	only	isolate	genome	analysed	without	a	nonsense	mutation	in	fleR.	However	closely	related	LiP1c	from	the	same	patient	as	LiP1a	does	harbour	the	nonsense	mutation	in	fleR	(figure	4.2).			Changes	to	oprD	likely	resulting	in	loss	of	function	have	occurred	independently	by	 nonsense	 mutations	 more	 than	 any	 other	 gene	 analysed	 in	 the	 U.K.	 LES	genomes.	 There	 is	 genetic	 evidence	 for	 loss	 of	 function	 in	 55/122	 genomes.	Inactivation	 of	 oprD	 in	 P.	 aeruginosa	 has	 been	 observed	 to	 result	 in	carbapenemase	 resistance356.	 Complete	 disruption	 in	oprD	 has	 not	 previously	been	 reported	 in	 the	 LES.	 However,	 decreased	 expression	 of	 oprD	 in	 LES400	and	 LES431	 compared	with	 PAO1	 has	 previously	 been	 linked	with	 increased	MICs	 for	 meropenem357.	 Loss	 of	 function	 in	 membrane-bound	 lytic	 murein	transporter	 gene	mltD	 is	 observed	 (table	 4.7).	 Disruptive	 mutations	 in	mltD	have	not	previously	been	observed	in	the	LES.	However	disruptive	mutations	in	PAO1	mltD	homolog	(PA1812)	have	been	associated	with	increased	beta-lactam	MIC’s358.	 Fosfomycin	 transporter	 gene	glpT	 has	 independently	 lost	 function	 8	times	and	loss	of	function	mutations	are	carried	in	13	isolate	genomes.	Loss	of	function	 has	 previously	 been	 observed	 in	 the	 LES280.	 In	 P.	 aeruginosa	 PA14	disruptive	mutations	in	glpT	gene	result	in	fosfomycin	resistance	but	limits	the	carbon	 source	 to	 glycerol-3-P359.	 Loss	 of	 function	 is	 observed	 in	 UDP-N-acetylmuramate-alanyl-gamma-D-glutamyl-meso-diaminopimelate-ligase	 gene	
mpl	 (how	 many	 times)	 and	 have	 previously	 been	 identified	 in	 the	 LES280.	
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Disruption	 of	 homologous	 mpl	 in	 P.	 aeruginosa	 has	 been	 associated	 with	piperacillin	and	ceftazidime	resistance	due	to	an	accumulation	of	immature	cell	wall	 components	 and	 up-regulation	 of	 AmpC	 expression329.	 LES	 gene	PLES_59241	carries	a	 loss	of	 function	mutation	 in	20	genomes	 that	have	been	acquired	 independently	 at	 least	 12	 times.	 Homolog	 of	 PLES_59241	 in	 PAO1,	PA5528	encodes	a	protein	of	unknown	function	but	that	is	associated	with	the	
amgRS	 two	 component	 system360.	 The	 amgRS	 two	 component	 system	 is	involved	 in	 aminoglycoside	 resistance.	 Loss	 of	 function	 mutations	 have	 not	previously	been	 identified	 in	 the	LES	 in	PLES_59241,	or	associated	with	other	chronic	P.	aeruginosa	 infections.	 Instead,	mutations	 in	 PLES_59241	have	 been	inferred	to	cause	gain	of	function	in	the	LES	previously352.	In	this	study	there	is	genetic	 evidence	 for	 loss	 of	 function	 in	mexB	 in	 26/122	 genomes,	 or	 31/122	genomes	 for	 the	 entire	mexAB-oprM	 operon	 due	 to	 additional	 genomes	 with	disruptions	in	mexA.			Ten	different	genes	among	the	genes	with	the	most	unique	missense	mutations	(n	 =	 13)	 were	 inferred	 to	 be	 under	 positive	 selection	 in	 the	 alleles	 in	 the	population	without	nonsense	mutations	(table	4.12).	Many	of	these	genes	were	adaptive	by	loss	of	function	in	other	members	of	the	population	suggesting	that	there	are	different,	within-patient,	selection	pressures	on	lineages	of	the	LES	or	that	 constraint	 is	 relaxed	 or	 deleterious	 missense	 mutations	 are	 adaptive	consistent	with	 the	 nonsense	 results.	 Others	 such	 as	 genes	 spoT,	 rpoD,	 pmrA,	
pmrB,	algG	exsD	and	exsA	did	not	appear	to	be	adaptive	by	loss	of	function	in	the	population.			
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4.4.1. Chapter	Summary	Whole	genome	sequencing	of	the	most	geographically	and	historically	diverse	set	of	LES	isolates	yet	was	sequenced	and	it	was	determined	that:		
• Canadian	and	UK	LES	are	genetically	distinct	
• Genomic	 Epidemiology	 correctly	 associates	 genomes	 to	 source	 of	isolation	
• Diversity	within	the	LES	in	the	LESB58	prophages	and	genomic	islands	
• Convergent	evolution	within	the	LES	by	loss	of	function																											
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Chapter	5	
Pseudomonas	 aeruginosa	 Adaptation	 to	 the	 non-Cystic	 Fibrosis	 Lung:	 Parallels	 with	 Cystic	 Fibrosis	Chronic	Lung	Infections	
5. Introduction	
5.1. Background		Bronchiectasis	is	a	chronic,	progressive	lung	disease	associated	with	a	widening	of	the	bronchi	69	that	affects	26.9%	of	males	and	35.2%	of	females	in	the	UK,	per	100,000	 in	 the	 UK361.	 CF-associated	 bronchiectasis	 may	 by	 CF	 associated	 is	detected	 early	 in	 life	 and	 results	 in	 life-long	 clinical	 interventions,	 including	exposure	to	antibiotics	from	an	early	age187.	Infection	with	P.	aeruginosa	occurs	in	 ~30%	 of	 cases	 of	 Bronchiectasis	 overall	 and	 has	 been	 associated	 with	increased	morbidity	and	mortality362,363.				Bacterial	infections	are	a	persistent	problem	for	CF	patients	and	in	many	cases	worsen	 overall	 prognosis362.	 P.	 aeruginosa	 is	 the	 leading	 cause	 of	 overall	morbidity	and	mortality	in	CF,	presenting	early	in	life190	and	often	establishing	a	chronic	 infection	 later	 in	 life.	 CF	 patients	 may	 also	 harbour	 heterogeneous	populations	complicating	treatment66,285	or	communities	of	distinct,	potentially	heterogeneous	 P.	 aeruginosa	 populations	 acquired	 from	 different	 sources,	coexisting	in	the	lungs.	Additionally	transmissible	lineages	of	P.	aeruginosa	exist	so	 that	 cross	 infection	 between	 patients	 whom	 otherwise	 attend	 the	 same	clinics	 has	 resulted	 in	 segregation	 procedures192,342.	 In	 the	 CF	 lung	 chronic	P.	
aeruginosa	 adapts	 in	 characteristic	 ways,	 including	 the	 adoption	 of	 a	 biofilm	
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lifestyle,	 switch	 to	 mucoidy,	 hypermutability,	 quorum	 sensing	 deficiency	 and	lack	of	motility66.	These	adaptations	are	associated	with	worsening	prognoses	and	chronicity68,362.	For	bronchiectasis	patients	without	CF	the	disease	presents	later	in	life,	typically	between	60	and	70	years	old363.	It	is	estimated	that	in	the	UK	 of	 ~150,000	 people	 living	 with	 bronchiectasis,	 90%	 is	 non-CF	bronchiectasis361.				As	 with	 non-CF	 bronchiectasis,	 primary	 ciliary	 dyskinesia	 (PCD)	 patients	 are	treated	 with	 intensive	 antibiotic	 chemotherapy,	 the	 lungs	 demonstrate	 poor	mucociliary	clearance,	clinical	risk	factors	of	persistent	infection364.	A	study	of	P.	
aeruginosa	infection	in	PCD	identified	genetic	similarities	in	adaptive	routes	to	chronic	infection	as	in	CF.	By	whole	genome	sequencing	of	isolates	from	12	PCD	patients	infected	with	P.	aeruginosa,	10	were	determined	to	be	a	chronic	lineage	and	convergent	evolution	was	inferred	in	8	genes,	mexZ,	algU,	mucA,	mexA,	pscP,	
pilG,	lasR	and	mexS364.												
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5.1.1. Aims		The	 aims	 of	 this	 chapter	 were	 to	 use	 whole	 genome	 sequencing	 of	bronchiectasis	associated	P.	aeruginosa	to	assess:		
• The	 representation	 of	 different	 lineages	 of	 P.	 aeruginosa	 in	 a	bronchiectasis	patient	populations	
• Whether	 there	 is	 genetic	 evidence	 for	 adaptation	 within	 the	 lung	comparable	to	that	of	cystic	fibrosis	isolates	
• Whether	 there	 is	 evidence	 for	 transmissible	 lineages	 or	 lineages	acquired	by	different	patients	from	a	common	nosocomial	source	
• Genetic	 diversity	 within	 P.	 aeruginosa	 populations	 in	 the	 lungs	 of	bronchiectasis	patients														
130	
5.2. Methods	Genomes	 were	 de	 novo	 assembled	 and	 scaffolded,	 reads	 were	 mapped	 and	variants	 called	 and	 annotated	 to	 the	 PAO1	 reference	 genome,	 core	 genomes	extracted,	 phylogenies	 approximated	 and	 annotated,	 MLST	 derived	 and	genomes	compared	by	pairwise	alignment	as	described	in	Chapter	Two:	General	Methods.			
5.2.1. Samples	and	isolates	used	in	this	study	189	 P.	 aeruginosa	 isolates	 were	 isolated	 from	 sputum	 samples	 of	 93	bronchiectasis	 patients	 across	 16	 UK	 centres	 (supplementary	 table	 2)	determined	to	have	a	chronic	infection	(two	or	more	positive	respiratory	tract	cultures	in	the	previous	12	months).	For	24	patients	two	or	more	isolates	were	obtained	 and	 for	 three	 of	 these	 patients	 (patients	 147,	 148,	 149)	 14	 or	 15	isolates	 were	 obtained	 for	 sequencing.	 A	 subset	 of	 isolates	 representative	isolates	per	patient,	or	multiple	if	they	harboured	multiple	lineages	(determined	by	carrying	separate	MLST	profiles)	of	99	isolates	from	91	patients.			
5.2.2. Inference	of	genes	adaptive	by	loss	of	function		To	infer	that	genes	are	adaptive	by	loss	of	function	in	the	representative	panel	of	 genomes	 variants	 were	 annotated	 as	 being	 nonsense	 mutations	 (frame-shifting	insertions	and	deletions	and	premature	stop	codons).	How	many	times	a	 gene	 was	 determined	 to	 have	 lost	 function	 independently	 across	 the	population	was	taken	as	evidence	for	inference	of	that	change	being	adaptive	in	non-CF	bronchiectasis	infections.	It	is	shown	in	supplementary	figure	1	how	the	assumptions	 that	 large	 numbers	 of	 independent	 acquisitions	 are	 more	 likely	
131	
due	 to	 adaptation	 in	 the	 lung	 than	 genetic	 background.	 Parsimoniously	 if	 an	allele	 includes	 a	 nonsense	 mutation	 or	 mutations	 that	 are	 both	 unique	 and	shared	by	position	and	base	change,	conservatively	that	which	is	shared	is	taken	as	 having	 occurred	 first.	 As	 such	 the	 model	 conservatively	 estimates	 the	minimum	amount	of	independence	thereby	ignoring	that	the	same	change	at	the	same	position	is	not	only	possible	but	in,	some	genes,	likely274.																			
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5.3. Results		
5.3.1. Genome	Assembly	Quality	In	 order	 to	 characterise	 P.	 aeruginosa	 during	 chronic	 non-CF	 bronchiectasis	lung	infections	189	isolates	were	obtained	from	91	patients	attending	16	adult	bronchiectasis	 clinics	 in	 the	 UK.	 Following	 adapter	 trimming	 and	 quality	filtering,	 189	 genomes	were	de	novo	 assembled	 and	 scaffolded.	The	quality	 of	these	draft	genomes	was	assessed	by	contig	length	metrics	the	N50	and	largest	contig	size.	Further	the	GC%	content	and	draft	genome	sizes	were	determined.			The	 number	 of	 contigs	 (longer	 than	 1000bp	 in	 length)	 ranged	 from	 that	 of	isolate	C88	with	32	to	that	of	A163	with	589.	The	median	number	of	contigs	per	genome	was	66.	In	total	74.07%	of	genomes	were	assembled	into	<100	contigs.	The	largest	single	contigs	assembled	in	the	genomes	ranged	from	that	of	isolate	A163	with	124,349bp	to	that	of	isolate	C118	with	1,231,324bp.	The	median	size	of	 the	 largest	 contig	 assembled	was	 662,406bp.	 The	N50	 ranged	 from	 that	 of	A163	 with	 an	 N50	 of	 18,934bp	 to	 that	 of	 C73	 with	 an	 N50	 548,081bp.	 The	median	N50	was	242,365bp.		Genome	sizes	ranged	from	that	of	isolate	C4	with	6,108,491bp	to	that	of	isolate	C124	 with	 7,917,225bp.	 The	 median	 genome	 size	 across	 the	 range	 is	6,685,627bp.	 The	 GC	 content	 as	 a	 percentage	 of	 the	 genomes	 ranged	 from	65.27%	to	66.21%.			
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5.3.2. Across	Patient	Population	Diversity	MLST	profiles	were	determined	for	all	189	genomes.	The	most	common	ST	was	that	of	‘clone	C’	(ST-17),	representing	22	of	189	genomes.	A	further	19	sequence	types	represented	just	one	genome	respectively	(Supplementary	Table	2).		Two	isolates,	A36	and	A163,	presented	the	LES	associated	MLST	profile,	ST-146.	Both	genomes	short	reads	were	mapped	to	reference	LES	genome	LESB58	and	variants	called.	A36	and	A163	were	determined	to	be	113	SNPs	&	25	indels	and	109	 SNPs	 and	 22	 indels	 different	 from	 LESB58	 respectively.	 They	 were	 also	adjacent	to	the	LES	on	the	core	SNP	tree	of	the	wider	P.	aeruginosa	population.		Some	 sequence	 types	 were	 partially	 determined	 and	 these	 are	 provisionally	characterised	as	sequence	type	not	found	(NF).	Of	189	genomes,	29	were	ST-NF	and	 as	 such	were	 further	 assessed	 to	 deduce	 the	 potential	 ST	 (or	 ST’s)	 from	MLST	loci	profiles	available.	Alternatively,	an	ST	may	be	genuinely	novel	where	all	loci	have	profiles	assigned	but	in	combination	do	not	pertain	to	an	ST.	It	was	determined	 that	 12	 genomes	 were	 ST-novel	 (table	 5.1),	 while	 the	 remainder	carried	6/7	which	combined	suggested	potential	profiles	to	assign	(table	5.1).								Table	5.1.	Incomplete	MLST	profiles	to	be	determined	legitimately	novel	or	‘nearest	to’	an	establish	profile	by	the	loci	that	can	be	resolved		
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Isolate	 ST	 Closest	ST	 MLST	loci	
		 		 		 acs	 aro	 gua	 mut	 nuo	 pps	 trp	
A19	 NF	 92	or	261	 105	 5	 30	 -	 1	 4	 14	
B37	 Novel	 		 107	 4	 3	 27	 12	 7	 128	
B62	 NF	 1404	 16	 -	 6	 3	 4	 7	 1	
C101	 NF	 303	(4	loci)	 16	 -	 12	 18	 3	 4	 9	
C102	 NF	 304	(4	loci)	 16	 -	 12	 18	 3	 4	 9	
C103	 NF	 305	(4	loci)	 16	 -	 12	 18	 3	 4	 9	
C106	 NF	 156,179,353,1494	(6	loci)	 -	 27	 28	 3	 4	 13	 7	
C119	 Novel	 		 5	 1	 109	 3	 1	 1	 47	
C120	 Novel	 		 17	 5	 11	 5	 4	 29	 2	
C164	 NF	 1240,1985	(4	loci)	 28	 5	 46	 5	 1	 -	 61	
C16	 NF	 27,120,2314	(5	loci)	 6	 -	 6	 113	 4	 6	 7	
C17	 NF	 27,120,2314	(5	loci)	 6	 -	 6	 113	 4	 6	 7	
C18	 NF	 158,179,180,1496,2063,2109	(6	loci)	
36	 27	 28	 -	 4	 13	 7	
C21	 Novel	 		 22	 6	 1	 3	 1	 76	 1	
C22	 Novel	 		 22	 6	 1	 3	 1	 76	 1	
C23	 Novel	 		 22	 6	 1	 3	 1	 76	 1	
C31	 NF	 155,677,1276	(5	loci)	 28	 5	 36	 -	 3	 13	 7	
C32	 NF	 155,677,1276	(5	loci)	 28	 5	 36	 -	 3	 13	 7	
C33	 NF	 155,677,1276	(5	loci)	 28	 5	 36	 -	 3	 13	 7	
C4	 NF	 260	(6	loci)	 14	 5	 -	 7	 4	 13	 7	
C55	 Novel	 		 28	 5	 11	 11	 15	 75	 1	
C56	 Novel	 		 28	 5	 11	 11	 15	 75	 1	
C57	 Novel	 		 28	 5	 11	 11	 15	 75	 1	
C58	 Novel	 		 28	 5	 11	 11	 15	 75	 1	
C59	 Novel	 		 28	 5	 11	 11	 15	 75	 1	
C60	 Novel	 		 28	 5	 11	 11	 15	 75	 1	
C69	 NF	 1707,	2055	(6	loci)	 16	 24	 1	 149	 4	 -	 19	
C83	 NF	 620	(6	loci)	 9	 7	 63	 13	 8	 -	 8	
C85	 NF	 156,	179,	353,	1494	(6	loci)	 -	 27	 28	 3	 4	 13	 7	
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All	genomes	sequenced	were	included	with	the	wider	P.	aeruginosa	population	and	 the	 core	 genome	 extracted.	 The	 core	 genome	 was	 861,928bp.	 The	phylogeny	was	 approximated	 (supplementary	 figure	 6).	 Gubbins	was	 used	 to	predict	 and	 filter	 recombinant	 SNPs	 from	 the	 alignment.	 There	 was	 507,635	SNPs	in	the	core	genome,	6.32%	of	which	were	recombinant.	After	filtering	the	core	 genome	 contained	 7,194	 polymorphic	 sites	 for	 approximating	 the	 clonal	frame.	The	 resulting	 clonal	 frame	 from	gubbins	 is	displayed	 in	 figure	5.1.	The	placement	 of	 the	 genomes	with	 diverse	 associated	MLST	was	 disparate,	 with	isolates	spread	across	the	tree	(figure	5.1).																
136	
		Figure	 5.1.	 Core	 genome	 of	 the	 bronchiectasis	 genomes	 and	 the	 wider	 P.	
aeruginosa	population	with	recombinant	SNPs	filtered	out.	Green	represents	P.	
aeruginosa	phylogenetic	group1,	blue	group	2	and	pink	group	3.	Bronchiectasis	genomes	are	labeled	in	blue						
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5.3.3. Multi-lineage	infections	A	subset	of	24	patients	provided	more	than	one	sample	to	this	study	and	as	such	it	was	possible	 to	determine	 that,	 as	 in	CF,	whether	patients	were	harbouring	multiple	 distinct,	 coexisting,	 infecting	 lineages.	 This	 was	 determined	 by	identifying	 those	 patients	 with	 more	 than	 one	 MLST	 determined	 from	sequenced	isolates	(supplementary	table	2).			Patients	42,	72,	73	84,	85	and	148	presented	with	two	different	sequence	types	and	 Patient	 92	 carried	 three	 different	 sequence	 types	 ST-235,	 ST164	 and	 ST-871.	Isolates	representative	of	each	sequence	type	are	highlighted	per	patient	in	supplementary	 table	2.	 	Polymorphism	 in	no	more	 than	MLST	 loci	 in	 the	 lung	could	 result	 in	 distinct	 sequence	 types	 and	 false	 determination	 of	 separate	populations.	 Figure	 5.2	 highlights	 by	 linking	 isolates	 provided	 by	 the	 same	patient	that	when	placed	in	the	wider	P.	aeruginosa	population	(figure	5.1)	the	isolates	 with	 different	 sequence	 types	 are	 phylogenetically	 distinct,	 further	demonstrating	that	these	patients	are	harbouring	multi-lineage	infections.											
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				Figure	5.2.	Cladogram	representing	a	maximum	likelihood	approximation	of	the	
P.	 aeruginosa	 core	 genome.	 Green	 represents	 P.	 aeruginosa	 phylogenetic	group1,	 blue	 group	 2	 and	 pink	 group	 3.	 Representative	 genomes	 of	 each	 ST	where	patients	harbor	>1	are	connected	per	patient	to	demonstrate	relatedness		
139	
5.3.4. Lineage	diversity	In	 order	 to	 assess	 the	 diversity	 of	 P.	 aeruginosa	 populations	 in	 the	 non-CF	bronchiectasis	 lung	 two	 or	 more	 isolates	 were	 sequenced	 from	 24	 patients.	Further	 15	 isolates	were	 sequenced	 from	 each	 of	 patients	 147,	 148	 and	 149.	Patient	148	however	was	determined	to	be	carrying	two	distinct	lineages	of	ST-17	(n	=	4)	and	ST-175	(n	=	11)	(figure	5.2)	and	as	such	were	treated	as	separate	populations	in	the	analysis.	Table	5.2	shows	the	descriptive	statistics	of	SNP	and	Indel	differences	of	all-against-all	comparisons	of	patients	147,	148	(ST-17/ST-175)	and	149’s	isolates.	The	greatest	median	SNP	and	indel	difference	was	that	of	 patient	 148	 (ST-17)	 with	 482.5	 and	 25.5	 respectively.	 The	 least	 within	median	population	diversity	of	SNPs	and	indels	was	patient	148	(ST-175)	with	179	and	5	respectively.			Table	5.2.	The	number	of	single	nucleotide	polymorphism	and	small	insertion	and	deletion	differences	between	genomes	isolated	from	the	same	patients	respectively	
Patients	 Median	
SNPs	
SNP	
range	
Median	
indels	
Indel	
range	
Patient	147	 261.00	 88-640	 14.00	 0-35	
Patient	148	(ST17)	 482.50	 159-654	 25.50	 6-34	
Patient	148	
(ST175)	
179.00	 79-403	 5.00	 0-36	
Patient	149	 206.00	 68-327	 10.00	 3-28	
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Overall	 three	or	more	isolates	were	sequenced	from	nine	patients	(figure	5.3).	The	within	population	diversity	of	isolates	sequenced	from	patient	42	displayed	the	 largest	 range	 of	 206-949	 SNPs	 and	 indels	 and	 the	 highest	 median	 with	875.5.	 The	 population	 sampled	 from	 patient	 65	 demonstrated	 the	 smallest	range	with	100-162	SNPs	and	indels	and	a	median	of	130.		
	
	
	Figure	5.3.	Boxplots	of	all	against	all	whole	genome	pairwise	variant	(SNPs	and	indels)	differences	within	patient	lineages	
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5.3.5. Representative	panel	of	bronchiectasis	isolate	genomes	A	 representative	 panel	 was	 created	 containing	 one	 isolate	 genome	 sequence	from	each	patient	or	one	of	each	sequence	type	if	there	were	multiple	infecting	lineages.	The	resulting	panel	consisted	of	99	isolate	genomes	from	91	patients.	Supplementary	table	2	highlights	these	99	isolates,	their	MLST	profiles	and	their	associated	patient	identifiers.		The	core	genome	of	the	representative	panel	was	3,847,369bp	containing	7,698	polymorphic	sites,	of	which	7,534	were	complete	(without	gaps	or	ambiguous	nucleotides),	of	which	4030	were	phylogenetically	informative.	 An	 ML	 phylogenetic	 tree	 was	 approximated	 using	 the	 HKY85	substitution	model	 (supplementary	 figure	 7)	 and	 used	 as	 the	 starting	 tree	 to	predict	 recombination.	 Gubbins	 predicted	 that	 6.98%	 of	 SNPs	 in	 the	 core	genome	 were	 as	 a	 result	 of	 recombination.	 The	 clonalframe	 is	 displayed	 in	figure	 5.4.	 Of	 the	 99	 panel	 genomes,	 27	 placed	 phylogenetically	 in	 P.	
aearuginosa	group	2	of	the	tree,	71	in	P.	aeruginosa	phylogenetic	group	1	and	a	single	isolate	(B113)	is	a	phylogenetic	outlier	but	is	not	PA7-like	that	bifurcates	from	 the	 branch	 between	 the	 two	 major	 clades.	 Bifurcation	 of	 P.	 aeruginosa	phylogenetic	groups	1	and	2	showed	100%	bootstrap	support.									
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	Figure	5.4.	Core	genome	SNP	phylogeny	of	representative	panel	of	non-CF	bronchiectasis	genomes	(n	=	99).	RAxML	tree	based	on	SNP	sites	filtered	to	remove	recombinant	SNPs	by	gubbins.	Tree	scale	is	in	number	of	SNPs,	the	branch	to	B113	is	truncated	for	clarity	
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5.3.6. Evidence	for	potential	common	source	of	isolates	or	
cross	infection	Where	MLST	profiles	were	the	same	between	isolates	from	different	patients	in	the	same	centre,	these	were	further	investigated	for	genetic	similarity	by	whole	genome	pairwise	alignment,	identifying	SNP	and	indel	differences.	In	five	cases	pairs	 of	 genomes	 differed	 by	 <200	 SNPs	 and	 indels,	 (C6/C7,	 C29/C30,	C105/C109,	 C139/C141,	 and	 C156/C159).	 The	 representative	 bronchiectasis	panel	genomes	core	SNP	tree	is	labeled	per	centre	in	figure	5.5.			The	between	patient	diversity	of	 isolates	 sampled	was	 lower	 in	 the	 five	 cases	(C6/C7,	 C29/C30,	 C105/C109,	 C139/C141,	 and	 C156/C159)	 identified	 than	between	 some	 isolate	 genomes	 from	 within	 the	 same	 patient.	 Isolates	 from	within	 individual	patients	determined	 to	be	of	 the	 same	 lineage	by	MLST	and	placement	on	the	core	SNP	tree	(figure	5.1)	varied	by	as	much	as	>750	SNPs	and	indels	(C125/C126)	(table	5.3).										
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 Figure	 5.5.	 Core	 genome	 phylogeny	 of	 representative	 panel	 of	 non-CF	bronchiectasis	 genomes	 (n	=	99).	 Final	ML	 tree	approximated	by	RaxML	after	recombinant	sites	in	the	core	genome	were	filtered	out	by	Gubbins	(figure	5.4).	Leaf	labels	are	coloured	according	to	centre	where	isolates	were	sampled						
C6
9
C61
C
6
C1
3C
16
1
C5
5
C2
A1
00
C6
3
C
10
4
C15
6
C51
A19
C2
9
A1
C91
A1
06
C11
C1
64
C74
B1
13
C7
3
C105
C77
A4
6
C3
1
B3
B3
4
C1
67
C1
01
C143
A1
19
C
12
7
C76
A3
C49
C2
0
C131
C
11
0
C5
4
C8
9
C1
68
C12
0
C8
8
C13
3
C1
0
C125
C
15
5
C1
41
B1
99
C1
49
C150
A2
C1
19
C1
35
C6
4
C12
C1
8
C1
60
B1
14
C1
23
C36
C79
C86
C1
24
C1
53
C42
C3
C
71
C1
08
C15
9
C3
0
C
7
C1
34
C
11
4
C116
C9
2
C109
C
15
8
B3
7
C1
39
C107
C4
3
C129
C78
C25
C1
37
C95
C1
42
B16
C
21
C100
A163
A1
2
C1
51
C
87
C94
C146
B6
2
C
ol
or
ed
 ra
ng
es
C
en
tre
 1
1
C
en
tre
 1
0
C
en
tre
 6
C
en
tre
 7
C
en
tre
 1
6
C
en
tre
 9
C
en
tre
 2
C
en
tre
 8
C
en
tre
 1
4
C
en
tre
 1
C
en
tre
 5
C
en
tre
 1
3
C
en
tre
 1
2
C
en
tre
 3
C
en
tre
 1
5
C
en
tre
 4
Tr
ee
 s
ca
le
: 1
00
00
145	
Table	 5.3.	 Whole	 genome	 all	 against	 all	 pairwise	 comparisons	 of	 isolate	genomes	with	 common	MLSTs	within	 the	 same	 centre.	 SNP	 and	 indel	 counts	displayed	per	pairwise	comparison		Isolate	 Centre	 Isolation	date	 Patient	 MLST	 Comparison	 SNPs	 INDELs	C6	 4	 03/03/2010	 38	 244	 					C6-C7	C6-C8	C6-C9	C6-C10	C7-C8	C7-C9	C8-C9	C7-C10	C8-C10	C9-C10	
						179	3790	3733	3833	3736	3714	281	3929	603	515	
								8								79								74	62	82	75	5	65	14	11	
C7	 4	 23/03/2010	 39	 244	C8	 4	 16/04/2010	 40	 244	C9	 4	 16/04/2010	 40	 244	C10	 4	 16/04/2010	 40	 244		 	 	 	 	 	 	 	C11	 4	 19/08/2010	 41	 282	 C11-C12	 340	 8	C12	 4	 20/08/2010	 42	 282	 	 	 		 	 	 	 	 	 	 	C29	 15	 03/06/2009	 48	 252	 C29-C30	 168	 3	C30	 15	 04/06/2009	 49	 252	 	 	 	C25	 15	 20/05/2009	 46	 253	 C25-C36	 3428	 43	C36	 15	 21/05/2010	 52	 253	 	 	 	C91	 2	 13/01/2011	 76	 253	 C76-C91	 846	 5	C76	 2	 12/05/2009	 70	 253	 	 	 		 	 	 	 	 	 	 	C77	 2	 03/07/2009	 71	 308	 C77-C86	 277	 1	C86	 2	 06/08/2009	 73	 308	 	 	 	C105	 13	 25/07/2009	 83	 840	 C105-C109	 131	 8		 	 	 	 	 	 	 	C109	 13	 11/08/2009	 85	 840	 	 	 	C104	 13	 16/05/2009	 82	 179	 C104-C108	C104-C110	C104-C111	C104-C112	C104-C114	C104-C115	C108-C110	C108-C111	C108-C112	C108-C114	C108-C115	C110-C111	
10,551	2863	2765	1913	6795	6972	4780	4852	3780	10,963	10,833	176	
114	39	52	25	96	105	78	66	62	136	133	8	
C108	 13	 11/08/2009	 84	 179	
C110	 13	 11/08/2009	 85	 179	
C111	 13	 11/08/2009	 85	 179	
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C112	 13	 11/08/2009	 85	 179	 C110-C112	C110-C114	C110-C115	C111-C112	C111-C114	C111-C115	C112-C114	C112-C115	C114-C115		
198	3115	3107	148	2838	2789	1941	1895	281	
7	40	45	4	43	57	29	31	4	
C114	 13	 05/12/2009	 86	 179	
C115	 13	 05/12/2009	 86	 179	
	 	 	 	 	 	 	 	C125	 7	 29/04/2010	 92	 253	 C125-C126	C125-C131	C125-C133	C125-C134	C126-C131	C126-C133	C126-C134	C131-C133	C131-C134	C133-C134	
736	1159	872	817	9636	5847	5883	3486	3400	330	
27	22	22	21	99	71	70	40	38	4	
C126	 7	 29/04/2010	 92	 253	C131	 7	 08/05/2010	 93	 253	C133	 7	 28/05/2010	 94	 253	
C134	 7	 19/12/2010	 95	 253	
	 	 	 	 	 	 	 	C156	 16	 16/11/2010	 108	 260	 C156-C159	 160	 3	C159	 16	 09/12/2010	 110	 260		 	 	 	 	 	 	 	C139	 14	 08/09/2010	 98	 ST2102	 C139-C141	 177	 3	C141	 14	 01/10/2010	 99	 ST2102												
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5.4. Adaptation	by	Loss	of	Function	To	identify	genes	that	may	be	adapting	by	loss	of	function	in	the	representative	panel	of	non-CF	bronchiectasis	isolate	genomes	the	independent	acquisition	of	nonsense	mutations	was	inferred.	Of	the	non-CF	bronchiectasis	representative	panel	of	genomes	there	were	1,480	different	genes	with	a	nonsense	mutation	in	at	least	one	genome.	There	were	308	genes	with	nonsense	mutations	in	two	or	more	genomes	(table	5.4).	One	gene,	mexB	has	acquired	a	nonsense	mutation	16	times	in	the	population,	also	frequently	independently	acquiring	loss	of	function	were	mucA	with	13	acquisitions	and	betT2	with	9	acquisitions.	All	genes	with	five	or	more	acquisitions	are	displayed	in	table	5.5.				Table	 5.4.	 The	 number	 of	 different	 genes	 with	 2	 or	 more	 independently	acquired	nonsense	mutations	in	the	representative	panel	population		
Number	of	
genes	
Number	of	independent	acquisitions	of	a	nonsense	mutation	
in	each	gene	in	the	panel	205	 2	47	 3	37	 4	8	 5	3	 6	5	 7	1	 9	1	 13	1	 16						Table	5.5.	Genes	in	which	nonsense	mutations	have	occurred	independently	>=5	times	in	the	representative	panel	population	
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Gene	 Independent	Acquisitions	
Maintained	
in	 Function	/	Comment	
mexB	 16	 18	 Transporter	from	MexAB-OprM	efflux	pump,	antibiotic	resistance,	virulence	
mucA	 13	 31	 Anti-sigma	factor,	mutations	can	lead	to	mucoidy.		
betT2		 9	 11	 Transporter,	uptake	of	small	molecules	such	as	choline	and	glycine	betaine,	contributing	to	growth	via	phosphatidyl	choline	metabolism	and	osmoprotection		
bifA	 7	 9	 Cyclic-di-GMP	phosphodiesterase,	inversely	regulates	biofilm	formation	
mexA	 7	 8	 Membrane	fusion	protein	from	MexAB-OprM	efflux	pump,	antibiotic	resistance,	virulence	
pcoA	 7	 15	 Copper	resistance	
PA4469	 7	 19	 Hypothetical	protein	in	same	operon	as	and	upstream	of	sodM	(superoxide	dismutase;	response	to	oxidative	stress)	
rbdA	 7	 24	 Cyclic-di-GMP	phosphodiesterase,	modulation	of	biofilm	dispersal,	negative	regulation	of	Pel	production	
pilJ	 6	 6	 Methyl	accepting	chemotaxis	receptor-like	protein	involved	in	twitching	motility	and	biofilm	formation	
oprM	 6	 8	 Outer	membrane	protein	from	MexAB-OprM	efflux	pump,	antibiotic	resistance,	virulence	
oprF	 6	 10	 Major	porin,	biofilm	formation	
chpA	 5	 6	 Chemotaxis-like	chemosensory	protein	involved	in	twitching	motility	
fimV	 5	 5	 Peptidoglycan-binding	protein,	promotes	type	IV	pilin	assembly,	twitching	motility	
ladS	 5	 5	 Sensor	kinase,	implicated	in	switch	between	acute	and	chronic	infection	
mutL	 5	 6	 Mismatch	repair	system,	DNA	repair,	mutation	can	lead	to	mutator	phenotype	
gmd	 5	 6	 GDP-mannose	4,6-dehydratase,		
mexS	 5	 6	 Mutations	promote	MexT-dependent	mexEF-oprN	expression	and	multidrug	resistance	
pchE	 5	 7	 Pyochelin	synthesis		PA0054	 5	 6	 Hypothetical	protein		
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Genes	 inferred	to	be	adaptive	by	 loss	of	 function	(table	5.5)	are	 involved	with	diverse	functions	such	as	antibiotic	resistance	(oprM,	mexB,	mexA,	mexS,	oprF),	hypermutability	 (mutL),	 regulation	 of	 alingate	 biosynthesis	 and	 the	 mucoidy	phenotype	 (mucA)	 and	motility	 (fimV).	Nonsense	mutations	 in	DNA	mismatch	repair	genes	are	observed	in	11	of	the	99	panel	isolates,	including	phylogenetic	outlier	B113	(table	5.4,	supplementary	figure	9).	In	7	of	the	11	isolates	there	is	a	frameshifting	 indel	 in	 mutL,	 in	 the	 remaining	 frame-shifting	 indels	 in	 mutS,	including	a	10bp	deletion	in	C123.			Table	 5.6.	 Isolate	 genomes	with	 nonsense	mutations	 in	DNA	mismatch	 repair	genes	mutS,	mutL,	uvrD	or	mutM	Isolate	 Genetic	basis	C123	 10bp	deletion	in	mutS	C31	 Frameshifting	indel	in	mutL	C78	 Frameshifting	indel	in	mutL	B113	 Frameshifting	indel	in	mutL	C129	 Frameshifting	indel	in	mutL	C133	 Frameshifting	indel	in	mutS	C134	 Frameshifting	indel	in	mutS	C127	 Frameshifting	indel	in	mutS	C79	 Stop	codon	gained	in	mutL	C18	 Stop	codon	gained	in	mutL	65-C74	 Stop	codon	gained	mutL			In	 total	 31	 genomes	presented	with	 a	 nonsense	mutation	 in	 anti-sigma	 factor	for	 alginate	 biosynthesis	 gene	 mucA.	 It	 was	 determined	 that	 nonsense	mutations	have	been	acquired	at	least	13	times	in	the	gene	in	the	bronchiectasis	panel.	 Further,	 an	 additional	 three	 genomes	 have	 larger	 deletions	 in	mucA	 so	that	there	was	a	total	of	34	of	99	genomes	with	evidence	for	loss	of	function	in	MucA.			
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The	 genes	mexA,	mexB	 and	 oprM	 that	 comprise	 the	mexAB-oprM	 efflux	 pump	were	individually	inferred	to	be	adaptive	by	loss	of	function.	Gene	mexA	carries	a	nonsense	mutation	in	8	genomes	and	they’ve	been	acquired	a	minimum	of	7	times.	 Eighteen	 genomes	 carried	 a	 nonsense	mutation	 in	mexB	 from	which	 it	could	be	determined	that	there	has	been	at	least	16	independent	acquisitions.	A	further	four	genomes	carry	a	larger	deletion	in	mexB,	ranging	from	an	estimated	43	 to	 280bp.	 Finally	 gene	 oprM	 carries	 a	 nonsense	 mutation	 in	 8	 genomes,	acquired	at	least	6	times.			Figure	 5.6	 plots	 the	 associated	 pseudoCAP	 functional	 categories	 of	 the	 genes	inferred	 to	 be	 adaptive	 by	 loss	 of	 function	 (table	 5.4).	 There	may	be	multiple	functional	associations	per	gene	and	each	are	counted	according	to	the	number	of	genomes	in	which	loss	of	function	is	maintained	in	the	respective	genes.	The	function	most	often	associated	was	‘Transport	of	Small	Molecules’	representing	15.95%	 of	 all	 associations	 followed	 by	 ‘Membrane	 Proteins’	 that	 represent	13.36%	 of	 associations.	 Regulatory	 genes	 are	 associated	 with	 inferred	adaptation	 by	 loss	 of	 function	 with	 ‘Transcriptional	 Regulators’	 representing	8.4%	 and	 ‘Two	 Component	 Systems’	 representing	 3.23%	 of	 functional	associations.					
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	Figure	5.6.	PseudoCAP	functional	categories	associated	with	genes	most	often	independently	acquiring	nonsense	mutations	(table	5.4)	as	a	function	of	the	number	of	genomes	in	which	the	loss	of	function	allele	is	carried												
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5.5. Discussion	This	study	represents	the	first	application	of	genomics	to	analyse	chronically	infecting	P.	aeruginosa	from	non-CF	Bronchiectasis	patients.	It	was	possible	to	determine	that	multi-lineage	infections	occur,	that	within	centre	and	within	patient	diversity	can	be	similar	suggesting	potential	common	source	or	cross	infection	of	isolates	not	know	to	be	transmissible.			Compared	with	CF	there	is	no	evidence	of	widespread	cross-infection	of	known	transmissible	 isolates	 in	 the	 non-CF	 bronchiectasis	 set208.	 There	 is	 however	evidence	for	the	presence	of	the	LES	in	one	patient.	The	LES	has	previously	been	observed	 to	 have	 spread	 to	 non-CF	 patients208,348.	 However,	 the	 pairwise	distance	between	isolates	from	different	patients	within	the	same	centre	was	at	times	less	than	the	mutational	diversity	of	isolates	within-patients.	Lineages	or	‘strains’	may	be	more	abundant	in	the	environment	such	as	PA14	and	clone	C289	were	among	 the	most	abundant	 in	 the	non-CF	bronchiectasis	 set	 too.	As	such,	their	 abundance	 isn’t	 indicative	 of	 cross	 infection	 or	 common	 source	 of	infection.	However,	by	pairwise	comparisons	of	isolate	genomes	sampled	from	different	patients	attending	the	same	centre	it	was	revealed	that	many	differed	by	<200	variants.	SNP	cutoffs	have	been	proposed	in	bacterial	genomics	for	the	inference	 of	 cross	 infection	 but	 lack	 a	 conceivable	 method	 to	 falsify	 their	conclusions.	 In	 P.	 aeruginosa	 reservoirs	 around	 a	 hospital	 have	 been	 reliably	determined	 from	WGS365	 however;	 demonstrating	 the	 potential	 for	 the	 same	approach	 to	 non-CF	 Bronchiectasis	 P.	 aeruginosa	 infections.	 Where	 the	 SNP	diversity	between	patients	 is	 small	 relative	 to	 typical	 environmental	 sampling	and	especially	when	relative	to	within	patient	diversity,	sampling	of	the	hospital	
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environment	 could	 reliably	 rule-out	 or	 confirm	 a	 common	 source	 of	 infection	within	the	clinic.	Further	segregation	policies	have	been	successful	in	CF	clinics	to	 stem	 cross	 infection	 of	 putative	 transmissible	 strains366;	 segregation	 of	patients	across	which	there	is	the	lowest	SNP	diversity	and	further	sampling	of	other	patients	may	confirm	the	patient	to	patient	infectivity	of	these	lineages	by	observing	a	reduction	in	new	cases.			Previously	paired	isolates	from	non-CF	Bronchiectasis,	9/10	patients	presented	a	 common	 genotype	 while	 one	 patient	 harboured	 two	 distinct	 genotypes367.	With	a	subsample	of	24	patients	multiple	isolates	were	obtained	and	sequenced	demonstrating	the	presence	of	multi-lineage	infections	in	non-CF	Bronchiectasis	with	as	many	as	3	infecting	lineages.	Figure	5.1	demonstrates	how	diverse	the	isolates	 carrying	 different	 MLST	 profiles	 are,	 rendering	 significantly	 less	probable	simple	mutation	within-lineage	of	an	informative	MLST	loci	resulting	in	different	genotypes.			The	first	P.	aeruginosa	genomic	study	of	non-CF	P.	aeruginosa	opportunistically	infecting	 diseased	 lungs,	 in	 PCD	 patients,	 confirmed	 pathoadaptive	mutations	typically	 observed	 in	 CF364.	 Similarly	 loss	 of	 function	 in	 mucA	 resulting	 in	mucoidy	 and	 lasR	 are	 observed	 in	 non-CF	 bronchiectasis	 P.	 aeruginosa	infections	 as	 in	CF66,214,325.	Other	 loss	 of	 function	mutations	 common	 in	 genes	
pliJ,	chpA	and	fimV	are	involved	in	twitching	motility	and	have	been	observed	in	CF66	 and	 artificial	 sputum349	 meaning	 that	 this	 adaptation	 may	 pertain	 to	survival	 in	 the	 physical	 conditions	 (comparable	 mucus	 viscosity)	 in	 non-CF	Bronchiectasis	as	in	CF.		
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Adaptation	 by	 loss	 of	 function	 in	 the	 non-CF	 Bronchiectasis	 P.	 aeruginosa	population	was	inferred	from	independence	as	described	in	general	methods.	It	was	 assumed	 that	 the	 genes	 with	 the	 greatest	 number	 of	 independent	acquisitions	 of	 loss	 of	 function	 were	 more	 likely	 to	 have	 occurred	 in	 their	common	 lung	 environment	 than	 in	 varied	 source	 niches.	 However,	 as	 each	genome	was	mapped	 to	 reference	 genome	 PAO1,	 genetic	 distance	 could	 be	 a	factor.	 Genomes	 with	 the	 greatest	 number	 of	 mutations	 compared	 to	 PAO1	would	 also	 have	 the	 greatest	 number	 of	 genes	 with	 nonsense	 mutations.	Supplementary	figure	9	demonstrates	that	this	 is	the	case.	Genomes	belonging	phylogenetically	 to	P.	aeruginosa	phylogenetic	group	3	(+	other	outliers	 to	 the	two	major	groups)	 that	 typically	have	the	greatest	distance	to	PAO1	also	have	the	greatest	number	of	genes	with	nonsense	mutations.	The	trend	follows	that	phylogenetic	group	2,	 that	of	PA14,	has	the	next	 largest	number	of	genes	with	nonsense	mutations	and	 the	 fewest	are	derived	 from	genomes	belonging	 to	P.	
aeruginosa	phylogenetic	group	1	within	which	PAO1	 is	nested.	By	comparison	inclusion	of	 genes	 inferred	 to	be	 adaptive	by	 loss	 of	 function	 (table	5.5)	 only,	does	not	display	this	effect	(supplementary	figure	1).			Genes	 that	 commonly	 lose	 function	 in	 chronic	 CF	 infections,	mucA	 and	 lasR66	were	observed	to	have	lost	 function.	Regulatory	genes	typically	adaptive	in	CF	such	 as	mexT,	 retS,	 exsD,	and	 ampR	 were	 not	 so	 in	 non-Bronchiectasis.	 In	 CF	there	 are	 multiple	 adaptive	 routes	 to	 chronic	 infection66,279	 and	 this	 is	 most	likely	 the	 same	 with	 non-CF	 Bronchiectasis.	 Other	 genes	 commonly	 carrying	loss	 of	 function	 mutations	 (pilJ,	 chpA,	 fimV)	 are	 implicated	 in	 disruption	 of	twitching	motility,	observed	in	CF66	and	artificial	sputum	media349.		
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P.	 aeruginosa	 will	 produce	 exopolysaccharides	 alginate,	 Psl	 and	 Pel	 that	contribute	 to	 biofilms	 to	 protect	 itself	 from	 hostile	 environments152.	 Psl	 is	integral	 to	 surface	 attachment	 and	 in	CF	 it’s	 been	 suggested	 that	 free-floating	biofilms	 are	 more	 typical	 during	 infection158.	 In	 non-CF	 bronchiectasis	 this	preference	towards	Pel	is	also	observed	with	36	genomes	with	one	or	more	loss	of	 function	 mutations	 in	 Psl	 genes	 with	 additional	 loss	 of	 function	 in	 genes	
bifA368,	rbdA369,	oprF370	and	ladS371	that	support	this	view.																		
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5.5.1. Chapter	Summary	By	sequencing	P.	aeruginosa	isolates	sampled	from	non-CF	bronchiectasis	lung	infections	it	could	be	determined:		
• Multi-lineage	infections	are	present	in	multiple	patients	sampled,	as	in	CF	
• Adaptive	routes	such	as	mucoidy	are	present	in	non-CF	Bronchiectasis	
• Evidence	of	a	common	source	of	isolates	within	centres	
• Significant	within-patient	diversity																	
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Chapter	Six	Integron	 Mediated	 Antibiotic	 Resistance	 in	
Pseudomonas	aeruginosa	from	a	Hospital	in	Thailand	
6. Introduction	
6.1. Background	
Pseudomonas	aeruginosa	poses	a	public	health	problem	as	a	major	nosocomial	pathogen	 with	 a	 standing	 diversity	 of	 intrinsic	 antibiotic	 resistance	mechanisms167.	 Increasingly,	 horizontally	 acquired	 antibiotic	 resistance,	 in	particular	 to	carbapenems,	 is	of	 serious	concern.	As	a	 result	 the	World	Health	Organisation	 (WHO)	 has	 designated	 P.	 aeruginosa	 a	 critical	 threat	 to	 public	health;	 its	 highest	 category	 concerned	 with	 antibiotic	 resistant	 bacteria.	Antibiotic	resistance	genes	(ARGs)	acquired	horizontally	are	present	in	hospital	and	environmental	P.	aeruginosa79,138,200.			
6.1.1. Antibiotic	Resistance	Awareness	 of	 antibiotics	 increased	 through	 the	 1930’s	 to	 1950’s	 and	 in	 the	1950’s	 the	 potential	 for	 horizontally	 acquired	 resistance	 became	 apparent372.	Bacteria	 may	 acquire	 genes	 horizontally	 by	 conjugation,	 transformation,	transduction	and	via	transposable	elements	such	as	integrons.	Conjugation	and	transformation	 have	 been	 observed	 to	 transfer	 ARGs	 in	 a	 variety	 of	environments	 including	 soil,	 marine	 sediment,	 seawater	 and	 sewage	wastewater373.	 Bacteriophage	 viral	 alterations	 of	 bacterial	 genomes	 occur374	across	broad	host	ranges	and	the	role	of	transduction	in	environmental	transfer	of	ARGs	has	also	been	observed	in	marine	environments375.	The	gene	encoding	
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methicillin	 resistance	 mecA,	 for	 instance,	 famously	 acquired	 by	 methicillin	resistant	S.	aureus	(MRSA),	 has	been	observed	within	bacteriophage	DNA	 in	 a	wastewater	systems376.			While	antibiotic	resistance	genes	and	antibiotics	have	naturally	been	present	in	the	 environment	 the	 scale	 and	 impact	of	human	pollution	of	 the	 environment	with	antibiotics377	 is	well	 evidenced.	During	2013	 for	example,	53,800	 tons	of	antibiotics	were	released	into	rivers	and	waterways	in	China378.	Environmental	pollution	 with	 antibiotics	 can	 be	 demonstrated	 to	 be	 associated	 with	 in	 an	increased	 abundance	 of	 ARGs379–381.	 Since	 the	 widespread	 manufacture	 of	antibiotics	ARGs	in	a	variety	of	environments	has	increased173,382,383.	A	study	by	Ali	 Khan	 et	 al.,384	 in	 Pakistan	 provides	 a	 clear	 demonstration	 of	 the	anthropogenic	 impact	 on	 environmental	 antibiotic	 resistance.	 Antibiotics	measured	 from	 five	 rivers	 matched	 unpolluted	 levels	 from	 other	 studies,	whereas	 downstream	 of	 Lahore	 oxytetracycline,	 trimethoprim	 and	sulfamethoxazole	were	measured	at	1100,	1700	and	2700ng	L-1384.	 The	 range	near	 drug	 formulation	 facilities	 was	 even	 higher	 with	 1,100-49,000ng	 L	 -1	of	antibiotics	 erythromycin,	 lincomycin,	 ciprofloxacin,	 ofloxacin,	 levofloxacin,	oxytetracycline,	 trimethoprim	 and	 sulfamethoxazole384.	 The	 levels	 of	 sul1	 and	
drfA1	genes	were	associated	with	this	antibiotic	pollution384.	A	study	by	Yong-Guan-Zhu	 et	 al.,385	 recently	 further	 demonstrated	 that	 in	 a	 sample	 of	 18	estuaries	in	China	248	antibiotic	resistance	genes	were	present	representing	all	major	mechanisms	of	resistance	with	antibiotic	deactivation,	efflux	pumps	and	cellular	 protection385.	 Network	 analysis	 showed	 an	 association	 between	 the	
159	
presence	 of	 ARGs	 and	 an	 integron	 integrase	 gene	 (int1)	 demonstrating	 the	probable	mobility	of	these	genes385.			
6.1.2. Mobile	genetic	element	associated	antibiotic	resistance	
in	P.	aeruginosa	
P.	 aeruginosa,	 largely	 as	 a	 result	 of,	 intrinsic	 and	 acquired	 resistances	 is	 a	complicated	nosocomial	pathogen167.	The	high	 level	of	 resistance	 in	various	P.	
aeruginosa	 worldwide386–388	 leaves	 only	 colistin	 as	 a	 ‘last	 resort’	 antibiotic.	However,	 in	 2016	 a	 study	 by	 Liu	 et	 al.,	 reported	 the	 discovery	 of	 the	MCR-1	colistin	 resistance	 conferring	 plasmid	 in	 E.	 coli389.	 MCR-1	 was	 subsequently	demonstrated	to	confer	resistance	to	P.	aeruginosa	in	vitro	and	in	vivo390.	Rather	than	 acquisition	 P.	 aeruginosa	 has	 also	 be	 observed	 to	 inherit	 resistance	 to	polymyxins	including	colistin	vertically;	mutations	accumulated	in	pmrAB	have	resulted	in	resistance	in	isolates	from	colistin	treated	CF	patients391.	Lineages	of	MDR	 P.	 aeruginosa	 have	 been	 observed	 to	 be	 overrepresented	 in	 hospitals	worldwide;	 ST-235,	 ST-132	 and	 ST-111	 are	 enriched	 for	 integron	 antibiotic	resistance	gene	 casettes392–394.	While	 ST-235’s	 are	 typically	 still	 susceptible	 to	colistin,	ST-235s	with	colistin	resistance	have	also	have	been	observed	in	South	Korea395.			In	 a	 study	 across	 tertiary	 centres	 in	 Thailand,	 261	 isolates	were	 assessed	 for	antibiotic	 resistance	 and	 it	 was	 demonstrated	 that	 71.65%	 were	 multidrug	resistant	with	carbapenem	resistance	and	with	>50%	of	isolates	in	each	hospital	carrying	resistance	to	meropenem396.	Molecular	investigation	of	multidrug	and	
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carbapenem	resistant	P.	aeruginosa	 in	Thailand	revealed	that	the	genetic	basis	was	not	always	clear	and	was	multi-factorial397.	However,	decreased	expression	of	OprD	was	observed	in	93.56%	of	isolates	and	increased	expression	of	MexXY	and	MexAB-oprM397.	Integron	associated	genes	IMP-1,	IMP-14	and	VIM-2	were	additionally	identified	397.	These	findings	are	consistently	observed	in	hospitals	in	other	countries76,398,399.																					
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6.1.3. Aims		The	aims	of	this	chapter	are	to	assess	the	antibiotic	resistance	of	clinical	
Pseudomonas	aeruginosa	isolates	from	a	hospital	in	Bangkok,	Thailand.	A	selection	of	isolates	are	to	be	sequenced	to	assess:		
• The	genetic	basis	of	different	resistance	profiles,	particularly		
• The	presence	of	integrons	with	antibiotic	resistance	genes	
• Potential	presence	of	international	MDR	strains	
• Potential	for	transmission	of	lineages	or	integrons	within	the	hospital																
162	
6.2. Methods	A	sample	of	P.	aeruginosa	 isolates	was	provided	by	Dr	Pitak	Santanirand	 from	Ramathibodi	 Hospital,	 Mahidol	 University,	 Bangkok,	 Thailand,	 to	 investigate	antibiotic	resistance	profiles	and	the	potential	for	integron	mediated	resistance.	Genomes	were	assembled,	reads	mapped	and	variants	called,	MLST	determined	and	core	SNP	phylogenies	approximated	as	described	in	the	general	methods.			
6.2.1. Antibiotic	susceptibility	and	resistance	Antimicrobial	 susceptibility	 testing	 was	 carried	 out	 according	 to	 the	 British	Society	of	Antimicrobial	Chemotherapy	(BSAC)	guidelines.	Briefly,	isolates	to	be	tested	were	cultured	onto	Columbia	plates	(overnight	37	°C).	From	these,	single	colonies	 were	 mixed	 with	 sterile	 distilled	 water	 to	 attain	 a	 standard	 optical	density	 (10	 MacFarland	 units),	 and	 10 μl	 spread	 onto	 iso-sense	 plates	 and	incubated	 overnight	 at	 37	 °C	 with	 Meropenem	 (10 μg),	 Ceftazidime	 (30	 μg),	Piperacillin/Tazobactam	(75/10	μg)/,	ciprofloxacin	(5	μg),	tobramycin	(10	μg)	and	 Colistin	 (25	 μg)	 antibiotic	 discs.	 Antibiotic	 sensitivity	was	 determined	 by	measuring	the	zone	of	inhibition	and	the	results	were	interpreted	as	sensitive,	intermediate	 resistant,	 or	 resistant	 consistent	 standardised	 BSAC	 protocols	(table	6.1).								
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Table	6.1.	Zone	diameter	breakpoints	for	Pseudomonas	spp.	
		 Interpretation	of	zone	diameters	
(mm)	 		
Antibiotic	 R>	 I	 S≤	 Disc	content	
(μg)	
Meropenem	 15	 16-19	 20	 10	
Ceftazidime		 23	 -	 24	 30	
Piperacillin/Tazobac
tam	
24	 -	 25	 75/10	
Ciprofloxacin	 19	 20-29	 30	 5	
Tobramycin	 19	 -	 20	 10	
Colistin	 4	 -	 4	 25*	*Disc	diffusion	is	no	longer	recommended	for	colistin	susceptibility	testing		
6.2.2. Antibiotic	Resistance	Gene	Predictions	Integrons,	whether	complete	In0	elements	(presence	of	a	integrase	gene	and	no	
attC	 sites),	 CALIN	elements	 (clusters	 of	attC	 sites	 lacking	 integron	 integrases)	and	complete	integrons	(an	integrase	and	at	least	one	attC	site)	were	discovered	from	assembled	genomes	using	 integron	 finder400.	The	 --local_max	option	was	used	 for	 optimum	 sensitivity	 and	 --func_annot	 that	 matches	 predicted	functional	 sequences	 with	 integron	 or	 integron	 like	 elements	 to	 the	 Resfams	database401.			
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6.3. Results	
P.	aeruginosa	isolates	from	Ramathibodi	Hospital,	Mahidol	University,	Bangkok,	Thailand	were	acquired	 from	a	range	of	patients	and	types	of	 infection	(Table	6.2)	 to	 assess	 the	 presence	 of	 antibiotic	 resistance	 and	 the	 potential	 for	determining	its	genetic	basis.	In	total	49	isolates	were	received	for	analysis,	all	of	which	were	 tested	 for	 resistance	against	 commonly	used	anti-pseudomonal	antibiotics.			Table	6.2.	All	Isolates	sampled	for	this	study	with	patient	age,	gender	and	relevant	pathology	
Isolate	 Age	 Sex	 Specimen	
A1(U2448)	 67	 M	 Urine	
A10(P2744)	 62	 M	 Stoma	
A2(H882)	 66	 M	 Blood	
A3(H638)	 90	 M	 Blood	
	A4(P2337)	 55	 F	 Chest	
A5(P2338)	 55	 F	 Chin	
A6(P2087)	 56	 M	 Wound		swab	
A7(P2010)	 61	 M	 Wound		swab	
A8(P1885)	 74	 M	 Foot	
A9(P2733)	 53	 F	 Chest	
B1(P2356)	 1	 F	 PCD	
B10(T2867)	 72	 F	 Sputum	
B2(E2758)	 48	 F	 Eye	(Plate)	
B3(T2101)	 81	 M	 Sputum	
B4(U2816)	 63	 M	 Urine	
B6(P2404)	 72	 F	 Foot	
B7(T2709)	 67	 F	 Sputum	
B8(T2584)	 80	 F	 Sputum	
B9(T2436)	 90	 M	 Sputum	
C1(T2548)	 98	 F	 Sputum	
C10(T3359)	 74	 M	 Nasopharynx	
C2(T2284)	 66	 F	 Sputum	
C3(T2924)	 90	 M	 Sputum	
C4(3139)	 52	 M	 Urine		(catheter)	
C9(P1814)	 1	 F	 Ascitic	
C6(T3044)	 81	 M	 Nasal	
C7(T3582)	 72	 F	 Sputum	
C8(T3532)	 83	 M	 Sputum	
C9(T3498)	 82	 M	 Sputum	
D1(T3354)	 55	 F	 Sputum	
D10(U4045)	 82	 F	 Urine	
D2(T3266)	 72	 F	 Sputum	
D3(T3141)	 52	 M	 Sputum	
D4(T3649)	 87	 F	 Sputum	
D5(T3677)	 82	 M	 Maxillary		sinus	
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D6(T3664)	 67	 F	 Sputum	
D7(U3171)	 78	 M	 Urine	
D8(T3382)	 79	 F	 Sputum	
D9(T3362)	 66	 M	 Sputum	
E1(T4189)	 55	 F	 Sputum	
E10(P4321)	 61	 M	 Wound		swab	
E2(E4656)	 59	 F	 Eye	(Plate)	
E3(T3979)	 92	 M	 Sputum	
E4(T4247)	 67	 M	 Sputum	
E5(U4030)	 8	 M	 Urine	
E6(U4117)	 77	 F	 Urine	
E7(E3885)	 39	 F	 Eye	(Plate)	
E8(U4082)	 62	 M	 Urine	
E9(U4068)	 81	 M	 Urine		(catheter)			
6.3.1. Antibiotic	Resistance	Profiles	Isolates	 were	 tested	 for	 resistance	 to	 meropenem,	 ceftazidine,	piperacillin/tazobactam,	 ciprofloxacin,	 tobramycin	 and	 colistin.	 Figure	 6.1	shows	the	respective	resistance	and	sensitivity	profiles	to	the	six	antibiotics.	Of	49	isolates,	13	were	susceptible	to	all	antibiotics	tested	except	colistin.	A	further	two	isolates	were	susceptible	to	all	except	colistin	and	intermediary	resistance	to	meropenem.	The	majority	 (n	=	34)	were	 resistant	 to	at	 least	one	antibiotic	tested	 and	 of	 those	 23	 are	 resistant	 to	 two	 or	 more.	 The	 most	 common	resistance	observed	was	 to	piperacillin/tazobactam	present	 in	29/49	 isolates,	followed	 by	 ciprofloxacin	 observed	 in	 19/49	 isolates	 and	 thirdly	 ceftazidine	observed	in	18/49	isolates.	 Intermediary	resistance	is	present	 for	meropenem	and	ciprofloxacin	in	7/49	and	4/49	isolates	respectively	(table	6.3).						
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Table	6.3.	Count	of	isolates	resistance,	susceptible	or	displaying	intermediary	results	to	each	antbiotic	tested	
Number	of	isolates	 MEM10	 CAZ30	 PTZ85	 CIP	 TN	 CO25	
Resistant	 9	 18	 29	 19	 17	 0	
Susceptible	 33	 31	 20	 26	 32	 49	
Intermediary	 7	 0	 0	 4	 0	 0		Isolates	 tested	 for	 resistance	 and	 susceptibility	 to	 the	 6	 antibiotics	 also	exhibited	 multiple	 resistances	 at	 once	 (figure	 6.1).	 Five	 isolates,	 A1U2448,	B3T2101,	 B9T2436,	 E1T4189	 and	 E9U4068	were	 resistance	 to	 all	 antibiotics	tested	except	colistin.	A	further	three	isolates	were	resistant	to	four	antibiotics	and	intermediary	for	meropenem.																	Figure	 6.1.	 Antibiotic	 resistance	 and	 susceptibility	 patterns	 to	 meropenem,	ceftazidine,	piperacillin/tazobactam,	ciprofloxacin,	tobramycin	and	colistin		
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Strains	 MEM10	 CAZ30	 PTZ85	 CIP	 TN	 CO25	
A10(P2744)	 S	 R	 S	 S	 S	 S	
A1(U2448)	 R	 R	 R	 R	 R	 S	
A2(H882)	 S	 S	 S	 S	 S	 S	
A3(H638)	 I	 R	 R	 R	 R	 S	
	A4(P2337)	 S	 S	 R	 	S	 R	 S	
A5(P2338)	 R	 S	 R	 R	 R	 S	
A6(P2087)	 S	 R	 R	 S	 S	 S	
A7(P2010)	 S	 S	 S	 R	 S	 S	
A8(P1885)	 S	 S	 S	 S	 S	 S	
A9(P2733)	 S	 S	 S	 S	 S	 S	
B10(T2867)	 S	 S	 R	 S	 S	 S	
B1(P2356)	 S	 R	 R	 S	 S	 S	
B2(E2758)	 S	 S	 S	 S	 S	 S	
B3(T2101)	 R	 R	 R	 R	 R	 S	
B4(U2816)	 I	 S	 S	 S	 S	 S	
B6(P2404)	 S	 S	 R	 I	 R	 S	
B7(T2709)	 S	 S	 S	 S	 S	 S	
B8(T2584)	 R	 S	 R	 R	 R	 S	
B9(T2436)	 R	 R	 R	 R	 R	 S	
C10(T3359)	 S	 S	 S	 S	 S	 S	
C1(T2548)	 S	 R	 R	 R	 R	 S	
C2(T2284)	 S	 S	 R	 I	 S	 S	
C3(T2924)	 S	 R	 R	 S	 S	 S	
C4(3139)	 S	 S	 R	 R	 S	 S	
C6(T3044)	 S	 S	 S	 S	 S	 S	
C7(T3582)	 I	 R	 R	 R	 R	 S	
C8(T3532)	 R	 R	 R	 R	 S	 S	
C9(P1814)	 I	 R	 R	 R	 R	 S	
C9(T3498)	 S	 S	 S	 S	 S	 S	
D10(U4045)	 S	 S	 S	 S	 S	 S	
D1(T3354)	 S	 S	 R	 I	 S	 S	
D2(T3266)	 I	 R	 R	 R	 R	 S	
D3(T3141)	 S	 S	 R	 R	 S	 S	
D4(T3649)	 S	 S	 R	 S	 S	 S	
D5(T3677)	 S	 S	 S	 S	 S	 S	
D6(T3664)	 S	 S	 R	 S	 S	 S	
D7(U3171)	 S	 S	 R	 I	 S	 S	
D8(T3382)	 I	 S	 R	 R	 S	 S	
D9(T3362)	 S	 S	 S	 S	 S	 S	
E10(P4321)	 S	 S	 S	 S	 R	 S	
E1(T4189)	 R	 R	 R	 R	 R	 S	
E2(E4656)	 I	 S	 S	 S	 S	 S	
E3(T3979)	 S	 S	 S	 S	 S	 S	
E4(T4247)	 S	 S	 S	 S	 S	 S	
E5(U4030)	 S	 R	 R	 R	 R	 S	
E6(U4117)	 S	 S	 R	 S	 S	 S	
E7(E3885)	 R	 R	 S	 R	 R	 S	
E8(U4082)	 S	 R	 S	 S	 S	 S	
E9(U4068)	 R	 R	 R	 R	 R	 S	
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6.3.2. Genome	assemblies	A	sample	of	isolates	with	a	variety	of	resistance	profiles	(n=24)	was	selected	for	sequencing	 (table	 6.4).	 The	 genomes	 ranged	 in	 size	 from	 6,250,924bp	 to	7,916,909bp.	Genome	quality	measured	by	the	N50	metric	ranged	from	84,855	to	765,594	and	number	of	contigs	from	20	to	617.			Table	6.4.	Genome	assembly	size	and	length	based	quality	metrics,	longest	scaffold	length,	number	of	contigs	and	N50	
OriginalID	 Contigs	 Scaffolds	 Genome
Size	
Longest	
Scaffold	
N50	
D9(3362)	 94	 93	 7184787	 555697	 250354	
C7(T3583)	 60	 58	 6908303	 679729	 270739	
A1(A2448)	 94	 89	 7092398	 423130	 210888	
B3(T2101)	 62	 58	 6919171	 504101	 347699	
A3(H638)	 78	 73	 7150152	 1003143	 328126	
B9(T2436)	 84	 80	 7150150	 604449	 262087	
E1(T4189)	 37	 32	 6334840	 951957	 507745	
C8(T3532)	 67	 63	 6912106	 784647	 269661	
C9(P1814)	 89	 82	 7142873	 931611	 255757	
E9(4068)	 74	 71	 7068852	 1411812	 554462	
D3(3141)	 56	 52	 6880848	 1121322	 480584	
E3(T3979)	 51	 47	 6272937	 692536	 385450	
A9(P2733)	 20	 20	 6250924	 1331236	 765594	
B6(P2404)	 40	 36	 6675891	 848636	 608561	
D5(T3677)	 43	 40	 6474838	 972162	 354473	
C6(T3044)	 47	 45	 6733566	 923035	 477284	
A8(P1885)	 44	 38	 6273981	 1230438	 564768	
B4(U2816)	 49	 46	 6369227	 615979	 287370	
E6(U4117)	 617	 609	 7916909	 282325	 84855	
B2(E2758)	 41	 35	 6398247	 772742	 426159	
B8(T2584)	 46	 39	 6993634	 870481	 355083	
D8(T3382)	 32	 27	 6582611	 775206	 478039	
E4(T4242)	 43	 36	 6408319	 779058	 472459	
D1(T3354)	 41	 34	 6937757	 868611	 583246		
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6.3.3. Antibiotic	resistance/susceptibility	of	those	sequenced	A	 sample	 of	 isolates	 tested	 for	 antibiotic	 resistance	 and	 susceptibility	 were	genome	 sequenced;	 table	 6.5	 lists	 the	 isolates,	 patient	 information	 and	pathologies.			Table	6.5.	Patient	information	of	those	that	provided	isolates	that	were	sequenced	
Isolates	 ST	 Patient	
Age	
Patient	
Gender	
Pathology	
D1(T3354)	 233	 55	 F	 Sputum	
C8(T3532)	 235	 83	 M	 Sputum	
C9(P1814)	 235	 82	 M	 Sputum	
D3(3141)	 244	 52	 M	 Sputum	
D9	3362	 253	 66	 M	 Sputum	
B8(T2584)	 260	 80	 F	 Sputum	
B4(U2816)	 270	 63	 M	 Urine	
A1(A2448)	 273	 67	 M	 Urine	
C6(T3044)	 277	 81	 M	 Nasal	
B6(P2404)	 309	 72	 F	 Foot	
D5(T3677)	 357	 82	 M	 Maxillary	sinus	
A9(P2733)	 379	 53	 F	 Chest	
E3(T3979)	 381	 92	 M	 Sputum	
D8(T3382)	 491	 79	 F	 Sputum	
B3(T2101)	 708	 81	 M	 Sputum	
C7(T3583)	 708	 72	 F	 Sputum	
A3(H638)	 1121	 90	 M	 Blood	
B9(T2436)	 1121	 90	 M	 Sputum	
B2(E2758)	 1330	 48	 F	 Eye	(Plate)	
E1(T4189)	 1459	 55	 F	 Sputum	
E9(4068)	 2191	 81	 M	 Urine	(catheter)	
A8(P1885)	 NF	 74	 M	 Foot	
E6(U4117)	 NF	 77	 F	 Urine	
E4(T4242)	 Novel	 67	 M	 Sputum				
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Multidrug	resistant	isolates	A1(U2448),	B3(T2101),	B9(T2436),	E1(T4189)	and	E9(U4068)	were	 among	 those	 sequenced.	 Eight	 isolates	were	 also	 sequenced	that	 are	 entirely	 susceptible	 to	 the	 antibiotics	 tested.	 An	 additional	 isolate,	B4(U2816)	 was	 completely	 susceptible	 except	 for	 intermediary	 resistance	 to	meropenem	reported.			
Isolates	 MEM10	 CAZ30	 PTZ85	 CIP	 TN	 CO25	
D9T3362	 S	 S	 S	 S	 S	 S	
C7T3582	 I	 R	 R	 R	 R	 S	
A1U2448	 R	 R	 R	 R	 R	 S	
B3T2101	 R	 R	 R	 R	 R	 S	
A3H638	 I	 R	 R	 R	 R	 S	
B9T2436	 R	 R	 R	 R	 R	 S	
E1T4189	 R	 R	 R	 R	 R	 S	
C8T3532	 R	 R	 R	 R	 S	 S	
C9P1814	 I	 R	 R	 R	 R	 S	
E9U4068	 R	 R	 R	 R	 R	 S	
D3T3141	 S	 S	 R	 R	 S	 S	
E3T3979	 S	 S	 S	 S	 S	 S	
A9P2733	 S	 S	 S	 S	 S	 S	
B6P2404	 S	 S	 R	 I	 R	 S	
D5T3677	 S	 S	 S	 S	 S	 S	
C6T3044	 S	 S	 S	 S	 S	 S	
A8P1885	 S	 S	 S	 S	 S	 S	
B4U2816	 I	 S	 S	 S	 S	 S	
E6U4117	 S	 S	 R	 S	 S	 S	
B2E2758	 S	 S	 S	 S	 S	 S	
B8T2584	 R	 S	 R	 R	 R	 S	
D8T3382	 I	 S	 R	 R	 S	 S	
E4T4247	 S	 S	 S	 S	 S	 S	
D1T3354	 S	 S	 R	 I	 S	 S	Figure	 6.2.	 Antibiotic	 resistance	 and	 susceptibility	 patterns	 to	 meropenem,	ceftazidine,	 piperacillin/tazobactam,	 ciprofloxacin,	 tobramycin	 and	 colistin	 of	the	isolates	sequenced					
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Of	 the	 isolates	 sequenced	 five	 were	 only	 susceptible	 to	 colistin,	 presenting	resistance	 to	 5/6	 antibiotics	 tested:	 A1(U2488),	 B3(T2101),	 B9(T2436),	E1(T4189)	 and	 E9(U4068)	 (table	 6.6).	 A	 further	 two	 isolates	 sequenced,	C7(T3582)	and	A3(H638)	were	resistant	 to	5/6	antibiotics	and	were	similarly	only	 susceptible	 to	 colistin	 but	 also	 were	 of	 only	 intermediary	 resistance	 to	meropenem	(Table	6.6).			Table	6.6.	Count	of	sequenced	isolates	resistance,	susceptible	or	displaying	intermediary	results	to	each	antibiotic	tested	
Number	of	isolates	 MEM10	 CAZ30	 PTZ85	 CIP	 TN	 CO25	
Resistant	 7	 9	 15	 12	 10	 0	
Susceptible	 12	 15	 9	 10	 14	 24	
Intermediary	 5	 0	 0	 2	 0	 0															
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6.3.4. Genome	Diversity	The	MLST	profiles	for	all	24	genomes	were	determined	and	it	was	observed	that	they	 represent	 21	 distinct	 sequence	 types	 (table	 6.7).	 For	 isolates	 A8(P1885)	and	E6(U4117)	the	ST	could	not	be	determined	from	6/7	and	5/7	loci	identified	respectively	 and	 isolate	 E4(T4242)	 carried	 a	 novel	 combination	 of	 profiles.	Sequence	types	235,	1121	and	708	were	each	represented	by	two	isolates	(table	6.7).			Table	6.7.	P.	aeruginosa	MLST	profiles	for	all	genomes	sequenced	
Isolate	 ST	 acs	 aro	 gua	 mut	 nuo	 pps	 trp	
D9	3362	 253	 4	 4	 16	 12	 1	 6	 3	
D1(T3354)	 233	 16	 5	 30	 11	 4	 31	 41	
D8(T3382)	 491	 16	 55	 7	 61	 1	 4	 45	
C7(T3583)	 708*	 11	 3	 -	 3	 1	 4	 60	
A1(A2448)	 273	 104	 4	 36	 71	 4	 -	 53	
B3(T2101)	 708	 11	 3	 11	 3	 1	 4	 60	
A3(H638)	 1121*	 67	 -	 65	 31	 1	 6	 26	
B9(T2436)	 1121*	 67	 -	 65	 31	 1	 6	 26	
E1(T4189)	 1459	 11	 2	 6	 3	 4	 38	 3	
C8(T3532)	 235	 38	 11	 3	 13	 1	 2	 4	
C9(P1814)	 235	 38	 11	 3	 13	 1	 2	 4	
E9(4068)	 2191*	 111	 30	 64	 26	 -	 59	 7	
D3(3141)	 244	 17	 5	 12	 3	 14	 4	 7	
E3(T3979)	 381	 11	 20	 1	 65	 4	 4	 10	
A9(P2733)	 379	 39	 5	 11	 28	 4	 4	 63	
B6(P2404)	 309	 13	 8	 9	 3	 1	 17	 15	
D5(T3677)	 357	 2	 4	 5	 3	 1	 6	 11	
C6(T3044)	 277	 39	 5	 9	 11	 27	 5	 2	
A8(P1885)	 NF*	 111	 30	 64	 58	 48	 24	 -	
B4(U2816)	 270	 22	 3	 17	 5	 2	 10	 7	
E6(U4117)	 NF*	 -	 5	 -	 7	 3	 12	 19	
B2(E2758)	 1330	 76	 5	 30	 3	 2	 12	 18	
B8(T2584)	 260	 14	 5	 10	 7	 4	 13	 7	
E4(T4242)	 Novel*	 6	 76	 1	 3	 3	 28	 3	*MLST’s	may	be	unresolved	(not	found,	NF),	novel	if	they	match	7	loci	without	a	defined	ST	or	they	may	be	approximated	based	on	the	loci	present	using	the	pubMLST	database.	Where	ST’s	are	approximate	the	only	possible	ST	for	the	combination	available	is	designated	though	it’s	possible	they	too	are	novel.				
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	To	further	analyse	the	diversity	of	genomes	sequenced	they	were	placed	in	the	context	 of	 the	 wider	 population	 of	 P.	 aeruginosa	 genomes,	 core	 genome	extracted	and	a	maximum	likelihood	tree	approximated	(Figure	6.3).	The	core	genome	 was	 comprised	 of	 2109	 complete	 polymorphic	 sites	 (gaps	 ignored),	1566	of	which	were	phylogenetically	informative.			Isolates	 identified	 with	 the	 same	 sequence	 type,	 ST-708	 isolates	 C7(T3583)-B3(T2101)	 	 and	 ST-1121	 isolates	 A3(H638)-B9(T2436)	 respectively	 were	adjacent	on	the	core	SNP	tree	and	ST-235	isolates	C8(T3532)-C9(P1814)	were	additionally	adjacent	to	AZPAE14726_2315.																
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		Figure	6.3.	Genomes	sequenced	and	the	wider	P.	aeruginosa	genome	population	core	 SNP	 phylogeny.	 RAxML	 tree	 based	 on	 SNP	 sites	 filtered	 to	 remove	recombinant	 SNPs	 by	 gubbins.	 Thai	 genomes	 leaf	 labels	 are	 in	 blue	 and	reference	P.	aeruginosa	genomes	in	yellow				
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6.3.4.1. Whole	genome	pairwise	differences	within	sequence	
types	Three	pairs	of	isolates	carried	the	same	sequence	type	C8(T3532)/(C9(P1814)	(ST-235),	 C7(T3583)/B3(T2101)	 	 (ST-708)	 and	 A3(H638)/B9(T2436)	 (ST-1121).	 These	 were	 further	 assessed	 for	 genetic	 similarity	 by	 whole	 genome	pairwise	 alignment	 and	 resulting	 SNP	 and	 indel	 counts.	 ST-1121	 isolates	A3(H638)	and	B9(T2436)	were	23	SNPs	and	5	indels	different,	ST-708	isolates	C7(T3583)	and	B3(T2101)	are	12	SNPs	and	7	 indels	different	whereas	ST235	isolates	C8(T3532)	and	C9(P1814)	were	6,249	SNPs	and	79	indels	different.		The	 pairs	 of	 isolates	 most	 genetically	 similar	 also	 presented	 similar	resistance/susceptibility	 profiles.	 A3(H638)	 and	B9(T2436)	 sampled	 from	 the	same	patient,	were	23SNPs	 and	5	 indels	 different	 and	displayed	 resistance	 to	ceftazidime,	 piperacillin/tazobactam,	 ciprofloxacin	 and	 tobramycin	 but	B9(T2436)	 is	 resistant	 to	 meropenem	while	 A3(H638)	 displays	 intermediary	resistance.	 C7(T3583)	 and	 B3(T2101)	 	 from	 different	 patients,	 were	 12SNPs	and	7	 indels	different	 show	 the	 same	antibiogram	except	where	C7(T3583)	 is	intermediary	for	resistance	to	meropenem	(figure	6.2).								
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6.3.5. CARD	database	Antibiotic	Resistance	Gene	Prediction	All	genomes	were	aligned	to	the	CARD	database	and	it	was	determined	whether	there	 was	 genetic	 evidence	 for	 antibiotic	 resistance	 (figure	 6.4).	 Genomes	ranged	from	A8(P1885)	that	perfectly	matched	four	antibiotic	resistance	genes	or	gene	variants	to	A1(A2448)	that	matched	21.	The	mean	number	of	elements	perfectly	matched	was	14.39.	Three	of	the	most	susceptible	isolates,	A1(A2448),	B3(T2101)	 and	 C7(T3583)	matched	 the	most	 elements	 perfectly	 with	 21,	 20	and	20	respectively.	E1(T4189),	B9(T2436)	and	E9(4068)	also	among	the	most	resistance	isolates	varied	in	their	predictions	however	from	8	to	16	elements.					
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Figure	6.4.	Results	of	search	all	genomes	against	the	CARD	database	for	the	presence	of	resistance	genes	and	variants						
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6.3.6. Integrons	Carrying	Antibiotic	Resistance	Genes	The	presence	of	integrons	was	determined	with	integron	finder	and	functional	annotation	using	the	resfams	database	to	determine	antibiotic	resistance	genes.	It	 was	 determined	 that	 12	 genomes	 carried	 a	 complete	 integron	 and	 two	 of	these	 carried	 an	 one	 additional	 CALIN	 element	 and	 A1(A2448)	 a	 complete	integron	and	two	CALIN	elements	(table	6.8).			Table	6.8.	Number	of	integron,	CALIN	elements	and	In0	elements	predicted	per	genome	by	Integron	Finder	
Isolate	 Complete	Integrons	 CALIN	 In0	
D1(T3354)	 1	 0	 0	
B8(T2584)	 1	 0	 0	
E6(U4117)	 1	 0	 0	
B6(P2404)	 1	 0	 0	
E9(4068)	 1	 0	 0	
C9(P1814)	 1	 0	 0	
C8(T3532)	 1	 1	 0	
B9(T2436)	 1	 0	 0	
A3(H638)	 1	 0	 0	
B3(T2101)	 1	 1	 0	
A1(A2448)	 1	 2	 0	
C7(T3583)	 1	 1	 0	
D9(3362)	 0	 0	 0	
E4(T4242)	 0	 0	 0	
D8(T3382)	 0	 0	 0	
B2(E2758)	 0	 0	 0	
B4(U2816)	 0	 0	 0	
A8(P1885)	 0	 0	 0	
C6(T3044)	 0	 0	 0	
D5(T3677)	 0	 0	 0	
A9(P2733)	 0	 0	 0	
E3(T3979)	 0	 0	 0	
D3(3141)	 0	 0	 0	
E1(T4189)	 0	 0	 0			
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Functional	 annotation	 of	 elements	 within	 integrons	 and	 CALIN	 elements	revealed	that	in	addition	to	attC	sites,	integrases,	attI	sites	and	promoters	there	are	 gene	 cassettes	 of	 antibiotic	 resistance	 associated	 genes,	 (Table	 6.9).	 All	integrons	 and	 CALIN	 elements	 present	 contain	 an	 antibiotic	 resistance	 gene.	The	 antibiotic	 resistance	 genes	 annotated	 include	 extended	 spectrum	 beta-lactamases	(VEB-PER),	quinolone	resistance	gene	(qnr),	metallo	beta-lactamase	(IMP),	class	D	beta-lactamases,	beta	lactamases	(PSE),	carbapenemases	(CARB),	chlor	efflux	pumps	and	emrE	a	multidrug	resistance	associated	transporter.				Table	6.9.	Integron	elements	present	as	predicted	from	sequenced	genomes	by	Integron	Finder			 Element	
size	(bp)	
Strand	 Element	type	 Annotation	
C7(T3583)	Integron01	CALIN	 671	 1	 protein	 protein	59	 -1	 attC	 attC	899	 -1	 protein	 VEB-PER	59	 -1	 attC	 attC	815	 -1	 protein	 ANT3	800	 -1	 protein	 ClassD	69	 -1	 attC	 attC	
C7(T3583)	Integron_02	complete		 110	 -1	 attC	 attC	914	 -1	 protein	 CARB-PSE	58	 -1	 attI	 attI_1	34	 1	 Promoter	 Pint_1	26	 -1	 Promoter	 Pc_1	1013	 1	 protein	 intI	
A1(A2448)	integron_01	CALIN	 59	 1	 attC	 attC	113	 1	 attC	 attC	1259	 1	 protein	 Chlor_Efflux_Pump	69	 1	 attC	 attC	800	 1	 protein	 ClassD	815	 1	 protein	 ANT3	59	 1	 attC	 attC	
A1(A2448)	integron_02	complete	 57	 -1	 attC	 attC	131	 1	 protein	 protein	132	 -1	 attC	 attC	740	 -1	 protein	 IMP	
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58	 -1	 attI	 attI_1	34	 1	 Promoter	 Pint_1	26	 -1	 Promoter	 Pc_1	1070	 1	 protein	 intI	
A1(A2448)	integron03	CALIN	 59	 1	 attC	 attC	1238	 1	 protein	 emrE	
B3(T2101)	integron_01	complete	 110	 -1	 attC	 attC	914	 -1	 protein	 CARB-PSE	58	 -1	 attI	 attI_1	34	 1	 Promoter	 Pint_1	26	 -1	 Promoter	 Pc_1	1013	 1	 protein	 intI	
B3(T2101)	integron_02	CALIN	 671	 1	 protein	 protein	59	 -1	 attC	 attC	899	 -1	 protein	 VEB-PER	59	 -1	 attC	 attC	815	 -1	 protein	 ANT3	800	 -1	 protein	 ClassD	69	 -1	 attC	 attC	476	 -1	 protein	 protein	
A3(H638)	integron_01	complete	 1013	 -1	 protein	 intI	26	 1	 Promoter	 Pc_1	34	 -1	 Promoter	 Pint_1	1208	 -1	 protein	 protein	899	 1	 protein	 VEB-PER	59	 1	 attC	 attC	113	 1	 attC	 attC	1259	 1	 protein	 Chlor_Efflux_Pump	69	 1	 attC	 attC	800	 1	 protein	 ClassD	815	 1	 protein	 ANT3	59	 1	 attC	 attC	
B9(T2436)	integron01	complete	 1013	 -1	 protein	 intI	26	 1	 Promoter	 Pc_1	34	 -1	 Promoter	 Pint_1	1208	 -1	 protein	 protein	899	 1	 protein	 VEB-PER	59	 1	 attC	 attC	113	 1	 attC	 attC	1259	 1	 protein	 Chlor_Efflux_Pump	69	 1	 attC	 attC	800	 1	 protein	 ClassD	815	 1	 protein	 ANT3	59	 1	 attC	 attC	
C8(T3532)	integron01	complete	 1013	 -1	 protein	 intI	26	 1	 Promoter	 Pc_1	34	 -1	 Promoter	 Pint_1	
181	
58	 1	 attI	 attI_1	203	 -1	 protein	 protein	60	 1	 attC	 attC	59	 1	 attC	 attC	
C8(T3532)	integron_02	CALIN	 59	 -1	 attC	 attC	
C9(P1814)	integron01	complete	 1013	 -1	 protein	 intI	26	 1	 Promoter	 Pc_1	34	 -1	 Promoter	 Pint_1	58	 1	 attI	 attI_1	203	 -1	 protein	 protein	60	 1	 attC	 attC	59	 1	 attC	 attC	
E9(4068)	integron01	complete	 1013	 -1	 protein	 intI	26	 1	 Promoter	 Pc_1	34	 -1	 Promoter	 Pint_1	58	 1	 attI	 attI_1	740	 1	 protein	 IMP	132	 1	 attC	 attC	59	 1	 attC	 attC	800	 1	 protein	 ClassD	71	 1	 attC	 attC	
B6(P2404)	integron01	complete	 1013	 -1	 protein	 intI	26	 1	 Promoter	 Pc_1	34	 -1	 Promoter	 Pint_1	58	 1	 attI	 attI_1	656	 1	 protein	 Qnr	71	 1	 attC	 attC	800	 1	 protein	 ClassD	815	 1	 protein	 ANT3	59	 1	 attC	 attC	
E6(U4117)	integron01	complete	 1013	 -1	 protein	 intI	26	 1	 Promoter	 Pc_1	34	 -1	 Promoter	 Pint_1	58	 1	 attI	 attI_1	656	 1	 protein	 Qnr	71	 1	 attC	 attC	800	 1	 protein	 ClassD	
B8(T2584)	integron01	complete	 1013	 -1	 protein	 intI	26	 1	 Promoter	 Pc_1	34	 -1	 Promoter	 Pint_1	58	 1	 attI	 attI_1	59	 1	 attC	 attC	1259	 1	 protein	 Chlor_Efflux_Pump	69	 1	 attC	 attC	
D1(T3354)	integron01	 1013	 -1	 protein	 intI	26	 1	 Promoter	 Pc_1	
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complete	 34	 -1	 Promoter	 Pint_1	58	 1	 attI	 attI_1	830	 1	 protein	 ClassD	89	 1	 attC	 attC	779	 1	 protein	 ANT3	59	 1	 attC	 attC	1259	 1	 protein	 Chlor_Efflux_Pump	69	 1	 attC	 attC			Lineages	 suspected	 of	 being	 common	 source/infection	 carried	 the	 same	integrons.	 Integron	 amino	 acid	 sequences	 for	 ST-235	 isolates	 C8(T3532)	 and	C9(P1814)	intgegron01	respectively	were	extracted	and	determined	to	have	no	variable	 sites	 (figure	 6.5).	 ST-708	 isolates	 C7(T3583)	 and	 B3(T2101)	integron02	 and	 integron01	 respectively	 amino	 acid	 sequences	were	 extracted	and	determined	to	have	no	variable	positions	(figure	6.6).													
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																			Figure	 6.5.	 C8(T3532)	 integron01	 (top)	 and	 C9(P1814)	 integron01	 (bottom).	Graphical	representation	of	integron	elements	as	determined	by	integron	finder						
184	
																				Fgure	 6.6.	 C7(T3583)	 integron02	 (top)	 and	 B3(T2101)	 integron01	 (bottom).	Graphical	representation	of	integron	elements	as	determined	by	integron	finder			
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6.4. Discussion	Using	 whole	 genome	 sequencing	 of	 a	 small	 sample	 of	 patient	 isolates	 whole	genome	 sequenced	 clinically	 useful	 information	 could	 be	 determined	 and	findings	added	to	the	knowledge	of	the	genetic	basis	of	antibiotic	resistance	in	P.	
aeruginosa	worldwide.	 While	 the	 genetic	 landscape	 of	 P.	 aeruginosa	 remains	complex,	it	is	increasingly	being	mapped76,356,390,402,403.	In	this	chapter,	genomic	investigation	 has	 contributed	 to	 the	 knowledge	 of	 resistance	 genes	 in	 P.	
aeruginosa	 in	 a	 clinic	 in	 Thailand.	 Analysis	 of	 antibiotic	 resistance	 genes	 has	shown	whether	they’re	integron	associated;	MLST	and	core	genome	phylogeny	has	demonstrated	the	strain	diversity	and	the	potential	for	a	common	source	of	infection,	revealing	the	presence	of	at	least	one	international	MDR	lineage.			Colistin	 was	 the	 only	 antibiotic	 to	 which	 none	 of	 the	 isolates	 were	 resistant.	Numerous	 isolates	 were	 also	 multidrug	 resistant	 to	 the	 five	 antibiotics	 for	which	 there	was	 any	 resistance	 (A1U2448,	 B3T2101,	 B9T2436,	 E1T4189	 and	E9U4068).	These	were	 selected	 from	a	 sample	of	diverse	patients	 in	 terms	of	pathology,	 age	 and	 gender.	 The	 sensitivity	 in	 all	 isolates	 tested	 to	 colistin	 is	reassuring	but	colistin	is	not	only	increasingly	a	 ‘last	resort’	antibiotic67,404	but	reports	of	P.	aeruginosa	and	other	bacteria	acquiring	resistance	to	polymyxins	are	emerging391,395.		Determining	 the	 MLST’s	 of	 the	 isolates	 sequenced	 (table	 6.4),	 alongside	phylogenetic	placement	 (figure	6.3)	demonstrated	 the	diversity	of	 the	 isolates	but	 also	 that	 some	 were	 potentially	 closely	 related.	 Further,	 some	 ST’s	 have	been	identified	as	overrepresented	in	the	hospital	setting	and	being	associated	
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with	multidrug	resistance.	The	genetic	background	of	MDR	isolates	is	diverse405	but	 lineages	 are	 emerging	 such	 as	 ST-244406–408	 and	 ST-235,	 identified	internationally	 is	 an	MDR	 lineage392,394,395,404,409–411,	 though	 antibiograms	may	vary.	 The	 genome	 sequence	 data	 indicates	 that	 there	 have	 been	 at	 least	 two	introductions	of	ST235’s	into	the	clinic	and	there	is	evidence	for	within-hospital	transmission	 of	 one	 ST235	 lineage	 carrying	 an	 antibiotic	 resistance	 integron.	The	 contributions	 of	 various	 factors	 to	 growing	 antibiotic	 resistance	 are	 not	assessed	within	 this	 study	but	evidence	 is	mounting	elsewhere	describing	 the	extent	 of	 the	 problem	 in	 P.	 aeruginosa	 alone,	 that	 it’s	 increasing	 and	 the	potential	for	anthropogenic	causes	of	increasing	resistance199,391,406,410,411.			In	the	CARD	results	(figure	6.5)	pmrB	is	in	many	isolates	flagged	as	a	resistance	gene,	 or	 for	 the	 mutations	 it	 carries,	 yet	 no	 isolates	 carry	 colistin	 resistance	(figure	6.4).	Entirely	susceptible	 isolate	E3(T3979)	 is	 reported	 to	carry	 fifteen	resistance	 conferring.	Many	 of	 these	 genes	 such	 as	mexS,	pmrA	 and	pmrB	 are	present	in	most	P.	aeruginosa	but	their	association	with	resistance	is	not	always	clear402.	 Aminoglycoside	 nucleotidyltransferase	 (ANT3)	 were	 contained	 in	integrons	 carried	 by	 seven	 isolates,	 C7(T3583),	 A1(A2448),	 B3(T2101),	A3(H6838),	B9(T2436),	B6(P2404)	and	D1(T3354)	(Table	6.9).	Aminoglycoside	nucleotidyltransferase	have	been	identified	transferring	between	Acinetobacter	spp.	 and	 confers	 resistance	 to	 streptomycin	 and	 spectinomycin412,413.	 Two	isolate	 genomes	 C7(T3583)	 and	 B3(T2101)	 carry	 the	 same	 two	 integrons	containing	between	 them,	an	ambler	 class	A	beta-lactamase	 (ANT3),	VEB-PER	beta-lactamase	 genes	 and	 a	 gene	 encoding	 a	 chloramphenicol	 efflux	 pump.	B3(T2101)	 displayed	 resistance	 to	 all	 antibiotics	 tested	 except	 colistin	 while	
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C7(T3583)	 displayed	 intermediary	 resistance	 to	meropenem	 as	 well.	 Isolates	A3(H6838)	and	B9(T2436)	 from	the	same	patient	also	carried	a	VEB-PER	and	phenotypically	A3(H638)	was	 resistant	 to	 all	 antibiotics	 tested	 except	 colistin	and	B9(T2436)	all	 except	 colistin	 and	 intermediary	 resistance	 to	meropenem.	Isolate	 genomes	B6(P2404)	 and	E6(U4117)	 both	 contain	 integrons	 that	 carry	quinolone	 resistance	 gene	 qnrVC1.	 The	 qnrVC1	 gene	 has	 been	 observed	 in	various	bacteria	such	as	Vibrio	cholerae	in	Brazil414,	E.	coli	in	Europe415	and	in	P.	
aeruginosa	 previously416–418.	 Though	B6(P2404)	 and	E6(U4117)	 carry	 the	qnr	gene	 they	 display	 intermediary	 resistance	 to	 ciprofloxacin	 and	 susceptibility	respectively	 (Figure	 6.2).	 One	 isolate	 genome,	 that	 of	 A1(A2448),	 carried	 and	integron	 with	 the	 emrE	 multidrug	 efflux	 encoding	 gene419.	 CARD	 analysis	reports	emrE	presence	in	the	majority	genomes	due	to	the	commonly	present	P.	
aeruginosa	 emrE	 homolog	 Pae-Emre420.	 Acquired	 metallo-beta-lactamases	(MBLs)	 in	 P.	 aeruginosa	 are	 associated	 with	 a	 heightened	 mortality	 rate421,	isolates	A1(A2448)	and	E9(4068)	were	observed	to	have	 integrons	containing	IMP14	 and	 IMP54.	 Both	 isolates	 were	 only	 susceptible	 to	 colistin	 including	presenting	resistance	to	meropenem.			
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6.4.1. Chapter	Summary	Whole	genome	sequencing	of	isolates	from	Ramathibodi	Hospital,	Thailand	successfully	demonstrated:		
• Antibiotic	resistance,	including	multi-drug	resistance	is	highly	prevalent	in	the	patient	isolate	population	in	this	clinic	
• International,	high	risk	MDR	lineages	were	present	
• Potential	for	a	common	source	of	infection	within	the	hospital	or	transmission	between	patients		
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Chapter	Seven	
7. General	discussion		
7.1. Comparative	 genomics	 to	 determine	 the	 genetic	 basis	 of	
phenotypic	heterogeneity	in	P.	aeruginosa	CF	lung	infections	In	CF	the	leading	cause	of	overall	morbidity	and	mortality	is	bacterial	infections	and	 in	 adult	 CF	 patients	P.	aeruginosa	 predominates65.	 As	P.	aeruginosa	 is	 an	environmental	bacterium	that	opportunistically	infects	CF	patients	the	diversity	of	 lineages	 infecting	 is	 expansive75,195.	 There	 are	 features	 of	 adaptation	 to	various	 environmental	 niches	 and	 through	 due	 to	 interactions	 with	 other	organisms	 that	 have	 selected	 for	 virulence	 factors	 that	 by	 chance	 are	problematic	 in	CF	 lung	 infections.	 Some	P.	aeruginosa	 lung	 infections	adapt	 to	the	lung	environment	and	establish	chronic	infections161,285.	As	an	opportunistic	pathogen	 the	 typical	 P.	 aeruginosa	 carries	 acute	 virulence	 features	 and	 the	versatility	due	 to	complex	gene	regulation	and	a	 large	genome	and	number	of	genes	 to	establish	a	 long-term	 infection285,422.	The	aim	 is	 to	better	understand	what	 predisposes	 P.	 aeruginosa	 to	 successfully	 establishing	 in	 the	 lungs,	 the	transition	 to	 chronicity	 and	 the	 changing	 state	 of	 pathogenicity	 along	 this	evolutionary	 trajectory.	 Lineages	 have	 also	 independently	 evolved	worldwide	capable	 of	 cross	 infection	 between	 patients208,	 patients	 harbouring	 these	epidemic	 strains	 are	 not	 infected	 by	 distinct	 lineages	 but	 a	 single	 population	that	has	emerged,	already	exposed	 to	 the	CF	 lung	environment	and	 treatment	regimes.	 Identifying	 commonality	 across	 P.	 aeruginosa	 CF	 lung	 infections	 is	further	confounded	by	multi-lineage	infections,	emerging	sub-lineages,	different	treatment	regimes	across	patients,	host	differences	and	genetic	confounders	as	
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neutral	changes	could	be	linked	to	adaptive	changes66.	This	is	all	in	the	context	of	a	changing	lung	environment	and	microbial	community,	much	of	which	is	not	understood.			This	 study	combined	comparative	genomics	approaches	applied	 to	various	CF	associated	 P.	 aeruginosa	 genomes	 (Chapter	 Three)	 and	 the	 transmissible	lineage,	 the	 LES	 (Chapter	 Four).	 Analysis	 was	 also	 expanded	 to	 non-CF	bronchiectasis,	 a	 lung	 condition	 similar	 to	 CF	 that	 P.	 aeruginosa	opportunistically	infects	(Chapter	Five)	and	isolate	genomes	from	a	hospital	in	Thailand	 to	 assess	 antibiotic	 resistance,	 particularly	MBE	 associated	 (Chapter	Six).	Genetic	and	phenotypic	studies	have	observed	that	during	CF	infections	P.	
aeruginosa	can	rapidly	adapt	by	loss	of	function.	Disruptive	mutations	and	gene	losses	 can	 generally	 be	 directly	 adaptive	 or	 result	 in	 remodeling	 of	 gene	regulation70,	 though	 no	 dedicated	 study	 so	 far	 has	 evaluated	 loss	 of	 function	specifically	across	a	diverse	panel	of	CF	isolates.			In	Chapter	Three	the	approach	was	to	determine	disruptive	mutations	and	gene	absence	 compared	 with	 PAO1	 in	 CF	 and	 environmental	 genomes.	 It	 was	determined	which	genes	were	overrepresented	for	loss	of	function,	with	the	aim	to	 identify	 those	 that	 might	 be	 biased	 for	 acquisition	 or	 have	 convergently	adapted.	 Overall	 90	 genes	 were	 identified	 to	 be	 overrepresented	 for	 loss	 of	function	 in	 CF	 encoding	 functionally	 diverse	 features.	 Taking	 the	 opposite	approach	 it	was	 then	determine	which	genes	are	underrepresented	 for	 loss	of	function	in	CF,	where	loss	of	the	gene	product	may	more	often	be	advantageous	in	 various	 environments	or	 at	 least	 constraints	be	 relaxed	more	often	 than	 in	
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CF.	 Many	 genes	 identified	 to	 be	 overrepresented	 for	 loss	 of	 function	 were	consistent	 with	 previous	 observations	 in	 CF.	 Loss	 of	 MucA	 results	 in	 the	chronicity-associated	change	to	the	mucoidy	phenotype	and	CF	genomes	were	overrepresented	for	nonsense	mutations	and	absences	of	 its	gene	mucA.	 It	has	previously	 been	 observed	 P.	 aeruginosa	 may	 adapt	 to	 preference	 iron	acquisition	 from	 heme	 rather	 than	 pyoverdine326.	 Consistent	 with	 this	 it	 was	observed	 that	 pyovderine	 biosynthesis	 and	 receptor	 genes	 fpvG,	 fpvA,	 pvdE,	
pvcC,	 pvdF,	 pvdA,	 fpvL,	 fpvR,	 pvdO,	 tonB,	 piuA,	 pvdS	 and	 pvdP	 were	 each	overrepresented	 for	 loss	 of	 function	 in	 CF	 (table	 3.6).	 In	 the	 COST	representative	panel	 it	was	 inferred	 that	genes	mexB	and	mexA	 of	 the	mexAB-
oprM	efflux	pump	encoding	operon	were	adaptive	by	loss	of	function	(table	3.4).	As	 such	 the	 entire	 operon	 was	 considered	 for	 overrepresentation	 for	 loss	 of	function	(table	3.6)	and	determined	to	be	significantly	overrepresented	for	loss	of	 function.	Because	 the	encoded	system	 is	 involved	 in	multidrug	resistance	 it	has	 been	 suggested	 that	 it	 could	 be	 targeted	 as	 a	 treatment	 for	P.	aeruginosa	infections423.			Chronic	lung	diseases,	CF,	CF	associated	bronchiectasis,	non-CF	bronchiectasis,	COPD	 and	 PCD	 include	 overlapping	 pathologies	 and	 the	 risk	 of	 P.	 aeruginosa	lung	 infections.	 In	 PCD	 a	 study	 was	 conducted	 identifying	 by	 sequencing	 of	infecting	 P.	 aeruginosa	 that	 there	 was	 shared	 mutational	 signatures	 between	PCD	and	CF364.	The	aim	in	Chapter	Five	was	to	sequence	infecting	P.	aeruginosa	from	 multiple	 non-CF	 bronchiectasis	 patients	 to	 determine	 the	 between	 and	within	 host	 genetic	 diversity,	 the	 potential	 for	 any	 overrepresentation	 of	environmental	lineages,	the	presence	of	transmissible	lineages	and	to	compare	
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adaptive	mutations	to	CF.	It	was	determined	that	there	was	probably	common	source	or	cross	 infection	of	some	lineages	(figure	5.5),	multi-lineage	infections	(figure	 5.2)	 and	 adaptive	 similarities	 with	 CF	 (table	 5.5).	 The	 model	 for	inference	of	adaptive	 loss	of	 function	developed	 (table	3.6),	was	expanded	 for	the	non-CF	bronchiectasis	dataset.	The	larger	dataset	afforded	greater	power	to	identify	 genes	 adaptive	 by	 loss	 of	 function	 and	 assess	 the	 potential	 impact	 of	population	structure	(supplementary	figure	9).	Many	genes	were	determined	to	be	 adaptive	 by	 loss	 of	 function	 in	 common	 with	 CF	 such	 as	 quorum	 sensing	regulator	 lasR	 and	mucA.	 Others	 that	 have	 been	 linked	with	 adaptation	 in	 CF	were	observed	infrequently	or	not	at	all	such	as	mexT,	retS,	exsD	and	ampR66,424.	Consistent	with	 previous	 findings	 in	 CF326	 and	 the	 genes	 overrepresented	 for	loss	of	function	in	Chapter	Three	in	CF	associated	isolate	genomes,	convergence	of	loss	of	function	in	pyoverdine	genes	was	inferred.	In	this	representative	panel	of	 isolate	 genomes	 across	 multiple	 non-CF	 bronchiectasis	 patients	mexB	 was	identified	to	carry	more	independent	nonsense	mutations	than	any	other	gene,	
mexA	 and	 oprM	 were	 also	 among	 the	 genes	 that	 have	 most	 often	 acquired	nonsense	mutations	(table	5.5).			In	 CF	 lung	 infections	 with	 P.	 aeruginosa	 transmissible	 lineages	 have	independently	 evolved	 globally208.	 In	 Chapter	 Four	 geographically	 and	historically	diverse	isolates	of	the	LES	were	sequenced	(table	4.2).	The	number	and	 diversity	 of	 these	 genomes	 enabled	 detailed	 analysis	 of	 the	 lineages	epidemiology,	adaptation	and	potential	origins.	Previous	studies	have	identified	the	LES	as	a	monophyletic	group	and	for	those	sampled	in	Canada	and	the	U.K.	to	 cluster	 separately214,334.	 For	 the	 first	 time	 the	 LES	 core	 genome	 phylogeny	
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was	 confidently	 rooted	 with	 a	 non-LES	 ougroup,	 the	 PAO1	 genome.	 Further	phylogeographic	 analysis	 could	 be	 used	 to	 assess	 whether	 the	 LES	 has	 its	origins	 in	 Canada425.	 A	 number	 of	 discrepancies	 were	 identified	 within	 the	genomic	epidemiology	but	resolved	with	follow-up	epidemiology	of	the	patients	backgrounds,	demonstrating	the	power	of	this	approach.			As	the	LES	is	a	single	population,	multiple	detailed	approaches	could	be	taken	to	identify	 potentially	 adaptive	 mutations:	 convergent	 evolution	 of	 non-synonymous	 mutations	 and	 maintenance	 and	 fixation	 of	 mutations	 since	 the	common	 ancestor	 with	 LESB58.	 Genes	mucA	 and	 lasR,	 previously	 associated	with	 adaptation	by	 loss	 of	 function	 in	CF,	were	observed	 to	be	 independently	acquiring	 nonsense	 mutations	 and	 potentially	 being	 maintained	 following	further	transmission	(table	4.7).	The	LES	has	been	observed	to	be	increasingly	resistant	 to	 antibiotics208,210.	 Antibiotic	 resistance	 can	 be	 increased	 by	disruption	 of	 	 porin	 encoding	 gene	 oprD	 .	 In	 the	 UK	 LES	 population	 oprD	independently	 acquired	 nonsense	 mutations	 more	 than	 any	 other	 gene.	Similarly	 disruption	 of	 genes	 mpl	 and	 piuA	 have	 been	 linked	 to	 increased	resistance	and	were	inferred	to	be	adaptive	by	loss	of	function	in	the	LES	(table	4.7).	 Alternatively	 antibiotic	 efflux	 pump	 operon	mexAB-oprM	 is	 disrupted	 in	32/122	 UK	 LES	 genomes	 and	 only	 oprD	 and	 lasR	 independently	 acquired	nonsense	mutations	more	 than	mexB.	 Disruption	 of	mexAB-oprM,	 particularly	
mexB	 is	 consistent	 with	 the	 findings	 in	 the	 IPCD	 CF	 genomes	 and	 the	bronchiectasis	genomes	datasets	in	this	study.			
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Genes	lasR,	mexB	and	mpl	were	identified	to	be	adaptive	by	loss	of	function	but	also	 inferred	 to	be	under	positive	selection	 in	 the	population	 (discounting	 the	alleles	with	nonsense	mutations)	(table	4.13).	Either	the	gene	is	under	different	selective	 pressures	 in	 different	 isolates	 or	 the	 inference	 of	 positive	 selection	actually	 results	 from	 relaxed	 constraint	 or	 selection	 for	 disruptive	 missense	mutations.	Detailed	study	of	potentially	adaptive	genes	in	transmissible	lineages	can	also	be	informative	to	wider	P.	aeruginosa	infections	analogous	to	the	study	of	within	host,	sequential	isolate	genomes273,280,282.			Across	 chapters	 3-5	 genomes	 were	 analysed	 for	 evidence	 of	 loss	 of	 function	mutations	 that	 were	 adaptive.	 The	 methods	 varied	 from	 identifying	independent	 acquisitions	 	 of	 nonsense	 mutations	 across	 lineages	 in	 various	chronic	lung	disease	infections	(Chapter	3,	COST	panel	genomes),	to	identifying	an	 association	 of	 nonsense	mutations	 and	 larger	 loss	 of	 function	 events	with	acute	 and	 chronic	 CF	 infection	 isolates	when	 compared	with	 environmentally	sampled	 isolate	 genomes	 (Chapter	3,	 IPCD	genomes),	 independent	 acquisition	of	nonsense	mutations	 in	 a	 single	 transmissible	 lineage	 infecting	primarily	CF	patients	 and	 a	 few	 non-CF	 patients	 (Chapter	 4,	 the	 LES	 genomes)	 and	independent	 acquisitions	 across	 lineages	 of	 chronic	 lung	 disease	 non-CF	bronchiectasis	 infection	 isolates	 (Chapter	 5,	 non-CF	 bronchiectasis	 panel	genomes).	 Table	 7.1	 displays	 the	 loss	 of	 function	 mutations	 inferred	 to	 be	adaptive	with	any	commonality	across	this	study.					
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Table	7.1.	Loss	of	function	mutations	inferred	to	be	adaptive	across	chapters	3-5	present	 in	 at	 least	 two	 of	 the	 COST	 panel,	 IPCD	 overrepresented	 in	 CF,	 LES	genomes	 or	 non-CF	 bronchiectasis	 datasets.	 PAO1	 locus	 tags	 are	 used	where	there	 is	 not	 an	 accepted	 gene	 name	 across	 lineages	 on	 pseudomonas.com290.	Loss	 of	 function	 of	 genes	 associated	with	 CF	 compared	with	 the	 environment	included	are	all	significant	after	BH	multiple	testing	correction			 COST	Panel	(Chapter	3)	 IPCD	overrepresented	in	CF		(Chapter	3)	
LES	(Chapter	4)	 Bronchiectasis	(Chapter	5)	
lasR	 +	 	 +	 	
mucA	 +	 	 +	 +	
mexA	 +	 	 	 +	
rbdA	 +	 	 	 +	
mexB	 +	 	 +	 +	PA4469	 +	 	 +	 +	
ladS	 +	 	 	 +	
pchE	 	 	 +	 +				The	genetic	basis	of	antibiotic	resistance	in	P.	aeruginosa	 is	complex	and	in	CF	increasing	antibiotic	resistance	during	chronic	infections	is	typical76,167,426,427.	In	this	 study	 analysis	 of	 mutations	 have	 identified	 adaptations	 associated	 with	antibiotic	 resistance	 such	 as	 positive	 selection	 in	 pmr	 genes,	 resistance	associated	 with	 loss	 of	 function	 in	 oprD,	 piuA	 and	 mpl328,329,356,391,399.	 These	results	were	mirrored	 in	 the	analysis	non-CF	bronchiectasis	associated	 isolate	genomes.	 In	 Chapter	 Six	 a	 sample	 of	 clinical	 isolates	 from	 a	 range	 of	 patients	and	pathologies	were	obtained	from	a	hospital	in	Bangkok,	Thailand	(Table	6.1).	Except	 for	 complete	 colistin	 susceptibility	 in	 the	 isolates	 tested,	 antibiotic	resistance	 was	 frequently	 observed	 in	 antibiotics	 commonly	 used	 in	 CF	treatments,	 meropenem,	 ceftazidime,	 piperacillin/tazobactam,	 ciprofloxacin	and	tobramycin.	By	aligning	the	genomes	to	the	CARD	database	resistance	was	
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predicted	but	many	genetic	elements	intrinsic	to	P.	aeruginosa	that	don’t	always	convey	 resistance	 were	 also	 identified,	 as	 demonstrated	 by	 the	 inclusion	 of	reference	strains	PAO1,	PA14	and	LESB58	(figure	6.4).	Genotyping	of	the	strains	and	 phylogenetic	 placement	 was	 informative,	 demonstrating	 the	 presence	 of	international	 MDR	 lineage	 ST-23576,409.	 Integron	 Finder	 analysis	 revealed	 the	ARGs	 associated	 with	 MBEs	 demonstrating	 the	 risk	 not	 only	 of	 vertical	adaptation	 towards	 antibiotic	 resistance	 but	 the	 expansive	 potential	 of	horizontally	acquired	resistance	in	P.	aeruginosa.			
P.	aeruginosa	 infections	are	complex	and	predicting	clinical	outcomes	remains	difficult.	 Genome	 sequencing	 is	 making	 inroads	 into	 this	 complexity	 though,	predicting	antibiotic	resistance428,	the	potential	for	rapid	typing	of	strains		and	detailed	genomic	epidemiology194.	A	wealth	of	information	has	been	generated	in	 this	 study	 and	 as	 Chapter	 Three	 demonstrates,	 more	 data	 can	 yield	 new	insights	 into	 the	potential	 genetic	 basis	 of	 pathogenicity.	 It	 also	demonstrates	that	 further	 sampling	 of	 environmental	 genomes	 would	 be	 beneficial	 for	comparison.	 Many	 genes	 analysed	 were	 also	 of	 unknown	 function	 and	 often	limited	 to	 comparison	 to	 the	 gene	 content	 of	 high	 quality	 reference	 genomes.	GWAS	 has	 demonstrated	 the	 potential	 for	 associating	 genes	 and	 alleles	 with	outcomes	 and	 in	 the	 future	 the	 predictive	 capacity	 of	 genes,	 alleles	 and	 their	combinations	 could	 be	 assessed	 with	 machine	 learning.	 Higher	 order	classifications	 too	 could	 be	 assessed	 such	 as	 transmissible/non-transmissible,	impact	 on	 patient	 FEV1	or	whether	 a	 lineage	 is	 predisposed	 to	 establishing	 a	chronic	infection.			
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9. Appendix		Supplementary	table	1.	Genes	significantly	(chi	squared	p	<	0.05)	underrepresented	for	loss	of	function	(gene	absence,	large	deletions	and	nonsense	mutations)	compared	with	the	environmental	genomes.	Naïve	p	values	and	BH	critical	values	shown,	p	values	<	BH	critical	values	in	bold		
PAO1	
locus	tag	
naïve	p	
value	
BH	
critical	
value	
PAO1	
locus	tag	
naïve	p	
value	
BH	
critical	
value	
PA4586	 1.49E-19	 8.92E-06	 PA2719	 5.63E-03	 4.20E-03	
PA4162	 2.75E-18	 1.78E-05	 PA2750	 5.63E-03	 4.21E-03	
PA3105	 9.22E-17	 2.68E-05	 PA2767	 5.63E-03	 4.22E-03	
PA4192	 1.09E-16	 3.57E-05	 PA2778	 5.63E-03	 4.23E-03	
PA4193	 1.09E-16	 4.46E-05	 PA2780	 5.63E-03	 4.24E-03	
PA4194	 1.09E-16	 5.35E-05	 PA2789	 5.63E-03	 4.25E-03	
PA4195	 1.09E-16	 6.24E-05	 PA2803	 5.63E-03	 4.26E-03	
PA4191	 3.04E-16	 7.14E-05	 PA2806	 5.63E-03	 4.26E-03	
PA1858	 8.22E-16	 8.03E-05	 PA2839	 5.63E-03	 4.27E-03	
PA3469	 2.16E-15	 8.92E-05	 PA2852	 5.63E-03	 4.28E-03	
PA5318	 4.56E-15	 9.81E-05	 PA2855	 5.63E-03	 4.29E-03	
PA3841	 1.44E-14	 1.07E-04	 PA2892	 5.63E-03	 4.30E-03	
PA4879	 3.28E-14	 1.16E-04	 PA2958	 5.63E-03	 4.31E-03	
PA3362	 4.91E-14	 1.25E-04	 PA3025	 5.63E-03	 4.32E-03	
PA2130	 5.15E-14	 1.34E-04	 PA3113	 5.63E-03	 4.33E-03	
PA3368_1	 1.99E-13	 1.43E-04	 PA3197	 5.63E-03	 4.34E-03	
PA2771	 5.79E-13	 1.52E-04	 PA3198	 5.63E-03	 4.34E-03	
PA2772	 8.97E-13	 1.61E-04	 PA3203	 5.63E-03	 4.35E-03	
PA1036	 2.49E-12	 1.69E-04	 PA3209	 5.63E-03	 4.36E-03	
PA5321	 6.52E-12	 1.78E-04	 PA3238	 5.63E-03	 4.37E-03	
PA4985	 8.84E-12	 1.87E-04	 PA3262	 5.63E-03	 4.38E-03	
PA0244	 2.69E-11	 1.96E-04	 PA3281	 5.63E-03	 4.39E-03	
PA2182	 3.13E-11	 2.05E-04	 PA3289	 5.63E-03	 4.40E-03	
PA0347	 4.21E-11	 2.14E-04	 PA3295	 5.63E-03	 4.41E-03	
PA0191	 4.31E-11	 2.23E-04	 PA3332	 5.63E-03	 4.42E-03	
PA2583	 6.50E-11	 2.32E-04	 PA3334	 5.63E-03	 4.42E-03	
PA2190	 7.91E-11	 2.41E-04	 PA3336	 5.63E-03	 4.43E-03	
PA1868	 8.24E-11	 2.50E-04	 PA3352	 5.63E-03	 4.44E-03	
PA3387	 2.48E-10	 2.59E-04	 PA3355	 5.63E-03	 4.45E-03	
PA4222	 2.48E-10	 2.68E-04	 PA3378	 5.63E-03	 4.46E-03	
PA2188	 2.49E-10	 2.77E-04	 PA3379	 5.63E-03	 4.47E-03	
PA2183	 2.64E-10	 2.85E-04	 PA3401	 5.63E-03	 4.48E-03	
PA2127	 3.11E-10	 2.94E-04	 PA3424	 5.63E-03	 4.49E-03	
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PA1576	 3.35E-10	 3.03E-04	 PA3558	 5.63E-03	 4.50E-03	
PA2184	 3.80E-10	 3.12E-04	 PA3559	 5.63E-03	 4.50E-03	
PA2200	 3.90E-10	 3.21E-04	 PA3578	 5.63E-03	 4.51E-03	
PA2185	 4.42E-10	 3.30E-04	 PA3586	 5.63E-03	 4.52E-03	
PA0261	 5.74E-10	 3.39E-04	 PA3662	 5.63E-03	 4.53E-03	
PA5404	 6.17E-10	 3.48E-04	 PA3667	 5.63E-03	 4.54E-03	
PA2135	 6.55E-10	 3.57E-04	 PA3668	 5.63E-03	 4.55E-03	
PA2112	 7.62E-10	 3.66E-04	 PA3706	 5.63E-03	 4.56E-03	
PA4063	 7.64E-10	 3.75E-04	 PA3733	 5.63E-03	 4.57E-03	
PA2187	 8.11E-10	 3.84E-04	 PA3748	 5.63E-03	 4.58E-03	
PA2296	 1.15E-09	 3.93E-04	 PA3793	 5.63E-03	 4.59E-03	
PA2186	 1.35E-09	 4.01E-04	 PA3809	 5.63E-03	 4.59E-03	
PA2440	 1.41E-09	 4.10E-04	 PA3810	 5.63E-03	 4.60E-03	
PA0499	 3.30E-09	 4.19E-04	 PA3830	 5.63E-03	 4.61E-03	
PA2295	 3.39E-09	 4.28E-04	 PA3859	 5.63E-03	 4.62E-03	
PA3063	 3.49E-09	 4.37E-04	 PA3863	 5.63E-03	 4.63E-03	
PA2167	 3.59E-09	 4.46E-04	 PA3870	 5.63E-03	 4.64E-03	
PA2116	 3.64E-09	 4.55E-04	 PA3882	 5.63E-03	 4.65E-03	
PA1223	 3.99E-09	 4.64E-04	 PA3898	 5.63E-03	 4.66E-03	
PA1865	 4.72E-09	 4.73E-04	 PA3903	 5.63E-03	 4.67E-03	
PA4914	 4.72E-09	 4.82E-04	 PA3906	 5.63E-03	 4.67E-03	
PA2109	 4.85E-09	 4.91E-04	 PA3907	 5.63E-03	 4.68E-03	
PA2164	 5.30E-09	 5.00E-04	 PA3926	 5.63E-03	 4.69E-03	
PA5218	 5.47E-09	 5.08E-04	 PA3951	 5.63E-03	 4.70E-03	
PA4225	 5.81E-09	 5.17E-04	 PA3956	 5.63E-03	 4.71E-03	
PA4344	 7.53E-09	 5.26E-04	 PA3964	 5.63E-03	 4.72E-03	
PA1930	 7.86E-09	 5.35E-04	 PA3981	 5.63E-03	 4.73E-03	
PA4282	 8.21E-09	 5.44E-04	 PA4003	 5.63E-03	 4.74E-03	
PA1225	 9.89E-09	 5.53E-04	 PA4033	 5.63E-03	 4.75E-03	
PA2154	 9.89E-09	 5.62E-04	 PA4037	 5.63E-03	 4.75E-03	
PA1224	 1.02E-08	 5.71E-04	 PA4279	 5.63E-03	 4.76E-03	
PA0497	 1.23E-08	 5.80E-04	 PA4284	 5.63E-03	 4.77E-03	
PA0013	 1.60E-08	 5.89E-04	 PA4285	 5.63E-03	 4.78E-03	
PA4796	 1.60E-08	 5.98E-04	 PA4287	 5.63E-03	 4.79E-03	
PA0498	 1.67E-08	 6.07E-04	 PA4302	 5.63E-03	 4.80E-03	
PA3368	 2.22E-08	 6.16E-04	 PA4305	 5.63E-03	 4.81E-03	
PA2055	 2.29E-08	 6.24E-04	 PA4341	 5.63E-03	 4.82E-03	
PA2834	 2.36E-08	 6.33E-04	 PA4342	 5.63E-03	 4.83E-03	
PA5219	 2.36E-08	 6.42E-04	 PA4347	 5.63E-03	 4.83E-03	
PA3222	 2.36E-08	 6.51E-04	 PA4357	 5.63E-03	 4.84E-03	
PA4849	 3.07E-08	 6.60E-04	 PA4365	 5.63E-03	 4.85E-03	
PA0251	 3.58E-08	 6.69E-04	 PA4369	 5.63E-03	 4.86E-03	
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PA2117	 4.53E-08	 6.78E-04	 PA4384	 5.63E-03	 4.87E-03	
PA0258	 5.14E-08	 6.87E-04	 PA4414	 5.63E-03	 4.88E-03	
PA1309	 5.45E-08	 6.96E-04	 PA4416	 5.63E-03	 4.89E-03	
PA3132	 9.43E-08	 7.05E-04	 PA4439	 5.63E-03	 4.90E-03	
PA0557	 9.49E-08	 7.14E-04	 PA4459	 5.63E-03	 4.91E-03	
PA0457_1	 1.27E-07	 7.23E-04	 PA4472	 5.63E-03	 4.92E-03	
PA0319	 1.31E-07	 7.31E-04	 PA4486	 5.63E-03	 4.92E-03	
PA0689	 1.87E-07	 7.40E-04	 PA4510	 5.63E-03	 4.93E-03	
PA2005	 2.15E-07	 7.49E-04	 PA4542	 5.63E-03	 4.94E-03	
PA2567	 3.74E-07	 7.58E-04	 PA4575	 5.63E-03	 4.95E-03	
PA2790	 3.74E-07	 7.67E-04	 PA4591	 5.63E-03	 4.96E-03	
PA5548	 3.83E-07	 7.76E-04	 PA4596	 5.63E-03	 4.97E-03	
PA5342	 4.34E-07	 7.85E-04	 PA4612	 5.63E-03	 4.98E-03	
PA3032	 5.82E-07	 7.94E-04	 PA4627	 5.63E-03	 4.99E-03	
PA3065	 7.33E-07	 8.03E-04	 PA4669	 5.63E-03	 5.00E-03	
PA3067	 7.33E-07	 8.12E-04	 PA4721	 5.63E-03	 5.00E-03	
PA2119	 8.50E-07	 8.21E-04	 PA4725	 5.63E-03	 5.01E-03	
PA2073	 8.91E-07	 8.30E-04	 PA4727	 5.63E-03	 5.02E-03	
PA2597	 9.19E-07	 8.39E-04	 PA4728	 5.63E-03	 5.03E-03	
PA3317	 9.19E-07	 8.47E-04	 PA4730	 5.63E-03	 5.04E-03	
PA3312	 1.11E-06	 8.56E-04	 PA4750	 5.63E-03	 5.05E-03	
PA2074	 1.14E-06	 8.65E-04	 PA4767	 5.63E-03	 5.06E-03	
PA1118	 1.30E-06	 8.74E-04	 PA4778	 5.63E-03	 5.07E-03	
PA2253	 1.34E-06	 8.83E-04	 PA4792	 5.63E-03	 5.08E-03	
PA0361	 1.38E-06	 8.92E-04	 PA4813	 5.63E-03	 5.08E-03	
PA0257	 1.89E-06	 9.01E-04	 PA4820	 5.63E-03	 5.09E-03	
PA4265	 2.01E-06	 9.10E-04	 PA4824	 5.63E-03	 5.10E-03	
PA4930	 2.66E-06	 9.19E-04	 PA4834	 5.63E-03	 5.11E-03	
PA0721	 3.63E-06	 9.28E-04	 PA4871	 5.63E-03	 5.12E-03	
PA2594	 4.77E-06	 9.37E-04	 PA4877	 5.63E-03	 5.13E-03	
PA2835	 4.77E-06	 9.46E-04	 PA4979	 5.63E-03	 5.14E-03	
PA3066	 5.03E-06	 9.55E-04	 PA4980	 5.63E-03	 5.15E-03	
PA1351	 5.48E-06	 9.63E-04	 PA4983	 5.63E-03	 5.16E-03	
PA0718	 6.67E-06	 9.72E-04	 PA4984	 5.63E-03	 5.17E-03	
PA4177	 9.57E-06	 9.81E-04	 PA4992	 5.63E-03	 5.17E-03	
PA1933	 1.08E-05	 9.90E-04	 PA5002	 5.63E-03	 5.18E-03	
PA1314	 1.11E-05	 9.99E-04	 PA5023	 5.63E-03	 5.19E-03	
PA5266	 1.15E-05	 1.01E-03	 PA5026	 5.63E-03	 5.20E-03	
PA2598	 1.40E-05	 1.02E-03	 PA5038	 5.63E-03	 5.21E-03	
PA2599	 1.40E-05	 1.03E-03	 PA5073	 5.63E-03	 5.22E-03	
PA2601	 1.40E-05	 1.03E-03	 PA5079	 5.63E-03	 5.23E-03	
PA1316	 1.55E-05	 1.04E-03	 PA5082	 5.63E-03	 5.24E-03	
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PA2336	 1.56E-05	 1.05E-03	 PA5144	 5.63E-03	 5.25E-03	
PA2335	 1.60E-05	 1.06E-03	 PA5157	 5.63E-03	 5.25E-03	
PA1771	 1.71E-05	 1.07E-03	 PA5185	 5.63E-03	 5.26E-03	
PA4127	 1.77E-05	 1.08E-03	 PA5196	 5.63E-03	 5.27E-03	
PA1348	 2.03E-05	 1.09E-03	 PA5220	 5.63E-03	 5.28E-03	
PA2503	 2.03E-05	 1.10E-03	 PA5230	 5.63E-03	 5.29E-03	
PA2774	 2.03E-05	 1.11E-03	 PA5249	 5.63E-03	 5.30E-03	
PA5184	 2.29E-05	 1.12E-03	 PA5277	 5.63E-03	 5.31E-03	
PA3298	 2.40E-05	 1.12E-03	 PA5294	 5.63E-03	 5.32E-03	
PA1169	 2.56E-05	 1.13E-03	 PA5310	 5.63E-03	 5.33E-03	
PA0014	 2.80E-05	 1.14E-03	 PA5330	 5.63E-03	 5.33E-03	
PA2220	 2.93E-05	 1.15E-03	 PA5349	 5.63E-03	 5.34E-03	
PA1488	 3.26E-05	 1.16E-03	 PA5352	 5.63E-03	 5.35E-03	
PA3340	 3.32E-05	 1.17E-03	 PA5357	 5.63E-03	 5.36E-03	
PA1312	 3.46E-05	 1.18E-03	 PA5358	 5.63E-03	 5.37E-03	
PA2192	 3.56E-05	 1.19E-03	 PA5379	 5.63E-03	 5.38E-03	
PA1984	 3.62E-05	 1.20E-03	 PA5383	 5.63E-03	 5.39E-03	
PA1932	 5.01E-05	 1.20E-03	 PA5476	 5.63E-03	 5.40E-03	
PA2602	 6.55E-05	 1.21E-03	 PA5495	 5.63E-03	 5.41E-03	
PA5542	 7.31E-05	 1.22E-03	 PA5502	 5.63E-03	 5.41E-03	
PA0206	 7.43E-05	 1.23E-03	 PA5517	 5.63E-03	 5.42E-03	
PA2294	 7.58E-05	 1.24E-03	 PA5532	 5.63E-03	 5.43E-03	
PA2334	 7.74E-05	 1.25E-03	 PA5543	 5.63E-03	 5.44E-03	
PA2669	 9.39E-05	 1.26E-03	 PA0095	 5.74E-03	 5.45E-03	
PA1922	 1.02E-04	 1.27E-03	 PA4119	 5.74E-03	 5.46E-03	
PA2096	 1.02E-04	 1.28E-03	 PA2175	 5.74E-03	 5.47E-03	
PA1397	 1.04E-04	 1.28E-03	 PA4101	 5.92E-03	 5.48E-03	
PA2180	 1.07E-04	 1.29E-03	 PA0631	 6.08E-03	 5.49E-03	
PA2333	 1.12E-04	 1.30E-03	 PA1297	 6.11E-03	 5.50E-03	
PA0573	 1.13E-04	 1.31E-03	 PA2145	 6.11E-03	 5.50E-03	
PA1315	 1.19E-04	 1.32E-03	 PA2682	 6.11E-03	 5.51E-03	
PA0205	 1.39E-04	 1.33E-03	 PA4805	 6.11E-03	 5.52E-03	
PA0207	 1.39E-04	 1.34E-03	 PA0246	 6.23E-03	 5.53E-03	
PA2155	 1.42E-04	 1.35E-03	 PA1247	 6.23E-03	 5.54E-03	
PA2596	 1.42E-04	 1.36E-03	 PA1599	 6.23E-03	 5.55E-03	
PA2158	 1.44E-04	 1.36E-03	 PA1970	 6.23E-03	 5.56E-03	
PA4802	 1.64E-04	 1.37E-03	 PA2922	 6.23E-03	 5.57E-03	
PA0202	 1.70E-04	 1.38E-03	 PA4960	 6.23E-03	 5.58E-03	
PA2603	 1.97E-04	 1.39E-03	 PA5099	 6.23E-03	 5.58E-03	
PA0844	 2.03E-04	 1.40E-03	 PA5442	 6.23E-03	 5.59E-03	
PA3884	 2.03E-04	 1.41E-03	 PA0092	 6.59E-03	 5.60E-03	
PA1471	 2.15E-04	 1.42E-03	 PA2315	 6.87E-03	 5.61E-03	
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PA1472	 2.15E-04	 1.43E-03	 PA0093	 7.46E-03	 5.62E-03	
PA4554	 2.22E-04	 1.44E-03	 PA0101	 7.58E-03	 5.63E-03	
PA2170	 2.35E-04	 1.45E-03	 PA1195	 7.59E-03	 5.64E-03	
PA3053	 2.53E-04	 1.45E-03	 PA0187	 8.38E-03	 5.65E-03	
PA0203	 2.54E-04	 1.46E-03	 PA4798	 8.41E-03	 5.66E-03	
PA1349	 2.55E-04	 1.47E-03	 PA0183	 8.62E-03	 5.66E-03	
PA1569	 2.64E-04	 1.48E-03	 PA0199	 8.62E-03	 5.67E-03	
PA0688	 2.67E-04	 1.49E-03	 PA0997	 8.62E-03	 5.68E-03	
PA1196	 2.72E-04	 1.50E-03	 PA1145	 8.62E-03	 5.69E-03	
PA3354	 2.72E-04	 1.51E-03	 PA1286	 8.62E-03	 5.70E-03	
PA5427	 2.72E-04	 1.52E-03	 PA1480	 8.62E-03	 5.71E-03	
PA1313	 2.90E-04	 1.53E-03	 PA1508	 8.62E-03	 5.72E-03	
PA2159	 2.90E-04	 1.53E-03	 PA1531	 8.62E-03	 5.73E-03	
PA1079	 3.10E-04	 1.54E-03	 PA2060	 8.62E-03	 5.74E-03	
PA1841	 3.10E-04	 1.55E-03	 PA2431	 8.62E-03	 5.74E-03	
PA2677	 3.10E-04	 1.56E-03	 PA2470	 8.62E-03	 5.75E-03	
PA3715	 3.10E-04	 1.57E-03	 PA3170	 8.62E-03	 5.76E-03	
PA4806	 3.10E-04	 1.58E-03	 PA3321	 8.62E-03	 5.77E-03	
PA2177	 3.27E-04	 1.59E-03	 PA3796	 8.62E-03	 5.78E-03	
PA0096	 3.42E-04	 1.60E-03	 PA4573	 8.62E-03	 5.79E-03	
PA0295	 3.57E-04	 1.61E-03	 PA5101	 8.62E-03	 5.80E-03	
PA0737	 3.57E-04	 1.61E-03	 PA5211	 8.62E-03	 5.81E-03	
PA4603	 3.57E-04	 1.62E-03	 PA1246	 8.71E-03	 5.82E-03	
PA0719	 3.63E-04	 1.63E-03	 PA2838	 8.71E-03	 5.83E-03	
PA0734	 3.71E-04	 1.64E-03	 PA3714	 8.71E-03	 5.83E-03	
PA1366	 3.73E-04	 1.65E-03	 PA4083	 8.71E-03	 5.84E-03	
PA0791	 3.77E-04	 1.66E-03	 PA4126	 8.71E-03	 5.85E-03	
PA1132	 3.77E-04	 1.67E-03	 PA4900	 8.71E-03	 5.86E-03	
PA1740	 3.77E-04	 1.68E-03	 PA1797	 8.85E-03	 5.87E-03	
PA2636	 3.77E-04	 1.69E-03	 PA2218	 9.47E-03	 5.88E-03	
PA2786	 3.77E-04	 1.69E-03	 PA1914	 9.94E-03	 5.89E-03	
PA3957	 3.77E-04	 1.70E-03	 PA0099	 1.02E-02	 5.90E-03	
PA1827	 3.91E-04	 1.71E-03	 PA2807	 1.09E-02	 5.91E-03	
PA1931	 3.96E-04	 1.72E-03	 PA4147	 1.09E-02	 5.91E-03	
PA4482	 3.99E-04	 1.73E-03	 PA4151	 1.09E-02	 5.92E-03	
PA2195	 4.11E-04	 1.74E-03	 PA3961	 1.18E-02	 5.93E-03	
PA4577	 4.31E-04	 1.75E-03	 PA0121	 1.18E-02	 5.94E-03	
PA0204	 4.52E-04	 1.76E-03	 PA0323	 1.18E-02	 5.95E-03	
PA1194	 4.99E-04	 1.77E-03	 PA0348	 1.18E-02	 5.96E-03	
PA1346	 4.99E-04	 1.78E-03	 PA0415	 1.18E-02	 5.97E-03	
PA1086	 5.43E-04	 1.78E-03	 PA0803	 1.18E-02	 5.98E-03	
PA1088	 5.43E-04	 1.79E-03	 PA1020	 1.18E-02	 5.99E-03	
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PA1089	 5.43E-04	 1.80E-03	 PA1056	 1.18E-02	 5.99E-03	
PA1090	 5.43E-04	 1.81E-03	 PA1168	 1.18E-02	 6.00E-03	
PA1095	 5.73E-04	 1.82E-03	 PA1211	 1.18E-02	 6.01E-03	
PA0996	 5.74E-04	 1.83E-03	 PA1212	 1.18E-02	 6.02E-03	
PA2760	 5.74E-04	 1.84E-03	 PA1217	 1.18E-02	 6.03E-03	
PA0574	 6.00E-04	 1.85E-03	 PA1218	 1.18E-02	 6.04E-03	
PA0051	 6.63E-04	 1.86E-03	 PA1242	 1.18E-02	 6.05E-03	
PA1096	 6.89E-04	 1.86E-03	 PA1260	 1.18E-02	 6.06E-03	
PA1021	 7.11E-04	 1.87E-03	 PA1266	 1.18E-02	 6.07E-03	
PA5284	 7.71E-04	 1.88E-03	 PA1280	 1.18E-02	 6.07E-03	
PA4149	 8.01E-04	 1.89E-03	 PA1515	 1.18E-02	 6.08E-03	
PA2673	 8.62E-04	 1.90E-03	 PA1693	 1.18E-02	 6.09E-03	
PA4649	 8.62E-04	 1.91E-03	 PA1729	 1.18E-02	 6.10E-03	
PA1091	 8.91E-04	 1.92E-03	 PA1810	 1.18E-02	 6.11E-03	
PA1271	 9.22E-04	 1.93E-03	 PA1898	 1.18E-02	 6.12E-03	
PA4100	 9.38E-04	 1.94E-03	 PA2430	 1.18E-02	 6.13E-03	
PA0819	 9.83E-04	 1.94E-03	 PA2524	 1.18E-02	 6.14E-03	
PA1093	 9.91E-04	 1.95E-03	 PA2920	 1.18E-02	 6.15E-03	
PA1094	 9.91E-04	 1.96E-03	 PA2927	 1.18E-02	 6.16E-03	
PA2131	 1.02E-03	 1.97E-03	 PA2931	 1.18E-02	 6.16E-03	
PA1001	 1.09E-03	 1.98E-03	 PA2934	 1.18E-02	 6.17E-03	
PA1015	 1.09E-03	 1.99E-03	 PA2940	 1.18E-02	 6.18E-03	
PA2665	 1.09E-03	 2.00E-03	 PA3175	 1.18E-02	 6.19E-03	
PA2678	 1.09E-03	 2.01E-03	 PA3207	 1.18E-02	 6.20E-03	
PA2924	 1.09E-03	 2.02E-03	 PA3329	 1.18E-02	 6.21E-03	
PA2926	 1.09E-03	 2.02E-03	 PA3669	 1.18E-02	 6.22E-03	
PA3871	 1.09E-03	 2.03E-03	 PA3910	 1.18E-02	 6.23E-03	
PA4539	 1.09E-03	 2.04E-03	 PA4239	 1.18E-02	 6.24E-03	
PA5399	 1.09E-03	 2.05E-03	 PA4278	 1.18E-02	 6.24E-03	
PA4896	 1.10E-03	 2.06E-03	 PA4374	 1.18E-02	 6.25E-03	
PA0995	 1.11E-03	 2.07E-03	 PA4448	 1.18E-02	 6.26E-03	
PA1350	 1.11E-03	 2.08E-03	 PA4650	 1.18E-02	 6.27E-03	
PA2764	 1.13E-03	 2.09E-03	 PA5102	 1.18E-02	 6.28E-03	
PA1149	 1.18E-03	 2.10E-03	 PA5181	 1.18E-02	 6.29E-03	
PA1092	 1.19E-03	 2.11E-03	 PA5260	 1.18E-02	 6.30E-03	
PA2172	 1.24E-03	 2.11E-03	 PA5466	 1.18E-02	 6.31E-03	
PA2291	 1.26E-03	 2.12E-03	 PA0100	 1.18E-02	 6.32E-03	
PA4102	 1.31E-03	 2.13E-03	 PA1147	 1.24E-02	 6.32E-03	
PA4103	 1.31E-03	 2.14E-03	 PA1251	 1.24E-02	 6.33E-03	
PA0400	 1.32E-03	 2.15E-03	 PA2676	 1.24E-02	 6.34E-03	
PA1680	 1.32E-03	 2.16E-03	 PA2921	 1.24E-02	 6.35E-03	
PA2675	 1.32E-03	 2.17E-03	 PA3842	 1.24E-02	 6.36E-03	
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PA2722	 1.32E-03	 2.18E-03	 PA4084	 1.27E-02	 6.37E-03	
PA2723	 1.32E-03	 2.19E-03	 PA0690	 1.31E-02	 6.38E-03	
PA2775	 1.32E-03	 2.19E-03	 PA2360	 1.31E-02	 6.39E-03	
PA2908	 1.32E-03	 2.20E-03	 PA2191	 1.37E-02	 6.40E-03	
PA4826	 1.32E-03	 2.21E-03	 PA1511	 1.45E-02	 6.40E-03	
PA5254	 1.32E-03	 2.22E-03	 PA1606	 1.54E-02	 6.41E-03	
PA1087	 1.41E-03	 2.23E-03	 PA1715	 1.57E-02	 6.42E-03	
PA1681	 1.46E-03	 2.24E-03	 PA2125	 1.57E-02	 6.43E-03	
PA5034	 1.46E-03	 2.25E-03	 PA2150	 1.57E-02	 6.44E-03	
PA5314	 1.46E-03	 2.26E-03	 PA4080	 1.57E-02	 6.45E-03	
PA0508	 1.48E-03	 2.27E-03	 PA5252	 1.57E-02	 6.46E-03	
PA0774	 1.48E-03	 2.27E-03	 PA0078	 1.58E-02	 6.47E-03	
PA0828	 1.48E-03	 2.28E-03	 PA0112	 1.58E-02	 6.48E-03	
PA0939	 1.48E-03	 2.29E-03	 PA0133	 1.58E-02	 6.49E-03	
PA1133	 1.48E-03	 2.30E-03	 PA0135	 1.58E-02	 6.49E-03	
PA1235	 1.48E-03	 2.31E-03	 PA0168	 1.58E-02	 6.50E-03	
PA1293	 1.48E-03	 2.32E-03	 PA0170	 1.58E-02	 6.51E-03	
PA1818	 1.48E-03	 2.33E-03	 PA0175	 1.58E-02	 6.52E-03	
PA2441	 1.48E-03	 2.34E-03	 PA0184	 1.58E-02	 6.53E-03	
PA2556	 1.48E-03	 2.35E-03	 PA0186	 1.58E-02	 6.54E-03	
PA2681	 1.48E-03	 2.36E-03	 PA0270	 1.58E-02	 6.55E-03	
PA2765	 1.48E-03	 2.36E-03	 PA0271	 1.58E-02	 6.56E-03	
PA3135	 1.48E-03	 2.37E-03	 PA0297	 1.58E-02	 6.57E-03	
PA3331	 1.48E-03	 2.38E-03	 PA0325	 1.58E-02	 6.57E-03	
PA3339	 1.48E-03	 2.39E-03	 PA0467	 1.58E-02	 6.58E-03	
PA3827	 1.48E-03	 2.40E-03	 PA0482	 1.58E-02	 6.59E-03	
PA3902	 1.48E-03	 2.41E-03	 PA0486	 1.58E-02	 6.60E-03	
PA3908	 1.48E-03	 2.42E-03	 PA0535	 1.58E-02	 6.61E-03	
PA3920	 1.48E-03	 2.43E-03	 PA0590	 1.58E-02	 6.62E-03	
PA3969	 1.48E-03	 2.44E-03	 PA0610	 1.58E-02	 6.63E-03	
PA4220	 1.48E-03	 2.44E-03	 PA0666	 1.58E-02	 6.64E-03	
PA4405	 1.48E-03	 2.45E-03	 PA0672	 1.58E-02	 6.65E-03	
PA4580	 1.48E-03	 2.46E-03	 PA0732	 1.58E-02	 6.65E-03	
PA4708	 1.48E-03	 2.47E-03	 PA0733	 1.58E-02	 6.66E-03	
PA4832	 1.48E-03	 2.48E-03	 PA0736	 1.58E-02	 6.67E-03	
PA5231	 1.48E-03	 2.49E-03	 PA0843	 1.58E-02	 6.68E-03	
PA5329	 1.48E-03	 2.50E-03	 PA0862	 1.58E-02	 6.69E-03	
PA5359	 1.48E-03	 2.51E-03	 PA0864	 1.58E-02	 6.70E-03	
PA5361	 1.48E-03	 2.52E-03	 PA0879	 1.58E-02	 6.71E-03	
PA5511	 1.48E-03	 2.52E-03	 PA0893	 1.58E-02	 6.72E-03	
PA5519	 1.48E-03	 2.53E-03	 PA0894	 1.58E-02	 6.73E-03	
PA5520	 1.48E-03	 2.54E-03	 PA0925	 1.58E-02	 6.74E-03	
230	
PA2514	 1.53E-03	 2.55E-03	 PA0927	 1.58E-02	 6.74E-03	
PA4585	 1.53E-03	 2.56E-03	 PA0951	 1.58E-02	 6.75E-03	
PA2126	 1.60E-03	 2.57E-03	 PA0952	 1.58E-02	 6.76E-03	
PA5267	 1.60E-03	 2.58E-03	 PA0955	 1.58E-02	 6.77E-03	
PA1826	 1.78E-03	 2.59E-03	 PA0998	 1.58E-02	 6.78E-03	
PA0089	 2.08E-03	 2.60E-03	 PA1028	 1.58E-02	 6.79E-03	
PA0842	 2.08E-03	 2.60E-03	 PA1038	 1.58E-02	 6.80E-03	
PA1646	 2.08E-03	 2.61E-03	 PA1043	 1.58E-02	 6.81E-03	
PA1917	 2.08E-03	 2.62E-03	 PA1054	 1.58E-02	 6.82E-03	
PA2018	 2.08E-03	 2.63E-03	 PA1066	 1.58E-02	 6.82E-03	
PA3843	 2.08E-03	 2.64E-03	 PA1069	 1.58E-02	 6.83E-03	
PA4118	 2.08E-03	 2.65E-03	 PA1109	 1.58E-02	 6.84E-03	
PA2219	 2.21E-03	 2.66E-03	 PA1110	 1.58E-02	 6.85E-03	
PA4148	 2.27E-03	 2.67E-03	 PA1136	 1.58E-02	 6.86E-03	
PA2600	 2.56E-03	 2.68E-03	 PA1137	 1.58E-02	 6.87E-03	PA3294	 2.71E-03	 2.69E-03	 PA1163	 1.58E-02	 6.88E-03	PA0480	 2.79E-03	 2.69E-03	 PA1205	 1.58E-02	 6.89E-03	PA0496	 2.79E-03	 2.70E-03	 PA1231	 1.58E-02	 6.90E-03	PA2002	 2.79E-03	 2.71E-03	 PA1237	 1.58E-02	 6.90E-03	PA2546	 2.79E-03	 2.72E-03	 PA1244	 1.58E-02	 6.91E-03	PA2563	 2.79E-03	 2.73E-03	 PA1250	 1.58E-02	 6.92E-03	PA2672	 2.79E-03	 2.74E-03	 PA1285	 1.58E-02	 6.93E-03	PA2925	 2.79E-03	 2.75E-03	 PA1289	 1.58E-02	 6.94E-03	PA3176	 2.79E-03	 2.76E-03	 PA1290	 1.58E-02	 6.95E-03	PA5097	 2.79E-03	 2.77E-03	 PA1330	 1.58E-02	 6.96E-03	PA4690_5	 2.92E-03	 2.77E-03	 PA1446	 1.58E-02	 6.97E-03	PA0759	 2.98E-03	 2.78E-03	 PA1467	 1.58E-02	 6.98E-03	PA4104	 3.00E-03	 2.79E-03	 PA1474	 1.58E-02	 6.98E-03	PA2417	 3.00E-03	 2.80E-03	 PA1491	 1.58E-02	 6.99E-03	PA4150	 3.00E-03	 2.81E-03	 PA1537	 1.58E-02	 7.00E-03	PA0262	 3.05E-03	 2.82E-03	 PA1542	 1.58E-02	 7.01E-03	PA0696	 3.13E-03	 2.83E-03	 PA1563	 1.58E-02	 7.02E-03	PA0910	 3.19E-03	 2.84E-03	 PA1592	 1.58E-02	 7.03E-03	PA2128	 3.19E-03	 2.85E-03	 PA1600	 1.58E-02	 7.04E-03	PA5032	 3.19E-03	 2.85E-03	 PA1604	 1.58E-02	 7.05E-03	PA5113	 3.19E-03	 2.86E-03	 PA1652	 1.58E-02	 7.06E-03	PA4105	 3.25E-03	 2.87E-03	 PA1653	 1.58E-02	 7.07E-03	PA4107	 3.65E-03	 2.88E-03	 PA1672	 1.58E-02	 7.07E-03	PA0050	 3.67E-03	 2.89E-03	 PA1689	 1.58E-02	 7.08E-03	PA0273	 3.67E-03	 2.90E-03	 PA1739	 1.58E-02	 7.09E-03	PA1014	 3.67E-03	 2.91E-03	 PA1792	 1.58E-02	 7.10E-03	PA1131	 3.67E-03	 2.92E-03	 PA1817	 1.58E-02	 7.11E-03	
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PA2437	 3.67E-03	 2.93E-03	 PA1850	 1.58E-02	 7.12E-03	PA2923	 3.67E-03	 2.93E-03	 PA1861	 1.58E-02	 7.13E-03	PA3125	 3.67E-03	 2.94E-03	 PA1876	 1.58E-02	 7.14E-03	PA3140	 3.67E-03	 2.95E-03	 PA1885	 1.58E-02	 7.15E-03	PA3589	 3.67E-03	 2.96E-03	 PA1886	 1.58E-02	 7.15E-03	PA3829	 3.67E-03	 2.97E-03	 PA1891	 1.58E-02	 7.16E-03	PA3840	 3.67E-03	 2.98E-03	 PA1895	 1.58E-02	 7.17E-03	PA4498	 3.67E-03	 2.99E-03	 PA2015	 1.58E-02	 7.18E-03	PA5477	 3.67E-03	 3.00E-03	 PA2499	 1.58E-02	 7.19E-03	PA1292	 3.68E-03	 3.01E-03	 PA2506	 1.58E-02	 7.20E-03	PA3288	 3.86E-03	 3.02E-03	 PA2516	 1.58E-02	 7.21E-03	PA2152	 4.28E-03	 3.02E-03	 PA2547	 1.58E-02	 7.22E-03	PA2165	 4.28E-03	 3.03E-03	 PA2569	 1.58E-02	 7.23E-03	PA0292	 4.47E-03	 3.04E-03	 PA2570	 1.58E-02	 7.23E-03	PA0479	 4.47E-03	 3.05E-03	 PA2579	 1.58E-02	 7.24E-03	PA1987	 4.47E-03	 3.06E-03	 PA2582	 1.58E-02	 7.25E-03	PA2421	 4.47E-03	 3.07E-03	 PA2588	 1.58E-02	 7.26E-03	PA2930	 4.47E-03	 3.08E-03	 PA2591	 1.58E-02	 7.27E-03	PA4088	 4.47E-03	 3.09E-03	 PA2664	 1.58E-02	 7.28E-03	PA4540	 4.47E-03	 3.10E-03	 PA2679	 1.58E-02	 7.29E-03	PA4584	 4.47E-03	 3.10E-03	 PA2721	 1.58E-02	 7.30E-03	PA0630	 4.68E-03	 3.11E-03	 PA2724	 1.58E-02	 7.31E-03	PA0674	 4.68E-03	 3.12E-03	 PA2761	 1.58E-02	 7.31E-03	PA0753	 4.68E-03	 3.13E-03	 PA2766	 1.58E-02	 7.32E-03	PA1120	 4.68E-03	 3.14E-03	 PA2810	 1.58E-02	 7.33E-03	PA1875	 4.68E-03	 3.15E-03	 PA2881	 1.58E-02	 7.34E-03	PA1884	 4.68E-03	 3.16E-03	 PA2887	 1.58E-02	 7.35E-03	PA2522	 4.68E-03	 3.17E-03	 PA2888	 1.58E-02	 7.36E-03	PA2716	 4.68E-03	 3.18E-03	 PA2900	 1.58E-02	 7.37E-03	PA2720	 4.68E-03	 3.18E-03	 PA2959	 1.58E-02	 7.38E-03	PA2785	 4.68E-03	 3.19E-03	 PA2969	 1.58E-02	 7.39E-03	PA2837	 4.68E-03	 3.20E-03	 PA3016	 1.58E-02	 7.40E-03	PA3035	 4.68E-03	 3.21E-03	 PA3034	 1.58E-02	 7.40E-03	PA3078	 4.68E-03	 3.22E-03	 PA3056	 1.58E-02	 7.41E-03	PA3738	 4.68E-03	 3.23E-03	 PA3080	 1.58E-02	 7.42E-03	PA3771	 4.68E-03	 3.24E-03	 PA3196	 1.58E-02	 7.43E-03	PA3806	 4.68E-03	 3.25E-03	 PA3219	 1.58E-02	 7.44E-03	PA4478	 4.68E-03	 3.26E-03	 PA3243	 1.58E-02	 7.45E-03	PA4613	 4.68E-03	 3.26E-03	 PA3267	 1.58E-02	 7.46E-03	PA4651	 4.68E-03	 3.27E-03	 PA3310	 1.58E-02	 7.47E-03	PA4716	 4.68E-03	 3.28E-03	 PA3325	 1.58E-02	 7.48E-03	PA4785	 4.68E-03	 3.29E-03	 PA3326	 1.58E-02	 7.48E-03	
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PA5017	 4.68E-03	 3.30E-03	 PA3330	 1.58E-02	 7.49E-03	PA5393	 4.68E-03	 3.31E-03	 PA3335	 1.58E-02	 7.50E-03	PA1283	 4.79E-03	 3.32E-03	 PA3341	 1.58E-02	 7.51E-03	PA4653	 4.79E-03	 3.33E-03	 PA3358	 1.58E-02	 7.52E-03	PA4106	 4.90E-03	 3.34E-03	 PA3365	 1.58E-02	 7.53E-03	PA0188	 5.00E-03	 3.35E-03	 PA3386	 1.58E-02	 7.54E-03	PA2129	 5.29E-03	 3.35E-03	 PA3474	 1.58E-02	 7.55E-03	PA0005	 5.63E-03	 3.36E-03	 PA3515	 1.58E-02	 7.56E-03	PA0007	 5.63E-03	 3.37E-03	 PA3518	 1.58E-02	 7.56E-03	PA0012	 5.63E-03	 3.38E-03	 PA3539	 1.58E-02	 7.57E-03	PA0020	 5.63E-03	 3.39E-03	 PA3549	 1.58E-02	 7.58E-03	PA0028	 5.63E-03	 3.40E-03	 PA3552	 1.58E-02	 7.59E-03	PA0048	 5.63E-03	 3.41E-03	 PA3555	 1.58E-02	 7.60E-03	PA0070	 5.63E-03	 3.42E-03	 PA3557	 1.58E-02	 7.61E-03	PA0072	 5.63E-03	 3.43E-03	 PA3584	 1.58E-02	 7.62E-03	PA0075	 5.63E-03	 3.43E-03	 PA3588	 1.58E-02	 7.63E-03	PA0122	 5.63E-03	 3.44E-03	 PA3591	 1.58E-02	 7.64E-03	PA0276	 5.63E-03	 3.45E-03	 PA3596	 1.58E-02	 7.64E-03	PA0293	 5.63E-03	 3.46E-03	 PA3613	 1.58E-02	 7.65E-03	PA0316	 5.63E-03	 3.47E-03	 PA3643	 1.58E-02	 7.66E-03	PA0324	 5.63E-03	 3.48E-03	 PA3671	 1.58E-02	 7.67E-03	PA0346	 5.63E-03	 3.49E-03	 PA3721	 1.58E-02	 7.68E-03	PA0357	 5.63E-03	 3.50E-03	 PA3795	 1.58E-02	 7.69E-03	PA0368	 5.63E-03	 3.51E-03	 PA3826	 1.58E-02	 7.70E-03	PA0397	 5.63E-03	 3.51E-03	 PA3905	 1.58E-02	 7.71E-03	PA0405	 5.63E-03	 3.52E-03	 PA3915	 1.58E-02	 7.72E-03	PA0412	 5.63E-03	 3.53E-03	 PA3944	 1.58E-02	 7.73E-03	PA0421	 5.63E-03	 3.54E-03	 PA3954	 1.58E-02	 7.73E-03	PA0422	 5.63E-03	 3.55E-03	 PA3984	 1.58E-02	 7.74E-03	PA0431	 5.63E-03	 3.56E-03	 PA3985	 1.58E-02	 7.75E-03	PA0463	 5.63E-03	 3.57E-03	 PA3988	 1.58E-02	 7.76E-03	PA0464	 5.63E-03	 3.58E-03	 PA4028	 1.58E-02	 7.77E-03	PA0492	 5.63E-03	 3.59E-03	 PA4111	 1.58E-02	 7.78E-03	PA0493	 5.63E-03	 3.60E-03	 PA4229	 1.58E-02	 7.79E-03	PA0529	 5.63E-03	 3.60E-03	 PA4281	 1.58E-02	 7.80E-03	PA0530	 5.63E-03	 3.61E-03	 PA4340	 1.58E-02	 7.81E-03	PA0531	 5.63E-03	 3.62E-03	 PA4392	 1.58E-02	 7.81E-03	PA0539	 5.63E-03	 3.63E-03	 PA4423	 1.58E-02	 7.82E-03	PA0546	 5.63E-03	 3.64E-03	 PA4424	 1.58E-02	 7.83E-03	PA0556	 5.63E-03	 3.65E-03	 PA4428	 1.58E-02	 7.84E-03	PA0584	 5.63E-03	 3.66E-03	 PA4543	 1.58E-02	 7.85E-03	PA0649	 5.63E-03	 3.67E-03	 PA4565	 1.58E-02	 7.86E-03	
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PA0663	 5.63E-03	 3.68E-03	 PA4601	 1.58E-02	 7.87E-03	PA0667	 5.63E-03	 3.68E-03	 PA4602	 1.58E-02	 7.88E-03	PA0772	 5.63E-03	 3.69E-03	 PA4640	 1.58E-02	 7.89E-03	PA0784	 5.63E-03	 3.70E-03	 PA4663	 1.58E-02	 7.89E-03	PA0806	 5.63E-03	 3.71E-03	 PA4682	 1.58E-02	 7.90E-03	PA0827	 5.63E-03	 3.72E-03	 PA4700	 1.58E-02	 7.91E-03	PA0829	 5.63E-03	 3.73E-03	 PA4705	 1.58E-02	 7.92E-03	PA0831	 5.63E-03	 3.74E-03	 PA4706	 1.58E-02	 7.93E-03	PA0841	 5.63E-03	 3.75E-03	 PA4772	 1.58E-02	 7.94E-03	PA0846	 5.63E-03	 3.76E-03	 PA4777	 1.58E-02	 7.95E-03	PA0852	 5.63E-03	 3.76E-03	 PA4800	 1.58E-02	 7.96E-03	PA0882	 5.63E-03	 3.77E-03	 PA4814	 1.58E-02	 7.97E-03	PA0921	 5.63E-03	 3.78E-03	 PA4838	 1.58E-02	 7.98E-03	PA0932	 5.63E-03	 3.79E-03	 PA4878	 1.58E-02	 7.98E-03	PA0942	 5.63E-03	 3.80E-03	 PA4894	 1.58E-02	 7.99E-03	PA0946	 5.63E-03	 3.81E-03	 PA4905	 1.58E-02	 8.00E-03	PA0953	 5.63E-03	 3.82E-03	 PA4949	 1.58E-02	 8.01E-03	PA0975	 5.63E-03	 3.83E-03	 PA4950	 1.58E-02	 8.02E-03	PA1031	 5.63E-03	 3.84E-03	 PA4975	 1.58E-02	 8.03E-03	PA1049	 5.63E-03	 3.84E-03	 PA4976	 1.58E-02	 8.04E-03	PA1051	 5.63E-03	 3.85E-03	 PA4978	 1.58E-02	 8.05E-03	PA1053	 5.63E-03	 3.86E-03	 PA4982	 1.58E-02	 8.06E-03	PA1065	 5.63E-03	 3.87E-03	 PA4994	 1.58E-02	 8.06E-03	PA1085	 5.63E-03	 3.88E-03	 PA5001	 1.58E-02	 8.07E-03	PA1138	 5.63E-03	 3.89E-03	 PA5027	 1.58E-02	 8.08E-03	PA1162	 5.63E-03	 3.90E-03	 PA5047	 1.58E-02	 8.09E-03	PA1185	 5.63E-03	 3.91E-03	 PA5092	 1.58E-02	 8.10E-03	PA1226	 5.63E-03	 3.92E-03	 PA5109	 1.58E-02	 8.11E-03	PA1227	 5.63E-03	 3.93E-03	 PA5131	 1.58E-02	 8.12E-03	PA1228	 5.63E-03	 3.93E-03	 PA5132	 1.58E-02	 8.13E-03	PA1233	 5.63E-03	 3.94E-03	 PA5163	 1.58E-02	 8.14E-03	PA1234	 5.63E-03	 3.95E-03	 PA5177	 1.58E-02	 8.14E-03	PA1322	 5.63E-03	 3.96E-03	 PA5183	 1.58E-02	 8.15E-03	PA1363	 5.63E-03	 3.97E-03	 PA5234	 1.58E-02	 8.16E-03	PA1473	 5.63E-03	 3.98E-03	 PA5248	 1.58E-02	 8.17E-03	PA1528	 5.63E-03	 3.99E-03	 PA5313	 1.58E-02	 8.18E-03	PA1529	 5.63E-03	 4.00E-03	 PA5328	 1.58E-02	 8.19E-03	PA1530	 5.63E-03	 4.01E-03	 PA5457	 1.58E-02	 8.20E-03	PA1545	 5.63E-03	 4.01E-03	 PA5471	 1.58E-02	 8.21E-03	PA1561	 5.63E-03	 4.02E-03	 PA5484	 1.58E-02	 8.22E-03	PA1565	 5.63E-03	 4.03E-03	 PA5487	 1.58E-02	 8.22E-03	PA1586	 5.63E-03	 4.04E-03	 PA5541	 1.58E-02	 8.23E-03	
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PA1635	 5.63E-03	 4.05E-03	 PA0912	 1.74E-02	 8.24E-03	PA1639	 5.63E-03	 4.06E-03	 PA0118	 1.77E-02	 8.25E-03	PA1733	 5.63E-03	 4.07E-03	 PA0911	 1.77E-02	 8.26E-03	PA1753	 5.63E-03	 4.08E-03	 PA1435	 1.77E-02	 8.27E-03	PA1760	 5.63E-03	 4.09E-03	 PA1710	 1.77E-02	 8.28E-03	PA1834	 5.63E-03	 4.09E-03	 PA2126_1	 1.77E-02	 8.29E-03	PA1867	 5.63E-03	 4.10E-03	 PA2568	 1.77E-02	 8.30E-03	PA1870	 5.63E-03	 4.11E-03	 PA2617	 1.77E-02	 8.31E-03	PA1877	 5.63E-03	 4.12E-03	 PA2674	 1.77E-02	 8.31E-03	PA2432	 5.63E-03	 4.13E-03	 PA2932	 1.77E-02	 8.32E-03	PA2448	 5.63E-03	 4.14E-03	 PA2976	 1.77E-02	 8.33E-03	PA2560	 5.63E-03	 4.15E-03	 PA3520	 1.77E-02	 8.34E-03	PA2566_1	 5.63E-03	 4.16E-03	 PA4008	 1.77E-02	 8.35E-03	PA2580	 5.63E-03	 4.17E-03	 PA4087	 1.77E-02	 8.36E-03	PA2581	 5.63E-03	 4.17E-03	 PA4089	 1.77E-02	 8.37E-03	PA2713	 5.63E-03	 4.18E-03	 PA4623	 1.77E-02	 8.38E-03	PA2714	 5.63E-03	 4.19E-03	 PA4822	 1.77E-02	 8.39E-03	PA5264	 1.77E-02	 8.39E-03	 PA1705	 2.51E-02	 1.05E-02	PA0252	 1.83E-02	 8.40E-03	 PA1722	 2.51E-02	 1.05E-02	PA1359	 1.83E-02	 8.41E-03	 PA1725	 2.51E-02	 1.05E-02	PA4152	 1.83E-02	 8.42E-03	 PA1738	 2.51E-02	 1.05E-02	PA4153	 1.83E-02	 8.43E-03	 PA1928	 2.51E-02	 1.05E-02	PA2137	 2.02E-02	 8.44E-03	 PA2056	 2.51E-02	 1.05E-02	PA1221	 2.04E-02	 8.45E-03	 PA2062	 2.51E-02	 1.05E-02	PA4109	 2.04E-02	 8.46E-03	 PA2496	 2.51E-02	 1.05E-02	PA5191	 2.05E-02	 8.47E-03	 PA2829	 2.51E-02	 1.05E-02	PA0025	 2.05E-02	 8.47E-03	 PA2909	 2.51E-02	 1.06E-02	PA0033	 2.05E-02	 8.48E-03	 PA3446	 2.51E-02	 1.06E-02	PA0037	 2.05E-02	 8.49E-03	 PA3479	 2.51E-02	 1.06E-02	PA0086	 2.05E-02	 8.50E-03	 PA3734	 2.51E-02	 1.06E-02	PA0116	 2.05E-02	 8.51E-03	 PA3750	 2.51E-02	 1.06E-02	PA0328	 2.05E-02	 8.52E-03	 PA4040	 2.51E-02	 1.06E-02	PA0340	 2.05E-02	 8.53E-03	 PA4296	 2.51E-02	 1.06E-02	PA0393	 2.05E-02	 8.54E-03	 PA4351	 2.51E-02	 1.06E-02	PA0460	 2.05E-02	 8.55E-03	 PA4447	 2.51E-02	 1.06E-02	PA0477	 2.05E-02	 8.55E-03	 PA4648	 2.51E-02	 1.06E-02	PA0542	 2.05E-02	 8.56E-03	 PA4899	 2.51E-02	 1.06E-02	PA0562	 2.05E-02	 8.57E-03	 PA4955	 2.51E-02	 1.07E-02	PA0577	 2.05E-02	 8.58E-03	 PA5006	 2.51E-02	 1.07E-02	PA0609	 2.05E-02	 8.59E-03	 PA5014	 2.51E-02	 1.07E-02	PA0658	 2.05E-02	 8.60E-03	 PA5033	 2.51E-02	 1.07E-02	PA0798	 2.05E-02	 8.61E-03	 PA5118	 2.51E-02	 1.07E-02	
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PA0807	 2.05E-02	 8.62E-03	 PA5209	 2.51E-02	 1.07E-02	PA0808	 2.05E-02	 8.63E-03	 PA0343	 2.62E-02	 1.07E-02	PA0836	 2.05E-02	 8.64E-03	 PA1352	 2.62E-02	 1.07E-02	PA0851	 2.05E-02	 8.64E-03	 PA1618	 2.62E-02	 1.07E-02	PA0886	 2.05E-02	 8.65E-03	 PA2141	 2.62E-02	 1.07E-02	PA0901	 2.05E-02	 8.66E-03	 PA2144	 2.62E-02	 1.07E-02	PA0906	 2.05E-02	 8.67E-03	 PA2147	 2.62E-02	 1.07E-02	PA0930	 2.05E-02	 8.68E-03	 PA2461	 2.88E-02	 1.08E-02	PA0957	 2.05E-02	 8.69E-03	 PA1148	 2.90E-02	 1.08E-02	PA1002	 2.05E-02	 8.70E-03	 PA4915	 2.90E-02	 1.08E-02	PA1004	 2.05E-02	 8.71E-03	 PA3292	 2.90E-02	 1.08E-02	PA1030	 2.05E-02	 8.72E-03	 PA2138	 3.08E-02	 1.08E-02	PA1042	 2.05E-02	 8.72E-03	 PA2595	 3.17E-02	 1.08E-02	PA1050	 2.05E-02	 8.73E-03	 PA2098	 3.24E-02	 1.08E-02	PA1075	 2.05E-02	 8.74E-03	 PA0804	 3.24E-02	 1.08E-02	PA1117	 2.05E-02	 8.75E-03	 PA1016	 3.24E-02	 1.08E-02	PA1329	 2.05E-02	 8.76E-03	 PA1130	 3.24E-02	 1.08E-02	PA1483	 2.05E-02	 8.77E-03	 PA1146	 3.24E-02	 1.08E-02	PA1492	 2.05E-02	 8.78E-03	 PA1213	 3.24E-02	 1.09E-02	PA1496	 2.05E-02	 8.79E-03	 PA2377	 3.24E-02	 1.09E-02	PA1572	 2.05E-02	 8.80E-03	 PA2439	 3.24E-02	 1.09E-02	PA1607	 2.05E-02	 8.80E-03	 PA3833	 3.24E-02	 1.09E-02	PA1615	 2.05E-02	 8.81E-03	 PA4637	 3.24E-02	 1.09E-02	PA1732	 2.05E-02	 8.82E-03	 PA3923	 3.25E-02	 1.09E-02	PA1805	 2.05E-02	 8.83E-03	 PA2794	 3.26E-02	 1.09E-02	PA1844	 2.05E-02	 8.84E-03	 PA5384	 3.50E-02	 1.09E-02	PA2449	 2.05E-02	 8.85E-03	 PA0030	 3.56E-02	 1.09E-02	PA2532	 2.05E-02	 8.86E-03	 PA0126	 3.56E-02	 1.09E-02	PA2535	 2.05E-02	 8.87E-03	 PA0156	 3.56E-02	 1.09E-02	PA2544	 2.05E-02	 8.88E-03	 PA0173	 3.56E-02	 1.10E-02	PA2552	 2.05E-02	 8.88E-03	 PA0176	 3.56E-02	 1.10E-02	PA2558	 2.05E-02	 8.89E-03	 PA0236	 3.56E-02	 1.10E-02	PA2574	 2.05E-02	 8.90E-03	 PA0238	 3.56E-02	 1.10E-02	PA2629	 2.05E-02	 8.91E-03	 PA0253	 3.56E-02	 1.10E-02	PA2649	 2.05E-02	 8.92E-03	 PA0267	 3.56E-02	 1.10E-02	PA2705	 2.05E-02	 8.93E-03	 PA0451	 3.56E-02	 1.10E-02	PA2711	 2.05E-02	 8.94E-03	 PA0669	 3.56E-02	 1.10E-02	PA2718	 2.05E-02	 8.95E-03	 PA0752	 3.56E-02	 1.10E-02	PA2739	 2.05E-02	 8.96E-03	 PA0758	 3.56E-02	 1.10E-02	PA2831	 2.05E-02	 8.97E-03	 PA0883	 3.56E-02	 1.10E-02	PA2850	 2.05E-02	 8.97E-03	 PA0934	 3.56E-02	 1.11E-02	PA2866	 2.05E-02	 8.98E-03	 PA0935	 3.56E-02	 1.11E-02	
236	
PA2894	 2.05E-02	 8.99E-03	 PA0954	 3.56E-02	 1.11E-02	PA2898	 2.05E-02	 9.00E-03	 PA0959	 3.56E-02	 1.11E-02	PA2899	 2.05E-02	 9.01E-03	 PA1000	 3.56E-02	 1.11E-02	PA2912	 2.05E-02	 9.02E-03	 PA1052	 3.56E-02	 1.11E-02	PA2937	 2.05E-02	 9.03E-03	 PA1135	 3.56E-02	 1.11E-02	PA2941	 2.05E-02	 9.04E-03	 PA1166	 3.56E-02	 1.11E-02	PA2964	 2.05E-02	 9.05E-03	 PA1188	 3.56E-02	 1.11E-02	PA2972	 2.05E-02	 9.05E-03	 PA1210	 3.56E-02	 1.11E-02	PA2977	 2.05E-02	 9.06E-03	 PA1364	 3.56E-02	 1.11E-02	PA2979	 2.05E-02	 9.07E-03	 PA1374	 3.56E-02	 1.12E-02	PA3008	 2.05E-02	 9.08E-03	 PA1395	 3.56E-02	 1.12E-02	PA3029	 2.05E-02	 9.09E-03	 PA1469	 3.56E-02	 1.12E-02	PA3042	 2.05E-02	 9.10E-03	 PA1489	 3.56E-02	 1.12E-02	PA3045	 2.05E-02	 9.11E-03	 PA1536	 3.56E-02	 1.12E-02	PA3084	 2.05E-02	 9.12E-03	 PA1578	 3.56E-02	 1.12E-02	PA3111	 2.05E-02	 9.13E-03	 PA1608	 3.56E-02	 1.12E-02	PA3127	 2.05E-02	 9.13E-03	 PA1634	 3.56E-02	 1.12E-02	PA3177	 2.05E-02	 9.14E-03	 PA1656	 3.56E-02	 1.12E-02	PA3182	 2.05E-02	 9.15E-03	 PA1660	 3.56E-02	 1.12E-02	PA3233	 2.05E-02	 9.16E-03	 PA1678	 3.56E-02	 1.12E-02	PA3260	 2.05E-02	 9.17E-03	 PA1679	 3.56E-02	 1.12E-02	PA3264	 2.05E-02	 9.18E-03	 PA1737	 3.56E-02	 1.13E-02	PA3273	 2.05E-02	 9.19E-03	 PA1799	 3.56E-02	 1.13E-02	PA3301	 2.05E-02	 9.20E-03	 PA1853	 3.56E-02	 1.13E-02	PA3314	 2.05E-02	 9.21E-03	 PA1913	 3.56E-02	 1.13E-02	PA3428	 2.05E-02	 9.21E-03	 PA1927	 3.56E-02	 1.13E-02	PA3493	 2.05E-02	 9.22E-03	 PA1929	 3.56E-02	 1.13E-02	PA3576	 2.05E-02	 9.23E-03	 PA1976	 3.56E-02	 1.13E-02	PA3597	 2.05E-02	 9.24E-03	 PA1979	 3.56E-02	 1.13E-02	PA3615	 2.05E-02	 9.25E-03	 PA2028	 3.56E-02	 1.13E-02	PA3619	 2.05E-02	 9.26E-03	 PA2083	 3.56E-02	 1.13E-02	PA3678	 2.05E-02	 9.27E-03	 PA2425	 3.56E-02	 1.13E-02	PA3724	 2.05E-02	 9.28E-03	 PA2466	 3.56E-02	 1.14E-02	PA3736	 2.05E-02	 9.29E-03	 PA2469	 3.56E-02	 1.14E-02	PA3820	 2.05E-02	 9.30E-03	 PA2518	 3.56E-02	 1.14E-02	PA3847	 2.05E-02	 9.30E-03	 PA2557	 3.56E-02	 1.14E-02	PA3881	 2.05E-02	 9.31E-03	 PA2587	 3.56E-02	 1.14E-02	PA3935	 2.05E-02	 9.32E-03	 PA2625	 3.56E-02	 1.14E-02	PA4017	 2.05E-02	 9.33E-03	 PA2699	 3.56E-02	 1.14E-02	PA4032	 2.05E-02	 9.34E-03	 PA2804	 3.56E-02	 1.14E-02	PA4038	 2.05E-02	 9.35E-03	 PA2816	 3.56E-02	 1.14E-02	PA4068	 2.05E-02	 9.36E-03	 PA2867	 3.56E-02	 1.14E-02	
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				Supplementary	figure	1.	PseudoCAP	functional	categories	associated	with	genes	significantly	underrepresented	for	loss	of	function	in	CF	compared	with	the	environment	with	p	values	smaller	than	the	BH	critical	value								
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			Supplementary	figure	2.	ML	approximation	of	LES	core	genome	alignment	(n	=	143)	 with	 IQtree,	 TVM+R3	 substituion	 model	 and	 1000	 ultrafast	 bootstraps.	Tree	scale	substitutions	per	base			
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			Supplementary	figure	3.	LES	core	genome	(n	=	143	genomes)	RAxML	tree	based	on	SNP	sites	filtered	to	remove	recombinant	SNPs	by	gubbins				
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Supplementary	 figure	 4.	 LES	 core	 genome	 recombination	 events	 alongside	RaxML	 tree	 based	 on	 polymorphic	 sites	 corrected	 for	 recombination.	 Blocks	represent	 recombination	 events	 based	 on	 position	 in	 the	 core	 genome.	 Red	blocks	are	present	in	multiple	genomes	while	blue	are	unique	
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																																															Supplementary	figure	5.	LES	(n	=	143	genomes)	and	PAO1	core	genome	RAxML	tree	based	on	SNP	sites	filtered	to	remove	recombinant	SNPs	by	gubbins	
JD329
79427
SED1
PHELES16
PHELES15
LESB65
8835
CF4S126
PHELES5
CF5S120
89224
89093
49492
JD304
417GLY
LiP8
LESB58
8995
SED20
10262
CF3S112
CF3S2 24
B9
LiP13
72G
139124
CF3S121
CF6S118
PHELES23
LESlike7
PHELES14
120MO
LiP5
PHELES7
49070
OSIRIS
LiP2a
CF8S127
89153
CF6S11
PHELES29
89570
49513
CF7S139
JD310
49348
CF10S111
LiP9
LiP10a
CF1S120
PHELES11
CF5S104
JD335
PHELES3
CF60P44
PHELES28
CF3S2 5
CF8S136
LESlike1
LiP1a
CF4S132
PHELES12
10333
CF7S136
9 CF8S1
119579
PHELES8
244
PHELES27
9920
89204
LiP1c
LES431
PHELES18
30642g
LiP10b
PHELES13
CF3S124
CF54NCTC13415
139125
CF3S2 35
PHELES21
89577
MdLES
LiP3
LiP7
LiP12
PHELES20
CF9S124
LiP2b
89150
CF1S133
CF10S121
PAO1
89192
PHELES6
49400
PHELES22
JD322
9857
89568
89212
LiP14
JD326
CF3S108
CF5S134
LESlike5
LESB582
CF7S115
89221
89347
PHELES4
CF8S133
LiP6
LES400
PHELES2
JD315
79426
CF3S2 25
PHELES10
CF4S12
11112
CF9S111
CF4S108
PHELES9
CF177P138
PHELES19
PHELES1
JD324
CF7S110
B35
CF3S2 19
LiP2c
PHELES30
LiP11
SED11
30567S
o59100
PHELES17
CF5S138
49388
LESlike4
CF3S2 31
PHELES25
Tree scale: 10
245	
Supplementary	table	2.	Non-CF	bronchiectasis	isolate	genomes.	Representative	bronchiectasis	panel	in	green.	MLSTs	provided,	patient	and	centre	information	provided	and	whether	DNA	mismatch	repair	genes	mutS,	mutL,	mutM	or	uvrD	contain	a	likely	loss	of	function	mutation		
Isolate	ID	 Center	 Date	 Patient	 ST	 Mutator	A1	 1	 09/10/2014	 1	 17	 	A2	 1	 16/10/2014	 2	 207	 	A3	 1	 10/10/2014	 3	 252	 	A4	 1	 10/10/2014	 3	 252	 	A5	 1	 10/10/2014	 3	 252	 	B3	 12	 01/11/2008	 8	 281	 	B16	 12	 25/11/2013	 9	 253	 	B34	 12	 03/09/2014	 11	 179	 	B37	 12	 18/01/2012	 12	 -	 	B62	 12	 03/09/2014	 15	 -	 	B113	 12	 23/10/2014	 18	 1328	 mutL	(INDEL)	B114	 12	 11/04/2012	 19	 198	 	B199	 12	 18/10/2011	 32	 1182	 	A12	 1	 14/11/2014	 35	 179	 	C2	 4	 14/10/2009	 36	 253	 	C3	 4	 25/02/2010	 37	 260	 	C4	 4	 25/02/2010	 37	 -a	 	C5	 4	 25/02/2010	 37	 260	a	 	C6	 4	 03/03/2010	 38	 244	 	C7	 4	 23/03/2010	 39	 244	 	C10	 4	 16/04/2010	 40	 244	 	C8	 4	 16/04/2010	 40	 244	 	C9	 4	 16/04/2010	 40	 244	 	C11	 4	 19/08/2010	 41	 282	 	C12	 4	 20/08/2010	 42	 282	 	C13	 4	 20/08/2010	 42	 27	b	 	C14	 4	 20/08/2010	 42	 27	b	 	C15	 4	 20/08/2010	 42	 27	b	 	C16	 4	 20/08/2010	 42	 -b	 	C17	 4	 20/08/2010	 42	 -	b	 	C18	 4	 15/04/2011	 43	 -	 mutL	(STOP)	C20	 4	 01/07/2011	 44	 878	 	C21	 15	 14/04/2009	 45	 -c	 	C22	 15	 14/04/2009	 45	 -	c	 	C23	 15	 14/04/2009	 45	 -	c	 	
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C25	 15	 20/05/2009	 46	 253	 	C29	 15	 03/06/2009	 48	 252	 	C30	 15	 04/06/2009	 49	 252	 	C31	 15	 25/08/2009	 50	 -	d	 mutL	(INDEL)	C32	 15	 25/08/2009	 50	 -d	 	C33	 15	 25/08/2009	 50	 -	d	 	C36	 15	 21/05/2010	 52	 253	 	C42	 15	 12/07/2010	 54	 309	 	C43	 15	 28/07/2010	 55	 108	 	C44	 15	 28/07/2010	 55	 108	 	C45	 15	 28/07/2010	 55	 108	 	C49	 15	 22/02/2011	 58	 395	 	C51	 15	 23/02/2011	 59	 683	 	C54	 15	 15/06/2011	 61	 1342	 	C55	 5	 26/06/2009	 62	 -	e	 	C56	 5	 26/06/2009	 62	 -e	 	C57	 5	 26/06/2009	 62	 -	e	 	C58	 5	 26/06/2009	 62	 -	e	 	C59	 5	 26/06/2009	 62	 -	e	 	C60	 5	 26/06/2009	 62	 -	e	 	C61	 5	 17/11/2009	 63	 620	 	C63	 3	 02/09/2009	 64	 27	 	C64	 3	 25/11/2009	 65	 274	 	C65	 3	 25/11/2009	 65	 274	 	C66	 3	 25/11/2009	 65	 274	 	C67	 3	 25/11/2009	 65	 274	 	C68	 3	 25/11/2009	 65	 274	 	C69	 3	 12/05/2010	 66	 -	 	C71	 9	 04/09/2009	 67	 968	 	C73	 9	 05/11/2010	 68	 17	 	C74	 9	 03/12/2010	 69	 1202	 mutL	(STOP)	C76	 2	 12/05/2009	 70	 253	 	C77	 2	 03/07/2009	 71	 308	 	C78	 2	 14/07/2009	 72	 840	 mutL	(INDEL)	C79	 2	 14/07/2009	 72	 620	f	 mutL	(STOP)	C80	 2	 14/07/2009	 72	 620	f	 	C81	 2	 14/07/2009	 72	 620	f	 	C82	 2	 14/07/2009	 72	 620	f	 	C83	 2	 14/07/2009	 72	 -f	 	C84	 2	 14/07/2009	 72	 620	f	 	
247	
C85	 2	 06/08/2009	 73	 -g	 	C86	 2	 06/08/2009	 73	 308	 	C87	 2	 06/08/2009	 73	 179	g	 	C88	 2	 15/12/2009	 74	 1251	 	C89	 2	 25/03/2010	 75	 1239	 	C91	 2	 13/01/2011	 76	 253	 	C92	 2	 01/02/2011	 77	 252	 	C94	 10	 03/07/2009	 78	 395	 	C95	 10	 29/07/2009	 79	 253	 	C96	 10	 29/07/2009	 79	 253	 	C97	 10	 29/07/2009	 79	 253	 	C98	 10	 29/07/2009	 79	 253	 	C99	 10	 29/07/2009	 79	 253	 	C100	 10	 13/10/2009	 80	 612	 	C101	 10	 21/10/2009	 81	 -	h	 	C102	 10	 21/10/2009	 81	 -h	 	C103	 10	 21/10/2009	 81	 -	h	 	C104	 13	 16/05/2009	 82	 179	 	C105	 13	 25/07/2009	 83	 840	 	C106	 13	 11/08/2009	 84	 -i	 	C107	 13	 11/08/2009	 84	 253	 	C108	 13	 11/08/2009	 84	 179	i	 	C109	 13	 11/08/2009	 85	 840	 	C110	 13	 11/08/2009	 85	 179	 	C111	 13	 11/08/2009	 85	 179	 	C112	 13	 11/08/2009	 85	 179	 	C114	 13	 05/12/2009	 86	 179	 	C115	 13	 05/12/2009	 86	 179	 	C116	 13	 04/06/2010	 87	 871	 	C117	 13	 04/06/2010	 87	 871	 	C118	 13	 04/06/2010	 87	 871	 	C119	 7	 23/01/2010	 88	 -	 	C120	 7	 29/01/2010	 89	 -	 	C123	 7	 02/04/2010	 90	 27	 mutS	(INDEL)	C124	 7	 08/04/2010	 91	 1753	 	C125	 7	 29/04/2010	 92	 253	 	C126	 7	 29/04/2010	 92	 253	 	C127	 7	 29/04/2010	 92	 164	 mutS	(INDEL)	C128	 7	 29/04/2010	 92	 164	 	C129	 7	 29/04/2010	 92	 871	 mutL	
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(INDEL)	C131	 7	 08/05/2010	 93	 253	 	C133	 7	 28/05/2010	 94	 253	 mutS	(INDEL)	C134	 7	 19/12/2010	 95	 253	 mutS	(INDEL)	C135	 14	 02/11/2009	 96	 160	 	C137	 14	 16/04/2010	 97	 260	 	C139	 14	 08/09/2010	 98	 2102	 	C141	 14	 01/10/2010	 99	 2102	 	C142	 14	 11/02/2011	 100	 252	 	C143	 8	 08/07/2010	 101	 253	 	C144	 8	 08/07/2010	 101	 253	 	C145	 8	 08/07/2010	 101	 253	 	C146	 8	 25/06/2010	 102	 395	 	C147	 8	 25/06/2010	 102	 395	 	C148	 8	 25/06/2010	 102	 395	 	C149	 8	 22/03/2011	 103	 108	 	C150	 6	 27/08/2010	 104	 253	 	C151	 6	 03/03/2011	 105	 1244	 	C153	 6	 07/04/2011	 106	 155	 	C155	 11	 04/12/2010	 107	 1211	 	C156	 16	 16/11/2010	 108	 260	 	C158	 16	 03/12/2010	 109	 155	 	C159	 16	 09/12/2010	 110	 260	 	C160	 16	 09/12/2010	 111	 1244	 	C161	 16	 03/03/2011	 112	 110	 	C164	 16	 08/12/2010	 113	 -	 	C167	 16	 21/04/2011	 114	 296	 	C168	 16	 21/12/2010	 115	 17	 	A19	 1	 16/12/2014	 120	 -	 	A163	 1	 19/05/2015	 137	 146	 	A36	 1	 17/02/2015	 137	 146	 	A46	 1	 07/04/2015	 147	 17	 	A48	 1	 07/04/2015	 147	 17	 	A52	 1	 07/04/2015	 147	 17	 	A53	 1	 07/04/2015	 147	 17	 	A54	 1	 07/04/2015	 147	 17	 	A55	 1	 07/04/2015	 147	 17	 	A56	 1	 07/04/2015	 147	 17	 	A58	 1	 07/04/2015	 147	 17	 	A60	 1	 07/04/2015	 147	 17	 	
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A70	 1	 07/04/2015	 147	 17	 	A71	 1	 07/04/2015	 147	 17	 	A72	 1	 07/04/2015	 147	 17	 	A73	 1	 07/04/2015	 147	 17	 	A75	 1	 07/04/2015	 147	 17	 	A76	 1	 07/04/2015	 147	 17	 	A100	 1	 07/04/2015	 148	 17	 	A106	 1	 07/04/2015	 148	 175	 	A107	 1	 07/04/2015	 148	 175	 	A77	 1	 07/04/2015	 148	 175	 	A78	 1	 07/04/2015	 148	 17	 	A80	 1	 07/04/2015	 148	 175	 	A81	 1	 07/04/2015	 148	 17	 	A82	 1	 07/04/2015	 148	 17	 	A85	 1	 07/04/2015	 148	 175	 	A86	 1	 07/04/2015	 148	 175	 	A90	 1	 07/04/2015	 148	 175	 	A91	 1	 07/04/2015	 148	 175	 	A92	 1	 07/04/2015	 148	 175	 	A95	 1	 07/04/2015	 148	 175	 	A97	 1	 07/04/2015	 148	 175	 	A119	 1	 15/05/2015	 149	 667	 	A122	 1	 15/05/2015	 149	 667	 	A123	 1	 15/05/2015	 149	 667	 	A126	 1	 15/05/2015	 149	 667	 	A130	 1	 15/05/2015	 149	 667	 	A134	 1	 15/05/2015	 149	 667	 	A137	 1	 15/05/2015	 149	 667	 	A141	 1	 15/05/2015	 149	 667	 	A144	 1	 15/05/2015	 149	 667	 	A147	 1	 15/05/2015	 149	 667	 	A148	 1	 15/05/2015	 149	 667	 	A151	 1	 15/05/2015	 149	 667	 	A154	 1	 15/05/2015	 149	 667	 	A156	 1	 15/05/2015	 149	 667	 		 	 	 	 	 							
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					Supplementary	 figure	 6.	 Non-CF	 bronchiectasis	 and	 the	 wider	 P.	 aeruginosa	population	 core	 genome	SNP	phylogeny	 (n	=	522).	HKY85	 substitution	model	and	ML	 approximation	 (MEGA)	 based	 on	 complete	 core	 genome	 polymorphic	sites							
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